10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

For the Quarterly Period Ended March 31, 2015

AMSURG CORP.

(Exact Name of Registrant as Specified in its Charter)

Tennessee	001-36531	62-1493316
(State or Other Jurisdiction of Incorporation)	(Commission  File Number)	(I.R.S. Employer  Identification No.)
1A Burton Hills Boulevard
Nashville, Tennessee		37215
(Address of Principal Executive Offices)		(Zip Code)

(615) 665-1283

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X]                   No [  ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X]                   No [  ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.   (Check one):

Large accelerated filer  [X]                                      Accelerated filer                  [  ]

Non-accelerated filer    [   ]                                      Smaller reporting company [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes [  ]                    No [X]

As of May 6, 2015 there were outstanding 48,413,184 shares of the registrant’s Common Stock, no par value.

Table of Contents to Form 10-Q for the Three Months EndedMarch 31, 2015

Part I	Financial Information
	Item 1.	Financial Statements	1
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	27
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	39
	Item 4.	Controls and Procedures	39
Part II	Other Information
	Item 1.	Legal Proceedings	40
	Item 1A.	Risk Factors	40
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	40
	Item 3.	Defaults Upon Senior Securities	40
	Item 4.	Mine Safety Disclosures	40
	Item 5.	Other Information	40
	Item 6.	Exhibits	41
	Signature		42

i

Part I

Item 1.  Financial Statements

AmSurg Corp. Consolidated Balance Sheets (unaudited) (In thousands)
	March 31,		December 31,
	2015		2014
Assets
Current assets:
Cash and cash equivalents	$	116,156	$	208,079
Restricted cash and marketable securities	10,957		10,219
Accounts receivable, net of allowance of $124,606 and $113,357, respectively	244,002		233,053
Supplies inventory	20,473		19,974
Prepaid and other current assets	97,361		115,362
Total current assets	488,949		586,687
Property and equipment, net	183,446		180,448
Investments in unconsolidated affiliates	79,311		75,475
Goodwill	3,500,668		3,381,149
Intangible assets, net	1,306,267		1,273,879
Other assets	25,368		25,886
Total assets	$	5,584,009	$	5,523,524
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	18,858	$	18,826
Accounts payable	25,808		29,585
Accrued salaries and benefits	144,607		140,044
Accrued interest	17,857		29,644
Other accrued liabilities	75,701		67,986
Total current liabilities	282,831		286,085
Long-term debt	2,229,994		2,232,186
Deferred income taxes	648,444		633,480
Other long-term liabilities	92,485		89,443
Commitments and contingencies
Noncontrolling interests – redeemable	183,459		184,099
Equity:
Mandatory convertible preferred stock, no par value, 5,000 shares authorized, 1,725 shares issued and outstanding	166,632		166,632
Common stock, no par value, 70,000 shares authorized, 48,413 and 48,113 shares issued and outstanding, respectively	888,748		885,393
Retained earnings	646,296		627,522
Total AmSurg Corp. equity	1,701,676		1,679,547
Noncontrolling interests – non-redeemable	445,120		418,684
Total equity	2,146,796		2,098,231
Total liabilities and equity	$	5,584,009	$	5,523,524

See accompanying notes to the unaudited consolidated financial statements.

1

Item 1. Financial Statements - (continued) Table of Contents

AmSurg Corp. Consolidated Statements of Earnings (unaudited) (In thousands, except earnings per share)
	Three Months Ended March 31,
	2015			2014
Revenues	$	638,197		$	259,561
Provision for uncollectibles	(67,752		)	—
Net revenue	570,445			259,561
Operating expenses:
Salaries and benefits	302,179			82,149
Supply cost	42,584			37,805
Other operating expenses	90,570			54,169
Transaction costs	1,471			—
Depreciation and amortization	22,818			8,259
Total operating expenses	459,622			182,382
Gain (loss) on deconsolidation	(223		)	2,045
Equity in earnings of unconsolidated affiliates	2,651			764
Operating income	113,251			79,988
Interest expense, net	30,247			6,960
Earnings from continuing operations before income taxes	83,004			73,028
Income tax expense	14,249			12,982
Net earnings from continuing operations	68,755			60,046
Net earnings from discontinued operations	—			68
Net earnings	68,755			60,114
Less net earnings attributable to noncontrolling interests	47,717			42,919
Net earnings attributable to AmSurg Corp. shareholders	21,038			17,195
Preferred stock dividends	(2,264		)	—
Net earnings attributable to AmSurg Corp. common shareholders	$	18,774		$	17,195
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	18,774		$	17,392
Loss from discontinued operations, net of income tax	—			(197		)
Net earnings attributable to AmSurg Corp. common shareholders	$	18,774		$	17,195
Basic earnings per share attributable to AmSurg Corp. common shareholders:
Net earnings from continuing operations	$	0.39		$	0.55
Net loss from discontinued operations	—			(0.01		)
Net earnings	$	0.39		$	0.54
Diluted earnings per share attributable to AmSurg Corp. common shareholders:
Net earnings from continuing operations	$	0.39		$	0.54
Net loss from discontinued operations	—			(0.01		)
Net earnings	$	0.39		$	0.54
Weighted average number of shares and share equivalents outstanding:
Basic	47,572			31,716
Diluted	47,905			32,120

See accompanying notes to the unaudited consolidated financial statements.

2

Item 1. Financial Statements - (continued) Table of Contents

AmSurg Corp. Consolidated Statements of Changes in Equity (unaudited) (In thousands)
	AmSurg Corp. Shareholders																	Noncontrolling
						Mandatory						Noncontrolling						Interests –
						Convertible						Interests –			Total			Redeemable
	Common Stock					Preferred Stock			Retained			Non-			Equity			(Temporary
	Shares		Amount			Shares	Amount		Earnings			Redeemable			(Permanent)			Equity)
Balance at December 31, 2014	48,113		$	885,393		1,725	$	166,632	$	627,522		$	418,684		$	2,098,231		$	184,099
Net earnings	—		—			—	—		21,038			15,037			36,075			32,680
Issuance of restricted stock	296		—			—	—		—			—			—			—
Cancellation of restricted stock	(6	)	—			—	—		—			—			—			—
Stock options exercised	77		1,746			—	—		—			—			1,746			—
Stock repurchased	(67	)	(3,684		)	—	—		—			—			(3,684		)	—
Share-based compensation	—		3,709			—	—		—			—			3,709			—
Tax benefit related to exercise of stock options	—		3,317			—	—		—			—			3,317			—
Dividends paid on preferred stock	—		—			—	—		(2,264		)	—			(2,264		)	—
Acquisitions and other transactions impacting noncontrolling interests	—		144			—	—		—			23,012			23,156			(646		)
Distributions to noncontrolling interests, net of capital contributions	—		—			—	—		—			(14,564		)	(14,564		)	(32,544		)
Disposals and other transactions impacting noncontrolling interests	—		(1,877		)	—	—		—			2,951			1,074			(130		)
Balance at March 31, 2015	48,413		$	888,748		1,725	$	166,632	$	646,296		$	445,120		$	2,146,796		$	183,459
Balance at January 1, 2014	32,353		$	185,873		—	$	—	$	578,324		$	361,359		$	1,125,556		$	177,697
Net earnings	—		—			—	—		17,195			12,219			29,414			30,700
Issuance of restricted stock	200		—			—	—		—			—			—			—
Stock options exercised	20		488			—	—		—			—			488			—
Stock repurchased	(68	)	(2,857		)	—	—		—			—			(2,857		)	—
Share-based compensation	—		2,458			—	—		—			—			2,458			—
Tax benefit related to exercise of stock options	—		1,727			—	—		—			—			1,727			—
Acquisitions and other transactions impacting noncontrolling interests	—		286			—	—		—			3,690			3,976			—
Distributions to noncontrolling interests, net of capital contributions	—		—			—	—		—			(12,753		)	(12,753		)	(30,441		)
Disposals and other transactions impacting noncontrolling interests	—		(1,081		)	—	—		—			(1,291		)	(2,372		)	(273		)
Balance at March 31, 2014	32,505		$	186,894		—	$	—	$	595,519		$	363,224		$	1,145,637		$	177,683

See accompanying notes to the unaudited consolidated financial statements.

3

Item 1. Financial Statements - (continued) Table of Contents

AmSurg Corp. Consolidated Statements of Cash Flows (unaudited) (In thousands)
	Three Months Ended March 31,
	2015			2014
Cash flows from operating activities:
Net earnings	$	68,755		$	60,114
Adjustments to reconcile net earnings to net cash flows provided by operating activities:
Depreciation and amortization	22,818			8,259
Amortization of deferred loan costs	2,074			498
Provision for uncollectibles	73,999			5,216
Net loss on sale of long-lived assets	—			604
Loss (gain) on deconsolidation	223			(2,045		)
Share-based compensation	3,709			2,458
Excess tax benefit from share-based compensation	(3,317		)	(1,727		)
Deferred income taxes	3,334			11,933
Equity in earnings of unconsolidated affiliates	(2,651		)	(764		)
Increases (decreases) in cash and cash equivalents, net of acquisitions and dispositions:
Accounts receivable	(74,214		)	(6,867		)
Supplies inventory	(30		)	(245		)
Prepaid and other current assets	13,842			(3,638		)
Accounts payable	(2,526		)	(3,578		)
Accrued expenses and other liabilities	(7,886		)	(606		)
Other, net	697			207
Net cash flows provided by operating activities	98,827			69,819
Cash flows from investing activities:
Acquisitions and related expenses	(126,578		)	(5,038		)
Acquisition of property and equipment	(14,783		)	(7,038		)
Proceeds from sale of interests in surgery centers	—			1,111
Other	(220		)	(418		)
Net cash flows used in investing activities	(141,581		)	(11,383		)
Cash flows from financing activities:
Proceeds from long-term borrowings	2,227			31,945
Repayment on long-term borrowings	(5,213		)	(50,853		)
Distributions to noncontrolling interests	(47,202		)	(43,194		)
Cash dividends for preferred shares	(2,264		)	—
Proceeds from issuance of common stock upon exercise of stock options	1,746			488
Repurchase of common stock	(3,684		)	(2,857		)
Excess tax benefit from share-based compensation	3,317			1,727
Other	1,904			584
Net cash flows used in financing activities	(49,169		)	(62,160		)
Net decrease in cash and cash equivalents	(91,923		)	(3,724		)
Cash and cash equivalents, beginning of period	208,079			50,840
Cash and cash equivalents, end of period	$	116,156		$	47,116
Supplemental cash flow information:
Interest payments	$	40,043		$	3,132
Income tax paid (received)	$	(88	)	$	65

See accompanying notes to the unaudited consolidated financial statements.

4

Item 1. Financial Statements - (continued) Table of Contents

AmSurg Corp.

Notes to the Unaudited Consolidated Financial Statements

(1) Basis of Presentation    

These unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial reporting and in accordance with Rule 10-01 of Regulation S-X.  In the opinion of management, the unaudited interim consolidated financial statements contained in this report reflect all adjustments, consisting of only normal recurring accruals, which are necessary for a fair presentation of the financial position and the results of operations for the interim periods presented.  The results of operations for any interim period are not necessarily indicative of results for the full year. The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s 2014 Annual Report on Form 10-K.

Ambulatory Services

AmSurg Corp. (the Company), through its wholly-owned subsidiaries, owns interests, primarily 51%, in limited partnerships (LPs) and limited liability companies (LLCs) which own and operate ambulatory surgery centers (ASCs, surgery centers or centers).  The Company does not have an ownership interest in a LP or LLC greater than 51% which it does not consolidate.  The Company has ownership interests of less than 51% in 13 LPs and LLCs, 2 of which it consolidates as the Company has substantive participation rights and 11 of which it does not consolidate as the Company’s rights are limited to protective rights only.  The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries and the consolidated LPs and LLCs.  Consolidation of such LPs and LLCs is necessary as the Company’s wholly-owned subsidiaries have primarily 51% or more of the financial interest of the LPs and LLCs, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the LPs and LLCs, and have control of the entities.  The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests.  Intercompany profits, transactions and balances have been eliminated.  All LPs and LLCs and noncontrolling partners are referred to herein as “partnerships” and “partners”, respectively.

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity.  However, for instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required.  Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of earnings; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary are measured at fair value.  Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows. 

Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests.  The partners of the Company’s center partnerships typically are organized as general partnerships, LPs or LLCs that are not subject to federal income tax.  Each partner shares in the pre-tax earnings of the center in which it is a partner.  Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings.  However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its tax expense.  In addition, distributions from the partnerships are made to both the Company’s wholly-owned subsidiaries and the partners on a pre-tax basis.

Physician Services

On July 16, 2014, the Company completed its acquisition of Sheridan Healthcare (Sheridan). Sheridan is a national provider of multi-specialty physician and administrative services to hospitals, ambulatory surgery centers and other healthcare facilities. Sheridan focuses on delivering comprehensive physician services, primarily in the areas of anesthesiology, children's services, radiology and emergency medicine to healthcare facilities. Through its contracts with healthcare facilities, Sheridan is authorized to bill and collect charges for fee for service medical services rendered by its healthcare professionals and employees in exchange for the provision of services to the patients of these facilities. Contract revenue is earned directly from hospital customers through a variety of payment arrangements that are established when payments from third-party payors are inadequate to support the costs of providing the services

5

Item 1. Financial Statements - (continued) Table of Contents

required under the contract. Sheridan also provides physician services and manages office-based practices in the areas of gynecology, obstetrics and perinatology. The consolidated financial statements include the accounts of Sheridan and its wholly-owned subsidiaries along with the accounts of affiliated professional corporations (PCs) with which Sheridan currently has management arrangements. Sheridan's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. These arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at the sole discretion of the Company. The Company has a contractual right to transfer the ownership of the PCs at any time to any person it designates as the nominee shareholder. The Company has the right to receive income, both as ongoing fees and as proceeds from the sale of its interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the Company’s interest in the PCs. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs. In addition, the agreements provide that the Company has the right, but not the obligation, to purchase, or to designate a person(s) to purchase, the stock of the PCs for a nominal amount. Separately, in its sole discretion, the Company has the right to assign its interest in the management and purchase agreements. Based upon the provisions of these agreements, the Company has determined that the PCs are variable interest entities and that the Company is the primary beneficiary as defined in the accounting guidance for consolidation.

Restricted Cash and Marketable Securities

As of March 31, 2015, the Company had $30.3 million of restricted cash and marketable securities in the accompanying consolidated balance sheets, which is restricted for the purpose of satisfying the obligations of the Company's wholly-owned captive insurance company. The Company has reflected $19.3 million of its restricted cash and marketable securities as a component of other assets in the accompanying consolidated balance sheets. The remaining $11.0 million is reflected as a component of total current assets in the accompanying consolidated balance sheets as such amount is available to satisfy the claims payments estimated to occur in the next twelve months. As of March 31, 2015, the Company had $3.0 million included in restricted cash and marketable securities, consisting of certificates of deposit with maturities less than 180 days, which approximates fair value.

Reclassifications

Certain prior year amounts in the accompanying consolidated financial statements and these notes have been reclassified to reflect the impact of additional discontinued operations as further discussed in note 6.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board (FASB) issued ASU 2014-08 “Presentation of Financial Statements and Property, Plant and Equipment,” which raised the threshold for a disposal to qualify as a discontinued operation and requires certain new disclosures for individually material disposals that do not meet the new definition of a discontinued operation. The ASU’s intent is to reduce the number of disposals reported as discontinued operations by focusing on strategic shifts that have or will have a major effect on the Company’s operations and financial results rather than routine disposals that are not a change in the Company’s strategy. The guidance is effective for interim and annual periods beginning after December 15, 2014, with earlier adoption permitted.  From time to time, the Company will dispose of certain of its entities due to management’s assessment of the Company’s strategy in the market and due to limited growth opportunities at those entities. Historically, these dispositions were classified as discontinued operations and recorded separately from continuing operations. The Company adopted this ASU effective January 1, 2015 and did not have any disposals during the three months ended March 31, 2015.  The Company does not believe this ASU will have a material impact on the Company’s consolidated financial position or cash flows.

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. In April 2015, the FASB proposed a one-year deferral of the ASU. The guidance in ASU 2014-09 would be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim

6

Item 1. Financial Statements - (continued) Table of Contents

periods therein. Early adoption would be permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows.

In February 2015, the FASB issued ASU No. 2015-02, "Consolidations (Topic 810) - Amendments to the Consolidation Analysis". The new guidance makes amendments to the current consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities will be considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows.

(2)  Revenue Recognition

Ambulatory Services

Ambulatory services revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers.  Such revenues are recognized when the related surgical procedures are performed.  Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor.

Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid.  During the three months ended March 31, 2015 and 2014, the Company derived approximately 25% of its ambulatory services revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs.  Concentration of credit risk with respect to other payors is limited due to the large number of such payors.

Physician Services

Physician services revenues primarily consists of fee for service revenue and contract revenue and are derived principally from the provision of physician services to patients of the healthcare facilities the Company serves. Contract revenue represents income earned from the Company's hospital customers to subsidize contract costs when payments from third-party payors are inadequate to support such costs.

The Company records revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors. The Company also recognizes revenue for services provided during the period that have not been billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patients’ healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections.

The Company's provision for uncollectibles includes its estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. The Company records net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries).

7

Item 1. Financial Statements - (continued) Table of Contents

Net revenue for the physician services segment consists of the following major payors (in thousands):

	Three Months Ended March 31, 2015 (1)
Medicare	$	38,173		13.3	%
Medicaid	13,972			4.9
Commercial and managed care	212,027			74.0
Self-pay	59,126			20.6
Net fee for service revenue	323,298			112.8
Contract and other revenue	30,989			10.8
Provision for uncollectibles	(67,752		)	(23.6	)
Net revenue for physician services	$	286,535		100.0	%

(1) On July 16, 2014, we completed the acquisition of Sheridan. As such, historical amounts for periods prior to that date are not included.

(3) Accounts Receivable

The Company manages accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. The Company tests its analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, on a contract by contract basis, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company’s billing operations to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. The Company also supplements its allowance for doubtful accounts policy for its physician services quarterly using a hindsight calculation that utilizes write-off data for all payor classes during the previous 12-month period to estimate the allowance for doubtful accounts at a point in time. Changes in these estimates are charged or credited to the consolidated statements of earnings in the period of change. Material changes in estimates may result from unforeseen write-offs of patient or third party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by the Company. Significant changes in payor mix, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on the Company’s estimates and significantly affect its results of operations and cash flows.

Due to the nature of the Company's operations, it is required to separate the presentation of its bad debt expense on the consolidated statement of earnings. The Company records the portion of its bad debts associated with its physician services segment as a component of net revenue in the accompanying consolidated statement of earnings, and the remaining portion, which is associated with its ambulatory services segment, is recorded as a component of other operating expenses in the accompanying consolidated statement of earnings. The bifurcation is a result of the Company's ability to assess the ultimate collection of the patient service revenue associated with its ambulatory services segment before services are provided. The Company's ambulatory services segment is generally able to verify a patient's insurance coverage and ability to pay before services are provided as those services are pre-scheduled and non-emergent. Bad debt expense for the ambulatory services segment is included in other operating expenses and was approximately $6.2 million for the three months ended March 31, 2015 and $5.2 million for the three months ended March 31, 2014. Bad debt expense related to physician services was $67.8 million for the three months ended March 31, 2015.

At March 31, 2015 and December 31, 2014 allowances for doubtful accounts were $124.6 million and $113.4 million, respectively. The change in the allowance for doubtful accounts is primarily a result of subsequent operations from acquisitions completed during the period. At March 31, 2015, approximately 72% of the Company’s allowance for doubtful accounts was related to receivables for fee for service patient visits. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance. Concentration of credit risk is limited by the diversity and number of facilities, patients, payors, and by the geographic dispersion of the Company's operations.

8

Item 1. Financial Statements - (continued) Table of Contents

(4)  Acquisitions

The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination.  The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control.  The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination.  Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.

Sheridan Acquisition

On July 16, 2014, the Company completed the acquisition of Sheridan in a cash and stock transaction. At closing, the Company paid approximately $2.1 billion in cash and issued 5,713,909 shares of its common stock to the former owners of Sheridan in exchange for all of the outstanding equity interests of Sheridan. The shares issued to Sheridan were valued at approximately $272.0 million based on the closing price of the Company's common stock on July 16, 2014. The acquisition of Sheridan enhances the growth profile and diversity of the Company focusing on complementary specialties across the healthcare continuum.

The accounting for the acquisition of Sheridan is expected to be completed during the second quarter of 2015. The Company continues to obtain information relative to the fair values of assets acquired, liabilities assumed and any noncontrolling interests in the transaction. Acquired assets and assumed liabilities include, but are not limited to, fixed assets, licenses, intangible assets and professional liabilities. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed.

Ambulatory Services Acquisitions

During each of the three months ended March 31, 2015 and 2014, the Company, through a wholly-owned subsidiary, acquired a controlling interest in one surgery center. The aggregate amount paid for the centers acquired and for settlement of purchase price payable obligations during the three months ended March 31, 2015 and 2014 was approximately $41.9 million and $5.0 million, respectively, and was paid in cash and funded by a combination of operating cash flow and borrowings under the Company’s revolving credit facility.  The total fair value of an acquisition includes an amount allocated to goodwill, which results from the centers’ favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company’s business model.

Physician Services Acquisitions

The Company completed the acquisition of three physician group practices in the three months ended March 31, 2015. The total consideration consisted of cash of $84.7 million, which was funded at closing through operating cash flow. As a result of certain acquisitions completed during the year ended December 31, 2014, the Company has agreed to pay as additional consideration, the exact amounts of which are contingent on the acquired entity achieving future performance metrics. As of March 31, 2015 and December 31, 2014, the Company had accrued $24.6 million and $20.7 million, respectively, as a component of accrued liabilities and other long-term liabilities in the accompanying consolidated balance sheets which represents management's estimate of the fair values of the contingent consideration. As of March 31, 2015, the Company estimates it may have to pay between $21.0 to $26.0 million in future contingent payments for acquisitions made prior to December 31, 2014 based upon the current projected financial performance or anticipated achievement of other targets of the acquired operations. The current estimate of future contingent payments could increase or decrease depending upon the actual performance of the acquisition over each respective measurement period. The acquisitions completed during the three months ended March 31, 2015 did not result in any contingent consideration.

The Company utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the contingent consideration. The fair value was determined utilizing future forecasts of both earnings and other performance metrics which are expected to be achieved during the performance period, in accordance with each respective purchase agreement. In estimating the fair value, management developed various scenarios and weighted the probable outcome of each scenario using a range of expected probability specific to each agreement. Management utilized a market rate to discount the results of such analysis in order to record the present value of the expected future payout. The timing of the payments of the additional consideration varies by agreement but is expected to occur within one to three years from the date of acquisition.

9

Item 1. Financial Statements - (continued) Table of Contents

Purchase Price Allocations

The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisitions completed in the three months ended March 31, 2015 and 2014, including post acquisition date adjustments recorded to purchase price allocations, are as follows (in thousands): 

	Three Months Ended March 31,
	2015 (1)			2014
Accounts receivable	$	11,355		$	417
Other current assets	4,091			81
Property and equipment	3,465			429
Goodwill	117,141			8,260
Intangible assets	44,663			—
Other long-term assets	35			—
Accounts payable	(1,023		)	(125		)
Other accrued liabilities	(6,774		)	(39		)
Deferred income taxes	(12,190		)	—
Other long-term liabilities	(4,301		)	—
Long-term debt	(735		)	—
Total fair value	155,727			9,023
Less:  Fair value attributable to noncontrolling interests	23,649			3,985
Acquisition date fair value of total consideration transferred	$	132,078		$	5,038

(1) Represents the preliminary allocation of fair value of acquired assets and liabilities associated with these acquisitions at March 31, 2015.

Fair value attributable to noncontrolling interests is based on significant inputs that are not observable in the market.  Key inputs used to determine the fair value include financial multiples used in the purchase of noncontrolling interests primarily from acquisitions of centers.  Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability.  The fair value of noncontrolling interests for acquisitions where the purchase price allocation is not finalized may be subject to adjustment as the Company completes its initial accounting for acquired intangible assets. 

During the three months ended March 31, 2015, the Company incurred approximately $1.5 million of transaction costs. During the three months ended March 31, 2014, the transaction costs incurred by the Company were not significant.

Net revenue and net earnings included in the three months ended March 31, 2015 and 2014 associated with completed acquisitions are as follows (in thousands):

	Three Months Ended March 31,
	2015		2014
Net revenue	$	14,989	$	1,031
Net earnings	2,613		245
Less:  Net earnings attributable to noncontrolling interests	761		151
Net earnings attributable to AmSurg Corp. common shareholders	$	1,852	$	94

10

Item 1. Financial Statements - (continued) Table of Contents

The unaudited consolidated pro forma results for the three months ended March 31, 2015 and 2014, assuming all acquisitions completed prior to March 31, 2015 had been consummated on January 1, 2014, and all 2014 acquisitions had been consummated on January 1, 2013 are as follows (in thousands):

	Three Months Ended March 31,
	2015		2014
Net revenue	$	581,696	$	551,877
Net earnings	71,267		59,152
Amounts attributable to AmSurg Corp. common shareholders:
Net earnings	23,140		13,571
Net earnings per common share:
Basic	$	0.44	$	0.24
Diluted	$	0.44	$	0.24

(5) Investments in Unconsolidated Affiliates

Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.

As of March 31, 2015 and December 31, 2014, the Company has recorded in the accompanying consolidated balance sheets its investments in unconsolidated affiliates of $79.3 million and $75.5 million, respectively. The Company's earnings from these investments during the three months ended March 31, 2015 and 2014, which are reflected in the accompanying consolidated statements of earnings, were approximately $2.7 million and $0.8 million, respectively.

During the three months ended March 31, 2015, the Company's ambulatory services division entered into a transaction whereby it contributed its controlling interest in one center in exchange for a noncontrolling interest in an entity that owned one ASC prior to the transaction and, after the completion of the transaction, controls the contributed center and the center it previously owned. During the three months ended March 31, 2014, the Company's ambulatory services division entered into a transaction whereby it contributed a controlling interest in one center in exchange for $0.6 million and a noncontrolling interest in an entity jointly owned by a hospital that, after the completion of the transaction, controls the contributed center and one additional center. Management of the Company believes these structures provide both economies of scale and potential future growth opportunities in the markets in which the centers are located. 

As a result of these transactions, the Company recorded in the accompanying consolidated balance sheets, as a component of investments in unconsolidated affiliates, the fair value of the Company's investment in the entities which control the contributed centers of approximately $1.3 million and $1.2 million as of the three months ended March 31, 2015 and 2014, respectively.

In each of these transactions, the gain or loss on deconsolidation was determined based on the difference between the fair value of the Company’s noncontrolling interest in the new entity and the carrying value of both the tangible and intangible assets of the contributed centers immediately prior to each transaction. During the three months ended March 31, 2015, the fair value of the Company’s noncontrolling interest was based on estimates of the expected future earnings. Accordingly, the Company recognized a net loss on deconsolidation in the accompanying consolidated statements of earnings of approximately $0.2 million during the three months ended March 31, 2015, which resulted primarily from the allocation of $1.1 million of goodwill, and a net gain of $2.0 million during the three months ended March 31, 2014.

11

Item 1. Financial Statements - (continued) Table of Contents

(6)  Dispositions

During the three months ended March 31, 2014, the Company initiated the disposition of centers due to management’s assessment of the Company’s strategy in the market and due to the limited growth opportunities at these centers. The Company did not dispose of any centers during the three months ended March 31, 2015. For disposals occurring in 2014 and prior, the results of operations of discontinued centers have been classified as discontinued operations in all periods presented. As of January 1, 2015, the Company adopted ASU 2014-08 which raised the threshold for a disposal to qualify as a discontinued operation. As a result, the Company expects that such future disposals of its centers will no longer meet the definition to be accounted for as discontinued operations, and any gain or loss from such disposals will be included in continuing operations.

Results of operations and associated gain (loss) on disposal of the centers discontinued for the three months ended March 31, 2014 are as follows (in thousands):

	Three Months Ended   March 31, 2014
Revenues	$	4,594
Earnings before income taxes	540
Results of discontinued operations, net of tax:
Earnings from operations of discontinued interests in surgery centers	430
Loss on disposal of discontinued interests in surgery centers	(362		)
Net earnings from discontinued operations	68
Less: Net earnings from discontinued operations attributable to noncontrolling interests	265
Net loss from discontinued operations attributable to AmSurg Corp. common shareholders	$	(197	)

Cash proceeds from disposal for the three months ended March 31, 2014 were $1.1 million.

(7)  Goodwill and Intangible Assets

The changes in the carrying amount of goodwill for the three months ended March 31, 2015 are as follows (in thousands):

Balance at December 31, 2014	$	3,381,149
Goodwill acquired, including post acquisition adjustments	120,588
Goodwill disposed, including impact of deconsolidation transactions	(1,069		)
Balance at March 31, 2015	$	3,500,668

Although the determination of goodwill generated as a result of the Sheridan transaction is still under evaluation as of March 31, 2015, the ambulatory services segment and the physician services segment had approximately $2.0 billion and $1.5 billion, respectively, of goodwill. During the three months ended March 31, 2015, goodwill increased $60.5 million for the ambulatory services segment primarily due to the acquisition of a center, net of one deconsolidation. During the three months ended March 31, 2015, goodwill increased by $59.0 million for the physician services segment primarily due to the acquisition of three physician practices. For the three months ended March 31, 2015 and 2014, respectively, approximately $49.4 million and $4.7 million of goodwill recorded was deductible for tax purposes.

12

Item 1. Financial Statements - (continued) Table of Contents

Intangible assets at March 31, 2015 and December 31, 2014 consisted of the following (in thousands):

	March 31, 2015							December 31, 2014
	Gross							Gross
	Carrying		Accumulated					Carrying		Accumulated
	Amount		Amortization			Net		Amount		Amortization			Net
Amortizable intangible assets:
Customer relationships with hospitals	$	1,015,763	$	(34,545	)	$	981,218	$	971,645	$	(22,145	)	$	949,500
Deferred financing cost	59,660		(7,225		)	52,435		59,574		(5,151		)	54,423
Capitalized software	54,529		(21,136		)	33,393		50,387		(19,197		)	31,190
Agreements, contracts and other	4,068		(2,842		)	1,226		3,523		(2,752		)	771
Total amortizable intangible assets	1,134,020		(65,748		)	1,068,272		1,085,129		(49,245		)	1,035,884
Non-amortizable intangible assets:
Trade name	228,000		—			228,000		228,000		—			228,000
Restrictive covenant arrangements	9,995		—			9,995		9,995		—			9,995
Total non-amortizable intangible assets	237,995		—			237,995		237,995		—			237,995
Total intangible assets	$	1,372,015	$	(65,748	)	$	1,306,267	$	1,323,124	$	(49,245	)	$	1,273,879

Approximately $44.1 million of intangible assets related to customer relationships were recorded during the three months ended March 31, 2015 and are estimated to be amortized over a weighted average period of 20 years with no expected residual values.

Amortization of intangible assets for the three months ended March 31, 2015 and 2014 was $16.6 million and $0.6 million, respectively. Estimated amortization of intangible assets for the remainder of 2015 and each of the following five years and thereafter is $50.8 million, $67.0 million, $65.7 million, $64.7 million, $62.0 million, $59.6 million and $698.5 million, respectively.  The Company expects to recognize amortization of all intangible assets over a weighted average period of 18.1 years with no expected residual values.

(8) Accrued Professional Liabilities

The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to self-insured retention, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss patterns, which are not discounted.

At March 31, 2015, the Company's accrued professional liabilities are presented in the accompanying consolidated balance sheets as a component of other accrued liabilities and other long-term liabilities as follows (in thousands):

	March 31, 2015
Estimated losses under self-insured programs	$	26,199
Incurred but not reported losses	31,342
Total accrued professional liabilities	57,541
Less estimated losses payable within one year	10,957
Total	$	46,584

13

Item 1. Financial Statements - (continued) Table of Contents

The changes to the Company's estimated losses under self-insured programs as of March 31, 2015 were as follows (in thousands):

Balance at December 31, 2014	$	53,785
Assumed liabilities through acquisitions	4,301
Provision related to current period reserves	3,300
Payments for current period reserves	(1,551		)
Payments for prior period reserves	(2,294		)
Balance at March 31, 2015	$	57,541

(9)Long-term Debt

Long-term debt at March 31, 2015 and December 31, 2014 consisted of the following (in thousands):

	March 31,		December 31,
	2015		2014
Term loan	$	863,475	$	865,650
5.625% Senior Unsecured Notes due 2020	250,000		250,000
5.625% Senior Unsecured Notes due 2022	1,100,000		1,100,000
Other debt due through 2025	19,854		20,156
Capitalized lease arrangements due through 2026	15,523		15,206
	2,248,852		2,251,012
Less current portion	18,858		18,826
Long-term debt	$	2,229,994	$	2,232,186

The fair value of fixed rate long-term debt, with a carrying value of $1,383.6 million, was $1,419.3 million at March 31, 2015. The fair value of variable rate long-term debt approximates its carrying value of $865.3 million at March 31, 2015.  With the exception of the Company’s 2020 and 2022 Senior Unsecured Notes, the fair value of fixed rate debt (Level 2) is determined based on an estimation of discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders.  The fair value of the Company’s 2020 and 2022 Senior Unsecured Notes (Level 1) is determined based on quoted prices in an active market.

a.     Term Loan and Credit Facility

On July 16, 2014, the Company terminated its revolving credit facility and entered into a new credit facility that is comprised of an $870.0 million term loan and a $300.0 million revolving credit facility.

The term loan matures on July 16, 2021 and bears interest at a rate equal to, at the Company’s option, the alternative base rate as defined in the agreement (ABR) plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00%, with a LIBOR floor of 0.75%, or a combination thereof (3.75% on March 31, 2015). The term loan requires quarterly principal payments of 0.25% of the face amount totaling $8.7 million annually.

The new revolving credit facility matures on July 16, 2019 and permits the Company to borrow up to $300.0 million at an interest rate equal to, at the Company’s option, the ABR plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00%, or a combination thereof; and provides for a fee of 0.375% of unused commitments. The Company has the option to increase borrowings under the new senior secured credit facility by an aggregate amount not to exceed the greater of $300.0 million and an unlimited amount as long as certain financial covenants are met and lender approval is obtained. The new senior credit facility contains certain covenants relating to the ratio of debt to operating performance measurements and interest coverage ratios and is secured by a pledge of the stock of the Company’s wholly-owned subsidiaries and certain of the Company’s partnership and membership interests in the LPs and LLCs. As of March 31, 2015, the Company was in compliance with the covenants contained in the term loan and credit facility and had not drawn upon the revolving credit facility.

Prior to entering into the Company's new credit facility, the Company maintained a revolving credit facility which had a maturity of June 2018 and permitted the Company to borrow up to $475.0 million at an interest rate equal to either the base rate plus 0.25% to 1.00% or LIBOR plus 1.25% to 2.00%, or a combination thereof. On July 3, 2014, the Company utilized proceeds received from its common and preferred stock offerings to repay its outstanding obligation under the existing revolving credit facility.

14

Item 1. Financial Statements - (continued) Table of Contents

b.     Senior Unsecured Notes

2020 Senior Unsecured Notes

On November 20, 2012, the Company completed a private offering of $250.0 million aggregate principal amount of 5.625% senior unsecured notes due 2020 (the 2020 Senior Unsecured Notes).  On May 31, 2013, the Company completed an offer to exchange the outstanding 2020 Senior Unsecured Notes for an equal amount of such notes that are registered under the Securities Act of 1933, as amended (the Securities Act). The net proceeds from the issuance of the 2020 Senior Unsecured Notes were used to reduce the outstanding indebtedness under the Company’s revolving credit agreement. The 2020 Senior Unsecured Notes are general unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized wholly-owned domestic subsidiaries. The 2020 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2020 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30 and November 30, through the maturity date of November 30, 2020.

Prior to November 30, 2015, the Company may redeem up to 35% of the aggregate principal amount of the 2020 Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings.  On or after November 30, 2015, the Company may redeem the 2020 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below:  

Period	Redemption Price
2015	104.219	%
2016	102.813	%
2017	101.406	%
2018 and thereafter	100.000	%

The 2020 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. Based on the terms of the 2020 Senior Unsecured Notes, the Company has adequate ability to meet its obligations to pay dividends as required under the terms of its mandatory convertible preferred stock. The Company was in compliance with the covenants contained in the indenture relating to the 2020 Senior Unsecured Notes at March 31, 2015.

2022 Senior Unsecured Notes

On July 16, 2014, the Company completed a private offering of $1.1 billion aggregate principal amount of 5.625% senior unsecured notes due 2022 (the 2022 Senior Unsecured Notes). On February 19, 2015, the Company completed an offer to exchange the outstanding 2022 Senior Unsecured Notes, for an equal amount of such notes that are registered under the Securities Act. The 2022 Senior Unsecured Notes are general unsecured obligations of the Company and are guaranteed by the Company and existing and subsequently acquired or organized wholly-owned domestic subsidiaries (the Guarantors). The 2022 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2022 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on January 15 and July 15, beginning on January 15, 2015, and ending on the maturity date of July 15, 2022.

Prior to July 15, 2017, the Company may redeem up to 35% of the aggregate principal amount of the 2022 Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings. On or after July 15, 2017, the Company may redeem the 2022 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below:

Period	Redemption Price
2017	104.219	%
2018	102.813	%
2019	101.406	%
2020 and thereafter	100.000	%

15

Item 1. Financial Statements - (continued) Table of Contents

The 2022 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict, the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. Based on the terms of the 2022 Senior Unsecured Notes, the Company has adequate ability to meet its obligations to pay dividends as required under the terms of its mandatory preferred stock. The Company was in compliance with the covenants contained in the indenture relating to the 2022 Senior Unsecured Notes at March 31, 2015.

c.     Senior Secured Notes

During 2010, the Company issued $75.0 million principal amount of senior secured notes (the Senior Secured Notes) pursuant to a note purchase agreement.  The Senior Secured Notes had a maturity date of May 28, 2020. On July 16, 2014, the Company redeemed the Senior Secured Notes utilizing proceeds received from its common and preferred stock offerings.

(10)  Shareholders’ Equity

a.   Common Stock

On July 2, 2014, the Company issued 9,775,000 shares of its common stock in a public offering, at $45.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $18.5 million. Proceeds from the issuance were used to satisfy certain debt obligations with the remaining amount utilized to fund a portion of the Sheridan acquisition. In addition, on July 16, 2014, the Company issued 5,713,909 shares of its common stock in a private offering to the former owners of Sheridan as part of the total consideration for the Sheridan acquisition.

On August 9, 2013, the Board of Directors authorized a stock purchase program for up to $40.0 million of the Company’s shares of common stock which expired on February 9, 2015. During the three months ended March 31, 2015, the Company did not purchase any shares under the stock repurchase program.

In addition, the Company repurchases shares by withholding a portion of employee restricted stock that vested to cover payroll withholding taxes in accordance with the restricted stock agreements.  During the three months ended March 31, 2015 and 2014, the Company repurchased 67,000 shares and 68,014 shares, respectively, of common stock for approximately $3.7 million and $2.9 million, respectively.

b. Mandatory Convertible Preferred Stock

On July 2, 2014, the Company issued 1,725,000 shares of its mandatory convertible preferred stock in a public offering, at $100.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $5.9 million.

The mandatory convertible preferred stock pays dividends at an annual rate of 5.25% of the initial liquidation preference of $100 per share. Dividends accrue and cumulate from the date of issuance and, to the extent lawful and declared by the Company's Board of Directors, will be paid on each January 1, April 1, July 1 and October 1 in cash or, at the Company's election (subject to certain limitations), by delivery of any combination of cash and shares of common stock. Each share of the mandatory convertible preferred stock has a liquidation preference of $100, plus an amount equal to accrued and unpaid dividends. Each share of the mandatory convertible preferred stock will automatically convert on July 1, 2017 (subject to postponement in certain cases), into between 1.8141 and 2.2222 shares of common stock (the “minimum conversion rate” and “maximum conversion rate,” respectively), each subject to adjustment. The number of shares of common stock issuable on conversion will be determined based on the average volume weighted average price per share of the Company's common stock over the 20 consecutive trading day period commencing on and including the 22nd scheduled trading day prior to July 1, 2017. At any time prior to July 1, 2017, holders may elect to convert all or a portion of their shares of mandatory convertible preferred stock into shares of common stock at the minimum conversion rate. If any holder elects to convert shares of mandatory convertible preferred stock during a specified period beginning on the effective date of a fundamental change the conversion rate will be adjusted under certain circumstances and such holder will also be entitled to a fundamental change dividend make-whole amount.

On March 3, 2015, the Company's Board of Directors declared a dividend of $1.3125 per share in cash, or $2.3 million, for the Company’s 5.25% Mandatory Convertible Preferred Stock. As of March 31, 2015, the dividend was funded to the paying agent to be paid to shareholders of record as of March 15, 2015.

16

Item 1. Financial Statements - (continued) Table of Contents

c.   Stock Incentive Plans

In May 2014, the Company adopted the AmSurg Corp. 2014 Equity and Incentive Plan.  The Company also has unvested restricted stock and fully vested options outstanding under the AmSurg Corp. 2006 Stock Incentive Plan, as amended, and the AmSurg Corp. 1997 Stock Incentive Plan, as amended, under which no additional awards may be granted.  Under these plans, the Company has granted restricted stock and non-qualified options to purchase shares of common stock to employees and outside directors from its authorized but unissued common stock.  At March 31, 2015, 1,200,000 shares were authorized for grant under the 2014 Equity and Incentive Plan and 773,718 shares were available for future equity grants.  Restricted stock granted to outside directors vests on the first anniversary of the date of grant.  Restricted stock granted to employees vests over four years in three equal installments beginning on the second anniversary of the date of grant. The fair value of restricted stock is determined based on the closing bid price of the Company’s common stock on the grant date.  Under Company policy, shares held by outside directors and senior management are subject to certain holding restrictions and anti-pledging activities.

No options have been issued subsequent to 2008 and all outstanding options are fully vested.  Options were granted at market value on the date of the grant and vested over four years.  Outstanding options have a term of ten years from the date of grant.

Other information pertaining to share-based activity during the three months ended March 31, 2015 and 2014 was as follows (in thousands):

	Three Months Ended March 31,
	2015		2014
Share-based compensation expense	$	3,709	$	2,458
Fair value of shares vested	11,474		9,175
Cash received from option exercises	1,746		488
Tax benefit from option exercises	3,317		1,727

As of March 31, 2015, the Company had total unrecognized compensation cost of approximately $24.9 million related to non-vested awards, which the Company expects to recognize through 2018 and over a weighted average period of 1.4 years.

For the three months ended March 31, 2015 and 2014, there were no options that were anti-dilutive.

A summary of the status of non-vested restricted shares at March 31, 2015 and changes during the three months ended March 31, 2015 is as follows:

			Weighted
	Number		Average
	of Shares		Grant Price
Non-vested shares at December 31, 2014	668,109		$	33.51
Shares granted	295,527		55.40
Shares vested	(208,701	)	26.62
Shares forfeited	(5,328	)	35.06
Non-vested shares at March 31, 2015	749,607		$	44.05

In addition to the non-vested restricted shares, during the three months ended March 31, 2015, the Company granted 68,945 performance-based restricted stock units to certain of its officers and physician employees. The fair value of our common stock on the grant date of these performance-based units was $55.40. The vesting of these restricted stock units is contingent on the Company’s achievement of a specified one-year financial performance goal for the year ended December 31, 2015. The performance-based restricted stock units will vest ratably over a three year period from the grant date. If the financial performance goal is not achieved, the restricted stock units will be forfeited. The number of performance-based units that ultimately vest will range from 0% to 150% of the units granted, depending on the Company’s level of achievement with respect to the financial performance goal. At March 31, 2015, the Company believes the performance-based units will vest at approximately 100%.

17

Item 1. Financial Statements - (continued) Table of Contents

A summary of stock option activity for the three months ended March 31, 2015 is summarized as follows:

					Weighted
			Weighted		Average
			Average		Remaining
	Number		Exercise		Contractual
	of Shares		Price		Term (in years)
Outstanding at December 31, 2014	158,721		$	22.89	1.7
Options exercised with total intrinsic value of $2.9 million	(76,962	)	22.68
Options terminated	(5,000	)	25.76
Outstanding, Vested and Exercisable at March 31, 2015 with an aggregate intrinsic value of $3.0 million	76,759		$	22.92	0.7

The aggregate intrinsic value represents the total pre-tax intrinsic value received by the option holders on the exercise date or that would have been received by the option holders had all holders of in-the-money outstanding options at March 31, 2015 exercised their options at the Company’s closing stock price on March 31, 2015.

d. Earnings per Share

Basic net earnings attributable to AmSurg Corp. common stockholders, per common share, excludes dilution and is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to AmSurg common stockholders, per common share is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable (1) upon the vesting of restricted stock awards as determined under the treasury stock method and (2) upon conversion of the Company's 5.250% Mandatory Convertible Preferred Stock as determined under the if-converted method. For purposes of calculating diluted earnings per share, preferred stock dividends have been subtracted from both net earnings from continuing operations attributable to AmSurg Corp. and net earnings attributable to AmSurg Corp. common shareholders in periods in which utilizing the if-converted method would be anti-dilutive. For the three months ended March 31, 2015, approximately 3.2 million common share equivalents related to the Mandatory Convertible Preferred Stock were anti-dilutive and therefore are excluded from the dilutive weighted average number of shares outstanding.

The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts):

	Three Months Ended March 31,
	Earnings		Shares	Per Share
	(Numerator)		(Denominator)	Amount
2015:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	18,774	47,572	$	0.39
Effect of dilutive securities, options and non-vested shares	—		333
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	18,774	47,905	$	0.39
2014:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	17,392	31,716	$	0.55
Effect of dilutive securities, options and non-vested shares	—		404
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	17,392	32,120	$	0.54

18

Item 1. Financial Statements - (continued) Table of Contents

(11)  Income Taxes

The Company files a consolidated federal income tax return.  Income taxes are accounted for under the asset and liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes.  In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its consolidated statement of earnings.  The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.

The Company and its subsidiaries file U.S. federal and various state tax returns.  With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2011.

(12)  Commitments and Contingencies

Litigation

From time to time the Company is named as a party to legal claims and proceedings in the ordinary course of business. The Company's management is not aware of any claims or proceedings that are expected to have a material adverse impact on the Company's consolidated financial condition, results of operations or cash flows.

Insurance Programs

Given the nature of the services provided, the Company and its subsidiaries are subject to professional and general liability claims and related lawsuits in the ordinary course of business. The Company maintains professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. In addition, the captive provides stop loss coverage for the Company’s self-insured employee health program. The assets, liabilities and results of operations of the wholly-owned captive are consolidated in the accompanying consolidated financial statements. The liabilities for self-insurance in the accompanying consolidated balance sheets include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. The Company also obtains professional liability insurance on a claims-made basis from third party insurers for its surgery centers and certain of its owned practices and employed physicians.

The Company’s reserves for professional liability claims within the self-insured retention are based upon periodic actuarial calculations. These actuarial estimates consider historical claims frequency and severity, loss development patterns and other actuarial assumptions and are not discounted to present value.

The Company also maintains insurance for director and officer liability, workers’ compensation liability and property damage.  Certain policies are subject to deductibles.  In addition to the insurance coverage provided, the Company indemnifies its officers and directors for actions taken on behalf of the Company and its subsidiaries. 

Redeemable Noncontrolling Interests

Certain of the Company’s wholly-owned subsidiaries, as general partners in the LPs, are responsible for all debts incurred but unpaid by the LPs. As manager of the operations of the LPs, the Company has the ability to limit potential liabilities by curtailing operations or taking other operating actions.

In the event of a change in current law that would prohibit the physicians’ current form of ownership in the partnerships, the Company would be obligated to purchase the physicians’ interests in a substantial majority of the Company’s partnerships.  The purchase price to be paid in such event would be determined by a pre-defined formula, as specified in the partnership agreements.  The Company believes the likelihood of a change in current law that would trigger such purchases was remote as of March 31, 2015. As a result, the

19

Item 1. Financial Statements - (continued) Table of Contents

noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets.

Physician Services Division Headquarters Operating Lease

On January 16, 2015, the Company entered into an agreement to lease approximately 222,000 square feet of office space in Plantation, Florida which it intends to be the future headquarters of the Company’s Physician Services Division. The Company expects to occupy approximately 167,000 square feet of office space by September 1, 2016 and an additional approximately 55,000 square feet of space commencing May 1, 2017. The initial term of this lease agreement is set to expire in February 2029. The Company expects to take possession in June of 2015 to begin tenant improvements. As the lease is expected to be operating in nature, the Company will begin to recognize rent expense on a straight line basis when possession is obtained. Annual rent expense is expected to be approximately $2.7 million.

(13) Segment Reporting

Prior to the Sheridan acquisition, the Company operated its centers as individual components of one operating and reportable segment. Upon completion of the Sheridan acquisition, the Company operates in two major lines of business - the operation of ambulatory surgery centers and providing multi-specialty outsourced physician services, which have been identified as its operating and reportable segments. Through the ambulatory services segment, the Company acquires, develops and operates ambulatory surgery centers in partnership with physicians. Through the physician services segment, the Company provides outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, children’s services, emergency medicine and radiology.

The Company’s financial information by operating segment is prepared on an internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the performance of the operating segments. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker which is its Chief Executive Officer. The following table presents financial information for each reportable segment (in thousands):

	Three Months Ended March 31,
	2015			2014
Net Revenue:
Ambulatory Services	$	283,910		$	259,561
Physician Services	286,535			—
Total	$	570,445		$	259,561
Adjusted EBITDA:
Ambulatory Services	$	47,308		$	46,006
Physician Services	46,447			—
Total	$	93,755		$	46,006
Adjusted EBITDA:	$	93,755		$	46,006
Earnings from continuing operations attributable to noncontrolling interests	47,717			42,654
Interest expense, net	(30,247		)	(6,960		)
Depreciation and amortization	(22,818		)	(8,259		)
Share-based compensation	(3,709		)	(2,458		)
Transaction costs	(1,471		)	—
Gain (loss) on deconsolidation	(223		)	2,045
Earnings from continuing operations before income taxes	$	83,004		$	73,028
Acquisition and Capital Expenditures:
Ambulatory Services	$	54,096		$	12,076
Physician Services	87,265			—
Total	$	141,361		$	12,076

20

Item 1. Financial Statements - (continued) Table of Contents

(14)  Financial Information for the Company and Its Subsidiaries

The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are senior unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized 100% owned domestic subsidiaries.  The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are guaranteed on a full and unconditional and joint and several basis, with limited exceptions considered customary for such guarantees, including the release of the guarantee when a subsidiary's assets are sold. The following condensed consolidating financial statements present the Company (as parent issuer), the subsidiary guarantors, the subsidiary non-guarantors and consolidating adjustments. These condensed consolidating financial statements have been prepared and presented in accordance with Rule 3-10 of Regulation S-X “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.”  The operating and investing activities of the separate legal entities are fully interdependent and integrated. Accordingly, the results of the separate legal entities are not representative of what the operating results would be on a stand-alone basis.

Condensed Consolidating Balance Sheet - March 31, 2015 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Assets
Current assets:
Cash and cash equivalents	$	30,118	$	38,681	$	47,357	$	—		$	116,156
Restricted cash and marketable securities	—		—		10,957		—			10,957
Accounts receivable, net	—		130,807		113,195		—			244,002
Supplies inventory	—		286		20,187		—			20,473
Prepaid and other current assets	51,155		32,196		19,729		(5,719		)	97,361
Total current assets	81,273		201,970		211,425		(5,719		)	488,949
Property and equipment, net	11,910		8,665		162,871		—			183,446
Investments in and receivables from unconsolidated affiliates	4,025,683		1,635,845		—		(5,582,217		)	79,311
Goodwill	—		1,549,964		—		1,950,704			3,500,668
Intangible assets, net	66,001		1,237,487		2,779		—			1,306,267
Other assets	3,734		1,040		20,594		—			25,368
Total assets	$	4,188,601	$	4,634,971	$	397,669	$	(3,637,232	)	$	5,584,009
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	8,700	$	—	$	10,158	$	—		$	18,858
Accounts payable	2,255		224		28,256		(4,927		)	25,808
Accrued salaries and benefits	19,652		111,525		13,430		—			144,607
Accrued interest	17,840		—		17		—			17,857
Other accrued liabilities	7,272		39,909		29,312		(792		)	75,701
Total current liabilities	55,719		151,658		81,173		(5,719		)	282,831
Long-term debt	2,204,775		—		56,204		(30,985		)	2,229,994
Deferred income taxes	218,564		429,880		—		—			648,444
Other long-term liabilities	7,867		65,622		18,996		—			92,485
Intercompany payable	—		1,228,136		21		(1,228,157		)	—
Noncontrolling interests – redeemable	—		—		62,793		120,666			183,459
Equity:
Total AmSurg Corp. equity	1,701,676		2,759,675		132,731		(2,892,406		)	1,701,676
Noncontrolling interests – non-redeemable	—		—		45,751		399,369			445,120
Total equity	1,701,676		2,759,675		178,482		(2,493,037		)	2,146,796
Total liabilities and equity	$	4,188,601	$	4,634,971	$	397,669	$	(3,637,232	)	$	5,584,009

21

Item 1. Financial Statements - (continued) Table of Contents

Condensed Consolidating Balance Sheet - December 31, 2014 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Assets
Current assets:
Cash and cash equivalents	$	134,351	$	23,471	$	50,257	$	—		$	208,079
Restricted cash and marketable securities	—		—		10,219		—			10,219
Accounts receivable, net	—		123,772		109,281		—			233,053
Supplies inventory	—		301		19,673		—			19,974
Prepaid and other current assets	47,997		58,388		13,795		(4,818		)	115,362
Total current assets	182,348		205,932		203,225		(4,818		)	586,687
Property and equipment, net	10,391		9,972		160,085		—			180,448
Investments in and receivables from unconsolidated affiliates	3,912,804		1,587,881		—		(5,425,210		)	75,475
Goodwill	—		1,490,981		—		1,890,168			3,381,149
Intangible assets, net	67,678		1,203,218		2,983		—			1,273,879
Other assets	3,323		943		23,086		(1,466		)	25,886
Total assets	$	4,176,544	$	4,498,927	$	389,379	$	(3,541,326	)	$	5,523,524
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	8,700	$	—	$	10,126	$	—		$	18,826
Accounts payable	1,849		35		31,781		(4,080		)	29,585
Accrued salaries and benefits	25,035		101,395		13,614		—			140,044
Accrued interest	29,621		—		23		—			29,644
Other accrued liabilities	8,051		44,305		16,368		(738		)	67,986
Total current liabilities	73,256		145,735		71,912		(4,818		)	286,085
Long-term debt	2,206,950		—		53,648		(28,412		)	2,232,186
Deferred income taxes	209,400		425,546		—		(1,466		)	633,480
Other long-term liabilities	7,391		63,616		18,436		—			89,443
Intercompany payable	—		1,219,979		8,010		(1,227,989		)	—
Noncontrolling interests – redeemable	—		—		63,544		120,555			184,099
Equity:
Total AmSurg Corp. equity	1,679,547		2,644,051		130,206		(2,774,257		)	1,679,547
Noncontrolling interests – non-redeemable	—		—		43,623		375,061			418,684
Total equity	1,679,547		2,644,051		173,829		(2,399,196		)	2,098,231
Total liabilities and equity	$	4,176,544	$	4,498,927	$	389,379	$	(3,541,326	)	$	5,523,524

22

Item 1. Financial Statements - (continued) Table of Contents

Condensed Consolidating Statement of Earnings - For the Three Months Ended March 31, 2015 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	7,091		$	285,579		$	286,629		$	(8,854	)	$	570,445
Operating expenses:
Salaries and benefits	17,643			211,601			73,063			(128		)	302,179
Supply cost	—			396			42,188			—			42,584
Other operating expenses	6,634			29,611			63,051			(8,726		)	90,570
Transaction costs	268			1,203			—			—			1,471
Depreciation and amortization	834			14,307			7,677			—			22,818
Total operating expenses	25,379			257,118			185,979			(8,854		)	459,622
Loss on deconsolidation	(188		)	(188		)	(35		)	188			(223		)
Equity in earnings of unconsolidated affiliates	60,387			54,583			—			(112,319		)	2,651
Operating income	41,911			82,856			100,615			(112,131		)	113,251
Interest expense, net	11,886			17,754			607			—			30,247
Earnings from operations before income taxes	30,025			65,102			100,008			(112,131		)	83,004
Income tax expense	8,987			4,903			359			—			14,249
Net earnings	21,038			60,199			99,649			(112,131		)	68,755
Net earnings attributable to noncontrolling interests	—			—			47,717			—			47,717
Net earnings attributable to AmSurg Corp. shareholders	21,038			60,199			51,932			(112,131		)	21,038
Preferred stock dividends	(2,264		)	—			—			—			(2,264		)
Net earnings attributable to AmSurg Corp. common shareholders	$	18,774		$	60,199		$	51,932		$	(112,131	)	$	18,774

23

Item 1. Financial Statements - (continued) Table of Contents

Condensed Consolidating Statement of Earnings - For the Three Months Ended March 31, 2014 (In thousands)
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Net revenue	$	6,127		$	—	$	258,043	$	(4,609	)	$	259,561
Operating expenses:
Salaries and benefits	14,485			—		67,785		(121		)	82,149
Supply cost	—			—		37,805		—			37,805
Other operating expenses	4,166			—		54,491		(4,488		)	54,169
Depreciation and amortization	825			—		7,434		—			8,259
Total operating expenses	19,476			—		167,515		(4,609		)	182,382
Gain on deconsolidation	2,045			2,045		—		(2,045		)	2,045
Equity in earnings of unconsolidated affiliates	48,052			48,052		—		(95,340		)	764
Operating income	36,748			50,097		90,528		(97,385		)	79,988
Interest expense	6,452			—		508		—			6,960
Earnings from continuing operations before income taxes	30,296			50,097		90,020		(97,385		)	73,028
Income tax expense	12,704			—		278		—			12,982
Net earnings from continuing operations	17,592			50,097		89,742		(97,385		)	60,046
Net earnings (loss) from discontinued operations	(397		)	—		465		—			68
Net earnings	17,195			50,097		90,207		(97,385		)	60,114
Net earnings attributable to noncontrolling interests	—			—		42,919		—			42,919
Net earnings attributable to AmSurg Corp. common shareholders	$	17,195		$	50,097	$	47,288	$	(97,385	)	$	17,195
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	17,592		$	50,097	$	47,088	$	(97,385	)	$	17,392
Discontinued operations, net of income tax	(397		)	—		200		—			(197		)
Net earnings attributable to AmSurg Corp. common shareholders	$	17,195		$	50,097	$	47,288	$	(97,385	)	$	17,195

24

Item 1. Financial Statements - (continued) Table of Contents

Condensed Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2015 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by (used in) operating activities	$	(33,779	)	$	91,981		$	102,821		$	(62,196	)	$	98,827
Cash flows from investing activities:
Acquisitions and related expenses	(62,056		)	(127,047		)	—			62,525			(126,578		)
Acquisition of property and equipment	(2,678		)	(2,538		)	(9,567		)	—			(14,783		)
Other	—			(1,322		)	1,102			—			(220		)
Net cash flows used in investing activities	(64,734		)	(130,907		)	(8,465		)	62,525			(141,581		)
Cash flows from financing activities:
Proceeds from long-term borrowings	—			—			2,227			—			2,227
Repayment on long-term borrowings	(2,175		)	—			(3,038		)	—			(5,213		)
Distributions to owners, including noncontrolling interests	—			(10,241		)	(99,157		)	62,196			(47,202		)
Capital contributions	—			62,056			—			(62,056		)	—
Cash dividends for preferred shares	(2,264		)	—			—			—			(2,264		)
Changes in intercompany balances with affiliates, net	(2,573		)	—			2,573			—			—
Other financing activities, net	1,292			2,321			139			(469		)	3,283
Net cash flows provided by (used in) financing activities	(5,720		)	54,136			(97,256		)	(329		)	(49,169		)
Net increase (decrease) in cash and cash equivalents	(104,233		)	15,210			(2,900		)	—			(91,923		)
Cash and cash equivalents, beginning of period	134,351			23,471			50,257			—			208,079
Cash and cash equivalents, end of period	$	30,118		$	38,681		$	47,357		$	—		$	116,156

25

Item 1. Financial Statements - (continued) Table of Contents

Condensed Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2014 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	18,482		$	48,096		$	96,257		$	(93,016	)	$	69,819
Cash flows from investing activities:
Acquisitions and related expenses	—			(5,082		)	—			44			(5,038		)
Acquisition of property and equipment	(1,237		)	—			(5,801		)	—			(7,038		)
Proceeds from sale of interests in surgery centers	—			1,111			—			—			1,111
Other	(629		)	211			—			—			(418		)
Net cash flows used in investing activities	(1,866		)	(3,760		)	(5,801		)	44			(11,383		)
Cash flows from financing activities:
Proceeds from long-term borrowings	30,000			—			1,945			—			31,945
Repayment on long-term borrowings	(47,679		)	—			(3,174		)	—			(50,853		)
Distributions to owners, including noncontrolling interests	—			(44,920		)	(91,290		)	93,016			(43,194		)
Changes in intercompany balances with affiliates, net	556			—			(556		)	—			—
Other financing activities, net	(641		)	584			43			(44		)	(58		)
Net cash flows used in financing activities	(17,764		)	(44,336		)	(93,032		)	92,972			(62,160		)
Net decrease in cash and cash equivalents	(1,148		)	—			(2,576		)	—			(3,724		)
Cash and cash equivalents, beginning of period	6,710			—			44,130			—			50,840
Cash and cash equivalents, end of period	$	5,562		$	—		$	41,554		$	—		$	47,116

(15)  Subsequent Events

The Company assessed events occurring subsequent to March 31, 2015 for potential recognition and disclosure in the consolidated financial statements.  In April 2015, the Company acquired one physician practice for an aggregate purchase price of approximately $16.5 million. Other than the items described above, no events have occurred that would require adjustment to or disclosure in the consolidated financial statements. 

26

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This report contains certain forward-looking statements (all statements other than with respect to historical fact) within the meaning of the federal securities laws, which are intended to be covered by the safe harbors created thereby.  Investors are cautioned that all forward-looking statements involve known and unknown risks and uncertainties including, without limitation, those described in this report and in our Annual Report on Form 10-K for the year ended December 31, 2014.  Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate.  Therefore there can be no assurance that the forward-looking statements included in this report will prove to be accurate.  Actual results could differ materially and adversely from those contemplated by any forward-looking statement.  In light of the significant risks and uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved.  We undertake no obligation to publicly release any revisions to any forward-looking statements in this discussion to reflect events and circumstances occurring after the date hereof or to reflect unanticipated events.

Forward-looking statements and our liquidity, financial condition and results of operations, may be affected by the following risks and uncertainties and the other risks and uncertainties discussed in this report, in our Annual Report on Form 10-K for the year ended December 31, 2014 under “Item 1A. – Risk Factors” as well as other unknown risks and uncertainties:

• the risk that we may face challenges managing our Physician Services Division as a new business and may not realize anticipated benefits;

• the risk of becoming subject to investigations by federal and state entities and unpredictable impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the Health Reform Law);

• our ability to successfully maintain effective internal controls over financial reporting;

• our ability to implement our business strategy, manage the growth in our business, and integrate acquired businesses;

• the risk that our substantial indebtedness and restrictions in our debt instruments could adversely affect our business or our ability to implement our growth strategy or limit our ability to react to changes in the economy or our industry;

• our ability to generate sufficient cash to service all of our indebtedness, including any future indebtedness;

• the risk of regulatory changes that may obligate us to buy out interests of physicians who are minority owners of our surgery centers;

• our failure to successfully maintain numerous complex information systems and processes, implement new systems and processes, and maintain the security of those systems and processes;

• our failure to effectively and timely transition to the ICD-10 coding system;

• the risk of litigation and investigations, and liability claims for damages and other expenses not covered by insurance;

• potential write-offs of the impaired portion of intangible assets;

• the risk that payments from third-party payors, including government healthcare programs, may decrease or not increase as costs increase;

• adverse developments affecting the medical practices of our physician partners;

• our ability to maintain favorable relations with our physician partners;

• our ability to grow revenues by increasing procedure volume while maintaining operating margins and profitability at our existing surgery centers;

• our ability to compete for physician partners, managed care contracts, patients and strategic relationships;

• adverse weather and other factors beyond our control that may affect our surgery centers;

• our legal responsibility to minority owners of our surgery centers, which may conflict with our interests and prevent us from acting solely in our best interests;

• the risk of changes in patient volume and patient mix;

• the risk related to revenue concentration resulting from several significant client relationships;

• the risk that contracts are cancelled or not renewed or that we are not able to enter into additional contracts under terms that are acceptable to us;

• the risk of potential decreases in our reimbursement rates, revenue and profit margin under our fee for service payor contracts;

• failure to timely or accurately bill for services;

• the risk that laws and regulations that regulate payments for medical services made by government healthcare programs could cause our revenues to decrease;

• our ability to enroll our providers in the Medicare and Medicaid programs on a timely basis;

• the risk that our strategic partnerships with certain healthcare providers are not successful;

27

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

• the high level of competition in our segments of the market for medical services;

• our ability to successfully recruit and retain physicians, nurses and other clinical providers with the qualifications and attributes desired by us and our clients;

• our ability to accurately assess the costs we will incur under new contracts;

• the risk that margins may be negatively impacted by cross-selling to existing clients or selling bundled services to new clients;

• our ability in some jurisdictions to enforce non-compete agreements with our physicians and other clinical employees;

• the risk of unfavorable changes in regulatory, economic and other conditions in the states where we operate;

• the risk that legislative or regulatory action may make our captive insurance company arrangement less feasible or otherwise reduce our profitability; and

• the inherent uncertainties relating to the reserves we establish with respect to our losses covered under our insurance programs.

Executive Overview

Prior to July 16, 2014, our business was solely the acquisition, operation and development of surgery centers in partnership with physicians. On July 16, 2014, we completed the acquisition of Sheridan, a physician services company, in a cash and stock transaction. At closing, we paid approximately $2.1 billion in cash and issued approximately 5.7 million shares of our common stock to the former owners of Sheridan in exchange for all of the outstanding equity interests of Sheridan. The 5.7 million shares of our common stock were valued at approximately $272.0 million in the aggregate based on the closing price of our common stock on July 16, 2014. See “— Liquidity and Capital Resources” for further discussion regarding the impact of the Sheridan transaction and associated financing transactions on our cash flows and debt financings.

Our operations consist primarily of two major divisions, ambulatory services and physician services.

Ambulatory Services Overview

We are the largest owner and operator of outpatient ambulatory surgery centers (ASCs, surgery centers or centers) in the United States based upon total number of surgery centers. We acquire, develop and operate surgery centers in partnership primarily with physicians.  Our surgery centers are typically located adjacent to or in close proximity to the medical practices of our partner physicians. At March 31, 2015, we operated 248 ASCs in 34 states and the District of Columbia in partnership with approximately 2,000 physicians. We generally own a majority interest, primarily 51%, in the surgery centers we operate. We also own a minority interest in certain surgery centers in partnerships with leading health systems and physicians and intend to continue to pursue such partnerships.

Of the continuing centers in operation at March 31, 2015, 150 centers performed gastrointestinal endoscopy procedures, 51 centers performed procedures in multiple specialties, 38 centers performed ophthalmology procedures and 9 centers performed orthopaedic procedures.

Physician Services Overview

We are a leading national provider of multi-specialty outsourced physician services to hospitals, ASCs and other healthcare facilities. At March 31, 2015, we delivered physician services, primarily in the areas of anesthesiology, children’s services, radiology and emergency medical services, to more than 330 healthcare facilities in 27 states. We receive reimbursement from third-party payors for fee for service medical services rendered by our affiliated healthcare professionals and employees to the patients who receive medical treatment at these facilities. In addition to this primary form of reimbursement, in certain cases, we also receive contract revenue directly from the facilities where we perform our services through a variety of payment arrangements that are established when reimbursement from third-party payors is inadequate to support the costs of providing our services. We also provide physician services and manage office-based practices in the areas of gynecology, obstetrics and perinatology. At March 31, 2015, we employed more than 2,900 physicians and other healthcare professionals in our physician services business who apply a care centric approach to medical care. At March 31, 2015, we owned physician practices in 27 states, with a significant presence in Florida, New Jersey, Texas and California.

Operating Environment

Our ASCs and physician services depend upon third-party reimbursement programs, including governmental and private insurance programs, to pay for substantially all of the services rendered to patients. For the three months ended March 31, 2015, we derived approximately 25% and 18%, respectively, of our ambulatory services and physician services net revenue from governmental healthcare programs, primarily Medicare and managed Medicare programs, and the remainder from a wide mix of commercial payors and patient co-pays and deductibles.  The Medicare program currently reimburses physician services and ASCs in accordance with

28

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

predetermined fee schedules.  We are not required to file cost reports for our centers or physician services and, accordingly, we have no unsettled amounts from governmental third-party payors.

ASCs are paid under the Medicare program based upon a percentage of the payments to hospital outpatient departments pursuant to the hospital outpatient prospective patient system and reimbursement rates for ASCs are increased annually based on increases in the consumer price index (CPI). Effective for federal fiscal year (FFY) 2011 and subsequent years the Health Reform Law provides for the annual CPI increases applicable to ASCs to be reduced by a productivity adjustment, which is based on historical nationwide productivity gains. In 2014, ASC reimbursement rates increased by 1.2%, which positively impacted our 2014 ambulatory services revenues by approximately $6.5 million, net of the continued effects of sequestration, as discussed below. In 2015, ASC reimbursement rates increased by 1.9%, which we estimate will positively impact our 2015 ambulatory services revenues by approximately $9.0 million. There can be no assurance that the Centers for Medicare and Medicaid Services will not revise the ASC payment system or that any annual CPI increases will be material. 

Physician services are paid under the Medicare program based upon the Medicare Physician Fee Schedule (MPFS), under which CMS has assigned a national relative value unit (RVU) to most medical procedures and services that reflects the various resources required by a physician to provide the services relative to all other services. Each RVU is calculated based on a combination of work required in terms of time and intensity of effort for the service, practice expense (overhead) attributable to the service and malpractice insurance expense attributable to the service. These three elements are each modified by a geographic adjustment factor to account for local practice costs, then aggregated. Historically, the aggregated amount was multiplied by a conversion factor calculated by the sustainable growth rate (SGR) to arrive at the payment amount for each service. In April 2015, the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) repealed the SGR physician payment methodology. Instead of tying payments to the SGR, MACRA provides for a 0% update to the MPFS through June 2015 and a 0.5% payment update for July 1, 2015 through December 31, 2015 and for each calendar year thereafter through 2019. In addition, MACRA requires the establishment of the Merit-Based Incentive Payment System (MIPS) beginning in 2019, under which physicians will receive performance-based payment incentives or payment reductions based on their performance with respect to clinical quality, resource use, clinical improvement activities, and meaningful use of electronic health records. MIPS will consolidate certain existing physician incentive programs, including payments to physicians for the meaningful use of electronic health records. MACRA also requires CMS beginning in 2019 to provide incentive payments for physicians and other eligible professionals that participate in alternative payment models, such as accountable care organizations.

In November 2012, CMS adopted a rule under the Health Reform Law that generally allows physicians in certain specialties who provide eligible primary care services to be paid at the Medicare reimbursement rates in effect in calendar years 2013 and 2014 instead of state-established Medicaid reimbursement rates (Medicaid-Medicare Parity). Generally, state Medicaid reimbursement rates are lower than federally established Medicare rates. During 2013, state agencies were required to submit their state plan amendments (SPAs) outlining how they will implement the rule, including frequency and timing of payments to CMS for review and approval. In December 2013, CMS indicated that all SPAs had been approved for enhanced Medicaid-Medicare Parity reimbursement through December 2014. Legislation has been proposed and has passed in certain states to extend Medicaid-Medicare Parity for calendar year 2015. Accordingly, we estimate our 2015 Medicaid program revenues will be reduced by approximately $3.4 million compared to a full fiscal 2014 if Medicaid-Medicare Parity is not extended for 2015.

The Budget Control Act of 2011 (BCA) requires automatic spending reductions of $1.2 trillion for FFYs 2013 through 2021, minus any deficit reductions enacted by Congress and debt service costs. The percentage reduction for Medicare may not be more than 2% for a FFY, with a uniform percentage reduction across all Medicare programs. These BCA-mandated spending cuts are commonly referred to as “sequestration.” Sequestration began on March 1, 2013, and CMS imposed a 2% reduction on Medicare claims as of April 1, 2013. These reductions have been extended through FFY 2024. We cannot predict with certainty what other deficit reduction initiatives may be proposed by Congress, whether Congress will attempt to restructure or suspend sequestration or the impact sequestration may have on our centers. 

The Health Reform Law represents significant change across the healthcare industry and contains a number of provisions designed to reduce Medicare program spending. However, the Health Reform Law also expands coverage of uninsured individuals through a combination of public program expansion and private sector health insurance reforms.  For example, the Health Reform Law has expanded eligibility under existing Medicaid programs in states that have not opted out of the expansion, created financial penalties on individuals who fail to carry insurance coverage, established affordability credits for those not enrolled in an employer-sponsored health plan, resulted in the establishment of, or participation in, a health insurance exchange for each state and allowed states to create federally funded, non-Medicaid plans for low-income residents not eligible for Medicaid.  The Health Reform Law also required a number of private health insurance market reforms, including a ban on lifetime limits and pre-existing condition exclusions, new benefit mandates and increased dependent coverage.

29

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Many health plans are required to cover, without cost-sharing, certain preventive services designated by the U.S. Preventive Services Task Force, including screening colonoscopies.  Medicare now covers these preventive services without cost-sharing, and states that provide Medicaid coverage of these preventive services without cost-sharing receive a one percentage point increase in their federal medical assistance percentage for these services.

Health insurance market reforms that expand insurance coverage may result in an increased volume of certain procedures at our centers. Most of the provisions of the Health Reform Law that are reducing the number of uninsured individuals are in effect, but, the employer mandate, which requires firms with 50 or more full-time employees to offer health insurance or pay fines, will not be fully implemented until January 1, 2016. Also, the federal online insurance marketplace and certain state exchanges experienced significant technical issues during their initial implementation that negatively impacted the ability of individuals to purchase health insurance. Additional implementation issues could lead to suspension of the individual mandate tax penalties, delays in individuals obtaining health insurance and a reduction in the number of individuals choosing to purchase health insurance rather than paying the individual mandate tax penalties.

Because of the many variables involved, including the law’s complexity, lack of implementing definitive regulations or interpretive guidance, gradual or partially delayed implementation, court challenges, amendments, repeal, or further implementation delays, we are unable to predict the net effect of the reductions in Medicare spending, the expected increases in revenues from increased procedure volumes, and numerous other provisions in the law that may affect us. We are further unable to foresee how individuals and employers will respond to the choices afforded them by the Health Reform Law. Thus, we cannot predict the full impact of the Health Reform Law on us at this time.

Critical Accounting Policies

A summary of significant accounting policies is disclosed in our 2014 Annual Report on Form 10-K.  Our critical accounting policies are further described under the caption “Critical Accounting Policies” in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2014 Annual Report on Form 10-K. There have been no changes in the nature of our critical accounting policies or the application of those policies since December 31, 2014.

Results of Operations

Our consolidated statement of earnings includes the results of both our ambulatory services segment and our physician services segment. Our consolidated revenue consists of both facility fees charged for surgical procedures performed in our ASCs and fee for service revenue, contract revenue and other revenue derived principally from the provision of physician services to patients of the healthcare facilities we serve through our physician services segment. Additionally, at certain of our centers (primarily centers that perform gastrointestinal endoscopy procedures), we charge for anesthesia services provided by medical professionals employed or contracted by our centers. As it relates to our ambulatory services segment, we generally own less than 100% of each of the entities that own the centers, and our consolidated statements of earnings include 100% of the results of operations of each of our consolidated entities, reduced by the noncontrolling partners’ share of the net earnings or loss of the surgery center entities.  The noncontrolling ownership interest in each LP or LLC is generally held directly or indirectly by physicians who perform procedures at the center.  With few exceptions, we generally own 100% of the entities included in our physician services segment. On a consolidated basis, our share of the profits and losses of non-consolidated entities is reported in equity in earnings of unconsolidated affiliates in our consolidated statement of earnings. 

Our revenues are influenced by national surgery trends, hospital specific factors, and other factors affecting patient needs for medical services. National surgery trends can change based on changes in patient utilization, population growth and demographics, weather related disruptions, as well as general economic factors. We believe patient utilization can be affected by changes in the portion of medical costs for which the patients themselves bear financial responsibility, by general economic conditions, and by other factors. Hospital-specific elements include changes in local availability of alternative sites of care to the patient, changes in surgeon utilization of the facility, construction and regulations that affect patient flow through the hospital.

Our ambulatory services revenues are directly related to the number of procedures performed at our centers.  Our overall growth in ASC procedure volume is impacted directly by the increase in the number of centers in operation and the growth in procedure volume at existing centers. We increase our number of centers through both acquisitions and developments. Procedure growth at an existing center may result from additional contracts entered into with third-party payors, increased numbers of procedures performed by our physician partners, additional physicians utilizing the center and/or scheduling and operating efficiencies gained at the surgery center.

Our physician services revenues consist of fee for service revenue, contract revenue and other revenue. Fee for service revenue is generated through the provision of anesthesiology, children's services, radiology and emergency medical services at the healthcare

30

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

facilities we serve. Contract revenue reflects payments received or receivable directly from certain of the facilities where we provide medical services, and typically arise in cases where our reimbursement from third-party payors is not sufficient to cover the costs of our medical services. We also earn other revenue for certain ancillary services performed.

Expenses associated with our ambulatory services segment relate directly and indirectly to procedures performed at our centers and include clinical and administrative salaries and benefits, supply cost and other operating expenses such as linen cost, repair and maintenance of equipment, billing fees and bad debt expense. The majority of our salary and benefits cost is associated directly with the number of centers we own and manage and tends to grow in proportion to the growth in our number of centers in operation. We also incur operating expenses resulting from our corporate oversight which includes salaries and benefits of our operators and administrative support infrastructure. Our centers also incur costs that are more fixed in nature, such as lease expense, legal fees, property taxes, utilities and depreciation and amortization.

Salaries and benefits expense is a significant component of the total expenses associated with our physician services segment and includes compensation and benefits for our employed physicians and other professional providers as well as the salaries and benefits of our administrative support staff. Other operating expenses of our physician services segment includes professional liability costs, costs of business development and marketing, information technology, dues and licenses, occupancy costs and other administrative functions that are indirectly related to the operations of our physician group practices. Our professional liability costs include provisions for paid and estimated losses for actual claims and estimates of claims likely to be incurred in the period, based on our past loss experience and actuarial analysis provided by a third party, as well as actual direct costs, including investigation and defense costs, and other costs related to provider professional liability. We have grown and plan to continue to expand our investment in administrative support initiatives as a result of our planned future growth from new contracts and acquisitions.

Our depreciation expense relates primarily to charges for equipment and leasehold improvements. Amortization expense relates primarily to intangible assets recorded for customer relationships, computer software and hardware, and other technologies arising from acquisitions that we have made.

Profits are allocated to our noncontrolling partners in proportion to their individual ownership percentages and reflected in the aggregate as total net earnings attributable to noncontrolling interests and are presented after net earnings. The noncontrolling partners are typically organized as general partnerships, LPs or LLCs that are not subject to federal income tax. Each noncontrolling partner shares in the pre-tax earnings of the entity of which it is a partner. Accordingly, net earnings attributable to the noncontrolling interests in each of our LPs and LLCs are generally determined on a pre-tax basis, and pre-tax earnings are presented before net earnings attributable to noncontrolling interests have been subtracted.

The effective tax rate on pre-tax earnings as presented is approximately 17% for the three months ended March 31, 2015. However, after removing the earnings attributable to non-controlling interest, our adjusted effective tax rate generally increases to approximately 40%. We file a consolidated federal income tax return and numerous state income tax returns with varying tax rates.  Our income tax expense reflects the blending of these rates.

Our interest expense results primarily from our borrowings used to fund acquisition and development activity, as well as interest incurred on capital leases and the amortization of deferred financing costs.

31

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Consolidated Operations

The following table shows certain statement of earnings items expressed as a percentage of revenues for the three months ended March 31, 2015 and 2014. The operating results of Sheridan are included in our operating results effective July 16, 2014.

	Three Months Ended March 31,
	2015		2014
Net revenue	100.0	%	100.0	%
Operating expenses:
Salaries and benefits	53.0		31.6
Supply cost	7.5		14.6
Other operating expenses	15.9		20.9
Transaction costs	0.3		—
Depreciation and amortization	4.0		3.2
Total operating expenses	80.6		70.3
Gain (loss) on deconsolidation	—		0.8
Equity in earnings of unconsolidated affiliates	0.5		0.3
Operating income	19.9		30.8
Interest expense, net	5.3		2.7
Earnings from continuing operations before income taxes	14.6		28.1
Income tax expense	2.5		5.0
Net earnings	12.1		23.2
Net earnings attributable to noncontrolling interests	8.4		16.5
Net earnings attributable to AmSurg Corp. shareholders	3.7	%	6.6	%

Quarter Ended March 31, 2015 compared to Quarter Ended March 31, 2014

We experienced significant changes in our consolidated operations during the three months ended March 31, 2015 as compared to the three months ended March 31, 2014, primarily as a result of the following:

• our operating results for the three months ended March 31, 2015 include the operating results of Sheridan, which are not included in the prior quarter results;

• we incurred additional interest expense associated with the debt financing required to complete the acquisition of Sheridan;

• we completed acquisitions in both our Ambulatory Services and Physician Services Divisions; and

• we experienced positive same center and contract organic growth during the period.

Net revenue increased $310.9 million, or 119.8%, to $570.4 million in the three months ended March 31, 2015 from $259.6 million in the three months ended March 31, 2014. Our consolidated net revenue was impacted primarily due to the following:

• an increase of $286.5 million associated with the business acquired from Sheridan; and

• an increase of $24.3 million associated with our Ambulatory Services Division.

Operating income increased $33.3 million, or 41.6%, to $113.3 million during the three months ended March 31, 2015, from $80.0 million in the three months ended March 31, 2014. Our operating income was impacted during the three months ended March 31, 2015 primarily due to the following:

• an increase of $30.0 million associated with the business acquired from Sheridan; and

• an increase of $2.3 million associated with results of our Ambulatory Services Division.

Interest expense increased to $30.2 million in the three months ended March 31, 2015 from $7.0 million in the three months ended March 31, 2014, primarily due to increased indebtedness as a result of the financings associated with the acquisition of Sheridan during the year ended December 31, 2014. See “- Liquidity and Capital Resources.” for additional information.

We recognized income tax expense of $14.2 million for the three months ended March 31, 2015, compared to $13.0 million in the three months ended March 31, 2014. Our effective tax rate during the three months ended March 31, 2015 was approximately 17.2%

32

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

of earnings from continuing operations. This differs from the federal statutory income tax rate of 35.0% primarily due to the exclusion of the noncontrolling interests’ share of pre-tax earnings and the impact of state income taxes.

Noncontrolling interests in net earnings for the three months ended March 31, 2015 increased $4.8 million from the three months ended March 31, 2014, primarily as a result of noncontrolling interests in earnings at surgery centers recently added to operations. All of the results of operations related to noncontrolling interests relate to our ownership of ASCs. Due to the inclusion of Sheridan's revenue in the three months ended March 31, 2015, noncontrolling interests in earnings as a percentage of revenues decreased to 8.4% in the three months ended March 31, 2015 from 16.5% in the three months ended March 31, 2014.

Ambulatory Services Operations

The following table presents the number of procedures performed at our continuing centers and changes in the number of ASCs in operation, under development and under letter of intent for the three months ended March 31, 2015 and 2014. An ASC is deemed to be under development when a LP or LLC has been formed with the physician partners to develop the ASC.

	Three Months Ended March 31,
	2015	2014
Procedures performed during the period at consolidated centers	404,519	384,697
Centers in operation at end of period (consolidated)	237	233
Centers in operation at end of period (unconsolidated)	11	4
Average number of continuing centers in operation (consolidated)	235	234
New centers added during the period	2	1
Centers discontinued during the period	—	1
Centers under development end of period	2	1
Centers under letter of intent, end of period	7	7

Of the continuing centers in operation at March 31, 2015, 150 centers performed gastrointestinal endoscopy procedures, 51 centers performed procedures in multiple specialties, 38 centers performed ophthalmology procedures and 9 centers performed orthopaedic procedures.

A significant measurement of how much our ambulatory services revenues grow from year to year for existing centers is our ambulatory services same-center revenue percentage. We define our same-center group each year as those centers that contain full year-to-date operations in both comparable reporting periods, including the expansion of the number of operating centers associated with a LP or LLC. Ambulatory services revenues at our 2015 same-center group, comprising 229 centers and constituting approximately 97% of our total number of consolidated centers, increased by 3.6% during the three months ended March 31, 2015 compared to the prior year period.

The following table presents selected statement of earnings data expressed in dollars (in thousands) and as a percentage of net revenue for our ambulatory services segment.

	Three Months Ended March 31,
	2015					2014
Net revenue	$	283,910		100.0	%	$	259,561	100.0	%
Operating expenses:
Salaries and benefits	89,796			31.6		82,149		31.6
Supply cost	42,188			14.9		37,805		14.6
Other operating expenses	60,359			21.3		54,169		20.9
Transaction costs	268			0.1		—		—
Depreciation and amortization	8,511			3.0		8,259		3.2
Total operating expenses	201,122			70.8		182,382		70.3
Gain (loss) on deconsolidation	(223		)	(0.1	)	2,045		0.8
Equity in earnings of unconsolidated affiliates	679			0.2		764		0.3
Operating income	$	83,244		29.3	%	$	79,988	30.8	%

33

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

Quarter Ended March 31, 2015 compared to Quarter Ended March 31, 2014

The number of procedures performed in our ASCs increased by 19,822, or 5.2%, to 404,519 in the three months ended March 31, 2015 from 384,697 in the three months ended March 31, 2014. Ambulatory services revenues increased $24.3 million, or 9.4%, to $283.9 million, in the three months ended March 31, 2015 from $259.6 million in the three months ended March 31, 2014. Our ambulatory services revenues were impacted during the three months ended March 31, 2015 primarily due to the following:

• centers acquired in 2014, which contributed $13.3 million of additional revenues in the three months ended March 31, 2015 due to having a full period of operations in 2015;

• revenue growth of $9.2 million for the three months ended March 31, 2015 recognized by our 2015 same-center group, reflecting a 3.6% increase in our 2015 same-center group;

• a center acquired in 2015, which generated $4.0 million in revenues during the three months ended March 31, 2015; and

• reduced revenue recognized during the three months ended March 31, 2015 of $2.7 million resulting from the deconsolidation of centers that were fully consolidated in the prior period. Our share of the results of operations from the deconsolidated centers are now reflected in equity in earnings in unconsolidated affiliates in our consolidated statement of earnings.

Salaries and benefits increased by $7.6 million, or 9.3%, to $89.8 million in the three months ended March 31, 2015 from $82.1 million in the three months ended March 31, 2014. The increase was a result of staffing at newly acquired and developed centers, as well as the additional staffing required at existing centers.

Supply cost increased $4.4 million, or 11.6%, to $42.2 million in the three months ended March 31, 2015 from $37.8 million in the three months ended March 31, 2014. The increase was primarily due to the additional supply cost of centers acquired in 2014, which were mainly multi-specialty centers that now have a full period of supplies costs as compared to the prior year.

Other operating expenses increased $6.2 million, or 11.4%, to $60.4 million in the three months ended March 31, 2015 from $54.2 million in the three months ended March 31, 2014. The additional expense in the three months ended March 31, 2015 resulted primarily from:

• centers acquired or opened during 2014, which resulted in an increase of $2.7 million in other operating expenses in the three months ended March 31, 2015;

• an increase of $1.6 million in other operating expenses at our 2015 same-center group in the three months ended March 31, 2015; and

• a center acquired during 2015, which resulted in an increase of $0.6 million in other operating expenses in the three months ended March 31, 2015.

During the three months ended March 31, 2015, we incurred $0.3 million of transaction costs as a result of ASC acquisition activity. During the three months ended March 31, 2014, the transaction costs incurred were not significant.

Depreciation and amortization expense increased $0.3 million, or 3.1%, to $8.5 million in the three months ended March 31, 2015 from $8.3 million in the three months ended March 31, 2014, primarily as a result of centers acquired during 2014.

Equity in earnings of unconsolidated affiliates was $0.7 million during the three months ended March 31, 2015 and $0.8 million during the three months ended March 31, 2014. During the three months ended March 31, 2015, we contributed our controlling interest in one center in exchange for a noncontrolling interest in an entity that owned one ASC prior to the transaction and, after the completion of the transaction, controls the contributed center and the center it previously owned. As a result of the transaction, we recognized a net loss on deconsolidation in the accompanying consolidated statements of earnings of approximately $0.2 million during the three months ended March 31, 2015.

Physician Services Operations

We expect to utilize certain measures for our physician services operations to monitor our net revenue growth, which include

same-contract revenue and net new contract revenue. Our same-contract revenue reflects revenue received from services provided through contracts in existence for the entire current period and the entire comparable period. Our net new contract growth reflects revenue growth from new contracts that have not been in effect for both the entire current and comparable periods minus the amount of revenue decline relating to contracts terminated during such periods. Net new contract revenue growth excludes the effect of revenue arising in both comparable periods from acquisitions that were completed during such periods. For the three months ended March 31, 2015 compared to the prior year period, Sheridan experienced contract organic growth of 9.0% which reflects a 6.6%

34

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

increase in same contract revenues and a 2.4% increase in new contract revenues.

We evaluate our physician services revenue net of contractual adjustments and provisions for uncollectible charges. Payors generally receive discounts from standard charges, which we refer to as contractual adjustments. In addition, patients our physicians treat may be personally responsible for the payment of the medical services they receive. Our contracts with hospitals and other facilities typically require us to provide care to all patients who present at our locations. While we seek to bill for all medical services we provide, a portion of our medical services are delivered to patients that have no insurance and for whose treatment we cannot collect full compensation. As a result, we establish a provision for uncollectible charges. Our net revenue from our physician services operations represents gross billings after provisions for contractual allowances and uncollectibles.

The following table shows selected statement of earnings data expressed in dollars (in thousands) and as a percentage of net revenue for our physician services segment for the three months ended March 31, 2015.

	Three Months Ended March 31, 2015 (1)
Net revenue	$	286,535	100.0	%
Operating expenses:
Salaries and benefits	212,383		74.1
Supply cost	396		0.1
Other operating expenses	30,211		10.5
Transaction costs	1,203		0.4
Depreciation and amortization	14,307		5.0
Total operating expenses	258,500		90.2
Equity in earnings of unconsolidated affiliates	1,972		0.7
Operating income	$	30,007	10.5	%

(1) On July 16, 2014, we completed the acquisition of Sheridan. As such, historical amounts for periods prior to that date are not included.

Included in total operating expenses above is approximately $220.4 million incurred for direct practice expenses, which primarily includes salaries and benefits costs of our physicians and other professional medical personnel and is generally higher in the first quarter due to the concentration of additional payroll taxes and other employee benefits during the period.

Also included in depreciation and amortization for our physician services segment is $12.4 million of amortization primarily resulting primarily from amortizable intangible assets related to our customer relationships with hospitals.

Liquidity and Capital Resources

Cash and cash equivalents at March 31, 2015 and December 31, 2014 were $116.2 million and $208.1 million, respectively. The decrease in cash is primarily due to the following:

• completed ambulatory services and physician services acquisitions totaling $126.6 million, which were paid with operating cash; and

• interest payments of $40.0 million, including $30.8 million paid on our 2022 Senior Unsecured Notes and $8.1 million paid on our term loan.

We believe that the cash provided by our operating activities, amounts available under our revolving credit facility and our current cash and cash equivalents will provide us with sufficient liquidity to maintain our current operations, capital expenditures and currently targeted acquisition activity.

At March 31, 2015, we had working capital of $206.1 million, compared to $300.6 million at December 31, 2014. The decrease is primarily due to the cash paid for acquisitions completed during the quarter. Operating activities for the three months ended March 31, 2015 generated $98.8 million in cash flow from operations, compared to $69.8 million for the three months ended March 31, 2014. Additionally, net cash flow provided by operating activities, net of distributions to noncontrolling interests, for the three months ended March 31, 2015 was $51.6 million, compared to $26.6 million for the three months ended March 31, 2014. The increase in operating cash flow resulted primarily from the additional earnings from our Physician Services Division, which we did not operate in the prior year period. Reflective in the operating cash flow is $1.5 million of transaction costs primarily related to recent acquisitions. For our Ambulatory Services Division, positive operating cash flows of individual centers are the sole source of cash used to make distributions to our wholly-owned subsidiaries, as well as to our physician partners, which we are obligated to make on a

35

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

monthly basis in accordance with each partnership’s partnership or operating agreement. Distributions to noncontrolling interests, which is considered a financing activity, were $47.2 million and $43.2 million during the three months ended March 31, 2015 and 2014, respectively.

The principal source of our operating cash flow is the collection of accounts receivable from governmental payors, commercial payors and individuals. Each of our subsidiaries bills for services as delivered, usually within a few days following the date the service is rendered for our Ambulatory Services Division and within five to ten days following the date the service is rendered for our Physician Services Division. Generally, unpaid amounts that are 30 to 45 days past due are rebilled based on a standard set of procedures. If amounts remain uncollected after 60 days, we proceed with a series of late-notice notifications until amounts are either collected, contractually written off in accordance with contracted rates or determined to be uncollectible, typically after 90 to 120 days. Receivables determined to be uncollectible are written off and such amounts are applied to our estimate of allowance for bad debts as previously established in accordance with our policy for bad debt expense. The amount of actual write-offs of account balances for each of our subsidiaries is continuously compared to established allowances for bad debt to ensure that such allowances are adequate. At March 31, 2015 and December 31, 2014, our Ambulatory Services Division net accounts receivable represented 40 and 37 days of revenue outstanding, respectively. At March 31, 2015 and December 31, 2014, our Physician Services Division net accounts receivable represented 40 and 41 days of revenue outstanding, respectively.

During the three months ended March 31, 2015, we had total acquisition and capital expenditures of $141.4 million, which included:

• $84.7 million for the acquisition of physician services practices;

• $41.9 million for the acquisition of an interest in a surgery center; and

• $14.8 million for new or replacement property.

At March 31, 2015, we had unfunded construction and equipment purchase commitments for our new corporate headquarters and for surgery centers under development or under renovation of approximately $5.0 million, which we intend to fund through additional borrowings of long-term debt and operating cash flow.

As of March 31, 2015, we had $30.3 million of restricted cash and marketable securities which is restricted for the purpose of satisfying the obligations of our wholly-owned captive insurance company.

During the three months ended March 31, 2015, we received approximately $1.7 million from the exercise of stock options under our employee stock incentive plans.  The tax benefit received from the exercise of those options and restricted stock vested was approximately $3.3 million.

On July 16, 2014, we completed the acquisition of Sheridan in a cash and stock transaction valued at approximately $2.35 billion. To fund the transaction, we completed offerings of common stock and mandatory convertible preferred stock on July 2, 2014, which resulted in the issuance of 9,775,000 shares of common stock and 1,725,000 shares of mandatory convertible preferred stock. Proceeds from the common stock offering and mandatory convertible preferred stock offering, net of estimated transaction fees, were approximately $421.3 million and $166.6 million, respectively. In addition, on July 16, 2014, we entered into a new senior secured credit facility comprised of an $870.0 million term loan and a $300.0 million revolving credit facility and completed a private offering of $1.1 billion aggregate principal amount of our 2022 Senior Unsecured Notes. As a result of these transactions, the obligations related to our previously existing revolving credit facility and senior secured notes were satisfied and terminated.

The mandatory convertible preferred stock pays dividends at an annual rate of 5.25% of the initial liquidation preference of $100 per share. Dividends began to accrue from the date of issuance and, to the extent lawful and declared by our board of directors, will be paid on each January 1, April 1, July 1 and October 1 in cash or, at our election (subject to certain limitations), by delivery of any combination of cash and shares of common stock. At any time prior to July 1, 2017, holders may elect to convert all or a portion of their shares of mandatory convertible preferred stock into shares of common stock at the minimum conversion rate of 1.8141 shares of common stock. On July 1, 2017, all outstanding shares of our mandatory convertible preferred stock will convert into common stock. On March 3, 2015, the Board of Directors declared a dividend of $1.3125 per share in cash, or $2.3 million, for our 5.25% Mandatory Convertible Preferred Stock. As of March 31, 2015, the dividend was funded to the paying agent to be paid to shareholders of record as of March 15, 2015.

On August 9, 2013, our Board of Directors approved a stock repurchase program for up to $40.0 million of our shares of common stock, which expired on February 9, 2015. During the three months ended March 31, 2015, we did not purchase any shares under the stock repurchase program.

During the three months ended March 31, 2015, we repurchased 67,000 shares of our common stock by withholding a portion of

36

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

employee restricted stock that vested, with a value of approximately $3.7 million, to cover payroll withholding taxes in accordance with the restricted stock agreements.

During 2012, we completed a private offering of $250.0 million aggregate principal amount of 5.625% senior unsecured notes due 2020 (the 2020 Senior Unsecured Notes). Interest accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30th and November 30th, through the maturity date on November 30, 2020. At March 31, 2015, we had approximately $4.7 million in accrued interest associated with the 2020 Senior Unsecured Notes reflected in other accrued liabilities which will be paid in May 2015. The 2020 Senior Unsecured Notes contain certain covenants which, among other things, limit our ability to enter into or guarantee additional borrowing, sell preferred stock, pay dividends and repurchase stock, in each case subject to certain exceptions.

Our $870.0 million term loan matures on July 16, 2021 and bears interest equal to, at our option, the alternative base rate as defined in the agreement (ABR) plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00%, with a LIBOR floor of 0.75%, or a combination thereof (3.75% on March 31, 2015). Our revolving credit facility, which matures on July 16, 2019, permits us to borrow up to $300.0 million, at an interest rate equal to, at our option, the ABR plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00%, or a combination thereof and provides for a fee of 0.375% of unused commitments. In accordance with the terms of the senior secured credit facility, principal payments are required quarterly in installments of an amount equal to 0.25% of the aggregate initial principal amount of the term loan. We have the option to increase borrowings under the senior secured credit facility beyond the initial term under both the term loan and revolver as long as certain financial covenants are met and lender approval is obtained.

During 2014, we completed a private offering of $1.1 billion aggregate principal amount of 5.625% senior unsecured notes due 2022 (the 2022 Senior Unsecured Notes). Interest on the 2022 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on January 15 and July 15 through the maturity date of July 15, 2022. At March 31, 2015, we had approximately $13.0 million in accrued interest associated with the 2022 Senior Unsecured Notes reflected in other accrued liabilities, which will be paid in July 2015.

For the three months ended March 31, 2015, we had net repayments on long-term debt of $3.0 million. At March 31, 2015, we had no balance outstanding under our revolving credit agreement, $250.0 million outstanding pursuant to our 2020 Senior Unsecured Notes, $1.1 billion outstanding pursuant to our 2022 Senior Unsecured Notes and $863.5 million outstanding pursuant to our term loan. In addition, as of March 31, 2015, we had available under our revolving credit agreement $300.0 million for acquisition borrowings.

As of March 31, 2015, we were in compliance with all covenants contained in our credit agreement, the indenture governing our 2020 Senior Unsecured Notes, and the indenture governing our 2022 Senior Unsecured Notes.

We expect our interest expense to be approximately $120.0 million on an annual basis primarily as a result of the indebtedness incurred in connection with the acquisition of Sheridan. We plan to fund the additional interest expense primarily through our increased operating cash flow as a result of the acquisition of Sheridan.

On January 16, 2015, we entered into an agreement to lease approximately 222,000 square feet of office space in Plantation, Florida which we intend to be the future headquarters of our Physician Services Division. We expect to take possession in June of 2015 to begin tenant improvements. Annual rent expense is expected to be approximately $2.7 million. Our rent obligation does not require cash payments until September 2016.

Based upon our current operations and anticipated growth, we believe our operating cash flow and borrowing capacity will be adequate to meet our working capital and capital expenditure requirements for the next 12 to 18 months. In addition to acquiring and developing ASCs and physician practices, we may from time to time consider other acquisitions or strategic joint ventures involving other companies, multiple-center chains or networks of ASCs. Such acquisitions, joint ventures or other opportunities may require an amendment to our current debt agreements or additional external financing. As previously discussed, we cannot assure you that any required financing will be available, or will be available on terms acceptable to us.

Recent Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board issued ASU 2014-08 “Presentation of Financial Statements and Property, Plant and Equipment,” which raised the threshold for a disposal to qualify as a discontinued operation and requires certain new disclosures for individually material disposals that do not meet the new definition of a discontinued operation. The ASU’s intent is to reduce the number of disposals reported as discontinued operations by focusing on strategic shifts that have or will have a major effect on our operations and financial results rather than routine disposals that are not a change in our strategy. The guidance is effective for interim and annual periods beginning after December 15, 2014, with earlier adoption permitted.  From time to time, we will dispose of certain of our entities due to management’s assessment of our strategy in the market and due to limited growth opportunities at those entities. Historically, these dispositions were classified as discontinued operations and recorded separately from continuing operations.

37

Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations - (continued) Table of Contents

We adopted this ASU effective January 1, 2015 and did not have any disposals during the three months ended March 31, 2015.  We do not believe this ASU will have a material impact on our consolidated financial position or cash flows.

In May 2014, Financial Accounting Standards Board issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. In April 2015, the FASB proposed a one-year deferral of the ASU. The guidance in ASU 2014-09 is now effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. Early adoption would be permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein. We have yet to assess the impact, if any, this ASU will have on our consolidated financial position, results of operations or cash flows.

In February 2015, the FASB issued ASU No. 2015-02, "Consolidations (Topic 810) - Amendments to the Consolidation Analysis". The new guidance makes amendments to the current consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities will be considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015. We have yet to assess the impact, if any, this ASU will have on our consolidated financial position, results of operations or cash flows.

38

Item 3.  Quantitative and Qualitative Disclosures About Market Risk

We are subject to market risk primarily from exposure to changes in interest rates based on our financing, investing and cash management activities.  We utilize a balanced mix of maturities along with both fixed rate and variable rate debt to manage our exposures to changes in interest rates.  Our variable debt instruments are primarily indexed to the prime rate or LIBOR.  Interest rate changes would result in gains or losses in the market value of our fixed rate debt portfolio due to differences in market interest rates and the rates at the inception of the debt agreements.  Based upon our indebtedness at March 31, 2015, a 100 basis point interest rate change would impact our net earnings and cash flow by approximately $5.2 million annually.  Although there can be no assurances that interest rates will not change significantly, we do not expect changes in interest rates to have a material effect on our net earnings or cash flows in 2015 based on our indebtedness at March 31, 2015.

Item 4.  Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management team, including our chief executive officer and chief financial officer, we conducted an evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of March 31, 2015.  Based on that evaluation, our chief executive officer (principal executive officer) and chief financial officer (principal accounting officer) have concluded that our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

As a result of the completion of the Sheridan acquisition on July 16, 2014, we have begun our analysis of the systems of disclosure controls and procedures and internal controls over financial reporting of Sheridan and to integrate them within our broader framework of controls. The SEC’s rules require us to include acquired entities in our assessment of the effectiveness of internal control over financial reporting no later than the annual management report following the first anniversary of the acquisition. We plan to complete the evaluation and the integration of Sheridan within the required time frames and report management’s assessment of our internal control over financial reporting in our first annual report in which such assessment is required for this acquisition. There has been no change in our internal control over financial reporting during the quarter ended March 31, 2015 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

39

Part II

Item 1.  Legal Proceedings

There have been no material changes to the legal proceedings we previously described in our 2014 Annual Report on Form 10-K during the three months ended March 31, 2015.

Item 1A. Risk Factors

Not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3.   Defaults Upon Senior Securities

None.

Item 4.   Mine Safety Disclosures

Not applicable.

Item 5.   Other Information

None.

40

Item 6.   Exhibits

Exhibit		Description
10.1		Office lease by and between 8000 Sunrise Lot B, as landlord and AmSurg Corp, as tenant (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K, dated January 22, 2015)
10.2	*	Employment Agreement dated, July 16, 2014, between the Company and Robert Coward
10.3	*	Form of Performance Share Unit Award Agreement (incorporated by reference to exhibit 10.1 of the Current Report on Form 8-K, dated February 9, 2015)
31.1		Certification of President and Chief Executive Officer pursuant to Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Executive Vice President and Chief Financial Officer pursuant to Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101		Interactive data files pursuant to Rule 405 of Regulation S-T: (i) the Consolidated Balance Sheets at March 31, 2015 and December 31, 2014, (ii) the Consolidated Statements of Earnings for the three month periods ended March 31, 2015 and 2014, (iii) the Consolidated Statements of Changes in Equity for the three month periods ended March 31, 2015 and 2014, (iv) the Consolidated Statements of Cash Flows for the three month periods ended March 31, 2015 and 2014 and (v) the notes to the Unaudited Consolidated Financial Statements for the three month periods ended March 31, 2015 and 2014
	*	Management contract or compensatory plan, contract or agreement

41

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		AMSURG CORP.
Date:	May 6, 2015
		By:	/s/ Claire M. Gulmi
			Claire M. Gulmi
			Executive Vice President and
			Chief Financial Officer
			(Principal Financial and Duly Authorized Officer)

42

EX-10.2

Exhibit 10.2

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (the “Agreement”), is entered into this 16th day of July, 2014, by and between Sheridan Healthcare, Inc., a Delaware corporation (“Company”), and Robert Coward (“Executive”).

WHEREAS, Executive is currently employed by the Company pursuant to that certain employment agreement dated as of June 15, 2007, and as amended on December 30, 2008, April 11, 2011, and March 19, 2013 (the “Prior Agreement”);

WHEREAS, AmSurg Corp. (“AMSURG”) and Sheridan Healthcare, Inc. have entered into an agreement pursuant to which Sheridan Healthcare, Inc. will become a wholly owned subsidiary of AMSURG (the “Transaction”); and

WHEREAS, the Company wishes to continue to employ Executive after the closing of the Transaction, and the parties wish to establish the terms and conditions of such employment pursuant to this Agreement and thereby supersede and replace the Prior Agreement in its entirety.

NOW, THEREFORE, in consideration of the promises and mutual covenants herein and for other good and valuable consideration, the parties agree as follows:

W I T N E S S E T H:

1.    EMPLOYMENT. The Company employs Executive and Executive hereby accepts employment under the terms and conditions hereinafter set forth.

2.    DUTIES. Executive will be engaged as Executive Vice President - Operations of the Company. His powers and duties in that capacity shall be those normally associated with the position of Executive Vice President - Operations. During the term of this Agreement, Executive shall also serve without additional compensation in such other offices of the Company and its parents, subsidiaries, and affiliates to which he may be elected or appointed.

3.    TERM. Subject to provisions of termination as hereinafter provided, the initial term of Executive’s employment under this Agreement shall commence upon the closing of the Transaction and terminate on December 31, 2015. On each December 31 during the term of this Agreement, commencing on December 31, 2015, unless the Company notifies Executive, pursuant to the following paragraph, that his employment under this Agreement will not be extended, his employment under this Agreement shall automatically be extended for a one (1) year period on the same terms and conditions as are set forth herein.

If the Company elects not to extend Executive’s employment under this Agreement, it shall do so by notifying Executive in writing not less than sixty (60) days prior to the applicable December 31 of this Agreement. If the Company does not elect to extend Executive’s employment under this Agreement other than for Cause (as hereinafter defined), Executive shall be considered to have been terminated without Cause upon the expiration of his employment, and Executive will receive the payments and benefits set forth in Section 8 hereof.

4.    COMPENSATION.

a. For all duties rendered by Executive, the Company shall pay Executive a minimum salary of $632,000.00 per year, payable in equal semi-monthly installments. In addition thereto, each year, beginning January 1, 2015, Executive’s compensation will be reviewed by the Board of Directors of AMSURG, or the Compensation Committee thereof, or its/their designee, and after taking into consideration performance and any other factors deemed relevant, the Committee may increase Executive’s salary. Executive will be eligible to receive an annual bonus on the terms and conditions approved by the Compensation Committee of AMSURG’s Board of Directors. Executive shall also be eligible to receive equity incentive awards as approved from time to time by the Compensation Committee of AMSURG’s Board of Directors.

b. All compensation payable hereunder shall be subject to withholding for federal income taxes, FICA and all other applicable federal, state and local withholding requirements.

c. The Company shall pay the reasonable expenses incurred by Executive in the performance of his duties under this Agreement (or shall reimburse Executive on account of such expenses paid directly by Executive) in accordance with the Company’s policies and procedures. Any such reimbursement of expenses shall be made by the Company promptly upon or as soon as reasonably practicable following receipt of supporting documentation reasonably satisfactory to the Company (but in any event not later than the close of Executive’s

taxable year following the taxable year in which the expense is incurred by Executive); provided, however, that upon Executive’s termination of employment with the Company, in no event shall any additional reimbursement be made prior to the Section 409A Payment Date (as such term is defined in Section 22) to the extent such payment delay is required under Section 409A(a)(2)(B)(i) of the Internal Revenue Code of 1986, as amended (the “Code”). In no event shall any reimbursement be made to Executive for such expenses after the later of (i) the first anniversary of the date of Executive’s death or (ii) December 31 of the calendar year following the year of the Executive’s termination of employment with the Company (other than by reason of Executive’s death).

d. Executive shall be eligible to receive such equity incentive awards under AMSURG’s equity incentive plans as may be approved from time to time by the Compensation Committee of the Board of Directors of AMSURG. Any such awards shall be subject to such vesting and other terms and conditions as shall be approved by the Compensation Committee of the Board of Directors of AMSURG. Any such awards that are subject solely to time-based vesting restrictions (including any such awards outstanding as of the date of this Agreement) shall automatically vest upon the termination of employment of Executive as a result of (i) the death of Executive, (ii) the Disability of Executive (as defined in Section 6), (iii) the termination of employment by Executive for Good Reason (as defined in Section 21), and (iv) the termination of employment by the Company without Cause (as defined in Section 7) following the second anniversary of the date of this Agreement; provided, that the vesting of such awards shall not accelerate upon the termination of Executive as a result of the termination of employment by the Company without Cause (as defined in Section 7) if such termination without Cause by the Company is a Performance Termination (as defined in Section 21).

5.    EXTENT OF SERVICE. Executive shall devote substantially his entire time, attention and energies to the business of the Company and shall not during the term of this Agreement take an active role in any other business activity without the prior written consent of the Company; but this shall not prevent Executive from making real estate or other investments of a passive nature or devoting time to charitable and non-profit activities and service as a director on the board(s) of directors of companies (whether public or private) other than the Company, in each case, in accordance with the Company’s or AMSURG’s Corporate Governance Guidelines and in a manner that does not interfere with the performance of his duties to the Company.

6.    DISABILITY. In the event Executive shall become disabled as defined in Treasury Regulation 1.409(A)-3(i)(4) (“Disability”), the Company shall provide the following payments and benefits:

a. The Accrued Rights (as defined in Section 7(a) below);

b. If Executive’s employment is terminated following the end of a fiscal year and prior to the payment date for the bonus described in Section 4(a), if any, that Executive would have been entitled to receive with respect to such completed fiscal year, based upon AMSURG’s or the Company’s actual results, as applicable, the Company shall pay to Executive, at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program, the amount of such bonus described in Section 4(a), if any, that Executive would have been entitled to receive with respect to such completed fiscal year had Executive’s employment not terminated prior to the payment date for such bonus; and a pro rata portion of the bonus described in Section 4(a), if any, that Executive would have been entitled to receive for the fiscal year in which the Disability Payment Date (as defined below) occurs, based upon AMSURG’s or the Company’s actual results, as applicable, for the year of termination and the percentage of the fiscal year that shall have elapsed through the Disability Payment Date, payable to Executive pursuant to Section 4(a) had Executive’s employment not terminated, which pro-rata bonus shall be paid at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program; and

c. Through insurance or on its own account coverage for Executive that will provide payment of Executive’s full salary and benefits for twelve (12) months, with (i) the payment of Executive’s salary to commence within thirty (30) days (with the date of such initial payment(s) determined by the Company in its sole discretion) of the Disability Payment Date (as defined below) and (ii) such payments being paid on the same terms and with the same frequency as Executive’s salary was paid prior to such incapacity or illness. For the period beyond twelve (12) months, the Company shall provide such coverage to Executive as is then available to Executive in accordance with Company policy. To the extent that payments are received from Worker’s Compensation or other Company paid disability plans, the Company’s obligations will be reduced by amounts so received.

The date on which it is determined that Executive is Disabled is referred to herein as the “Disability Payment Date.”

7.    TERMINATION FOR CAUSE.

a. The Company may terminate Executive’s employment for Cause, without any further liability hereunder to Executive, except that Executive shall be entitled to (i) payment of all accrued but unpaid salary through the date of termination, (ii) reimbursement for all incurred but unreimbursed expenses for which Executive is entitled to reimbursement in accordance with Section 4(g), and (iii) benefits to which the Executive is entitled as of the date of termination of employment under the terms of applicable benefit plans and programs (the “Accrued Rights”).

b. For the purposes of this Agreement, the Company shall have “Cause” to terminate Executive’s employment based upon the following grounds (i) a felony conviction of Executive or the failure of Executive to contest prosecution for a felony, (ii) conviction of a crime involving moral turpitude, or (iii) willful and continued misconduct or gross negligence by Executive in the performance of his duties as an Executive after written notice from the Company that reasonably identifies the manner in which the Company believes that he has committed gross negligence or willful misconduct and the failure by Executive to cure such failure within forty-five (45) days after delivery of such notice. For purposes of this Section 7, “willful” shall be determined by the Board of Directors of AMSURG. In making such determination, the Board of Directors of AMSURG shall not act unreasonably or arbitrarily and no act or omission by Executive shall be deemed willful if taken by Executive in a good faith belief that such act or omission to act was in the best interests of the Company or if done at the express direction of the Board.

c. Prior to making a determination to terminate the Executive’s employment for Cause, Executive shall have the opportunity, together with his counsel, to be heard before AMSURG’s Board of Directors.

8.    TERMINATION WITHOUT CAUSE OR FOR GOOD REASON. Executive’s employment under this Agreement may be terminated by the Company at any time without Cause or by the Executive for Good Reason (as defined in Section 21). Except as provided in Section 9 below, in the event Executive’s employment under this Agreement is terminated by the Company without Cause or by the Executive for Good Reason, the Company shall pay Executive the following payments and benefits:

a. The Accrued Rights;

b. a lump sum payment equal to two (2) times the sum of (i) the annual base salary payable to Executive as of the date of the Executive’s Separation from Service and (ii) the target bonus established by the Compensation Committee of the AMSURG Board of Directors for the Executive pursuant to the annual cash bonus plan for the year in which the Separation of Service occurs;

c. Executive shall also continue to be covered under health and life insurance plans of the Company for twenty-four (24) months, or the Company shall provide the economic equivalent thereof if such continuation is not permissible under the terms of the Company’s insurance plans;

d. If Executive’s employment is terminated following the end of a fiscal year and prior to the payment date for the bonus described in Section 4(a), if any, that Executive would have been entitled to receive with respect to such completed fiscal year, based upon AMSURG’s or the Company’s actual results, as applicable, the Company shall pay to Executive, at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program, the amount of such bonus described in Section 4(a), if any, that Executive would have been entitled to receive with respect to such completed fiscal year had Executive’s employment not terminated prior to the payment date for such bonus; and a pro rata portion of the bonus described in Section 4(a), if any, that Executive would have been entitled to receive for the fiscal year in which the termination of employment occurs, based upon AMSURG’s or the Company’s actual results, as applicable, for the year of termination and the percentage of the fiscal year that shall have elapsed through the date of termination of employment, payable to Executive pursuant to Section 4(a) had Executive’s employment not terminated, which pro-rata bonus shall be paid at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program;

Benefits due under Section 8(a)-(c) shall be payable (or commence) within sixty (60) days of the Executive’s Separation from Service, with the date of such payment determined by the Company in its sole discretion in accordance with Section 11 below. Receipt by Executive of the payment and other benefits under this Section 8 shall be subject to Executive’s execution and delivery,

pursuant to the terms of Section 11 below, to the Company of a General Release in form and substance reasonably acceptable to the Company and Executive.

9.    TERMINATION FOLLOWING A CHANGE IN CONTROL. In the event Executive’s employment under this Agreement is terminated by the Company without Cause within twelve (12) months following the occurrence of a Change in Control (as defined in Section 21 herein) or by Executive for Good Reason within twelve (12) months following the occurrence of a Change in Control (as defined in Section 21 herein), the Company shall pay Executive the following payments and benefits:

a. a lump sum payment equal to two (2) times the sum of (i) the annual base salary payable to Executive as of the date of the Executive’s Separation from Service and (ii) the target bonus established by the Compensation Committee of the AMSURG Board of Directors for the Executive pursuant to the annual cash bonus plan for the year in which the Separation of Service occurs;

b. Executive shall also continue to be covered under health and life insurance plans of the Company for two years (2) years, or the Company shall provide the economic equivalent thereof if such continuation is not permissible under the terms of the Company’s insurance plans; and

c. If Executive’s employment is terminated following the end of a fiscal year and prior to the payment date for the bonus described in Section 4(a), if any, that Executive would have been entitled to receive with respect to such completed fiscal year, based upon AMSURG’s or the Company’s actual results, as applicable, the Company shall pay to Executive, at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program, the amount of such bonus described in Section 4(a), if any, that Executive would have been entitled to receive with respect to such completed fiscal year had Executive’s employment not terminated prior to the payment date for such bonus; and a pro rata portion of the bonus described in Section 4(a), if any, that Executive would have been entitled to receive for the fiscal year in which the termination of employment occurs, based upon AMSURG’s or the Company’s actual results, as applicable, for the year of termination and the percentage of the fiscal year that shall have elapsed through the date of termination of employment, payable to Executive pursuant to Section 4(a) had Executive’s employment not terminated, which pro-rata bonus shall be paid at the time such bonus is paid to other executives of the Company according to the terms of the applicable bonus program.

Benefits due under this Section 9 shall be payable (or commence) within sixty (60) days of the Executive’s Separation from Service, with the date of such payment determined by the Company in its sole discretion in accordance with Section 11 below. Receipt by Executive of any payment or other benefits under this Section 9 shall be subject to Executive’s execution and delivery, pursuant to the terms of Section 11 below, to the Company of a General Release in form and substance reasonably acceptable to the Company and Executive.

10.    TERMINATION BY EXECUTIVE WITHOUT GOOD REASON. Executive may terminate his employment under this Agreement at any time other than for Good Reason (as defined in Section 21 herein) upon the provision of sixty (60) days prior written notice to the Company. In such event, the Company shall pay Executive the Accrued Rights, and Executive shall not be entitled to any other benefits under this Agreement following the date of termination of this employment with the Company. In the event Executive gives notice of his intent to terminate his employment other than for Good Reason, the Company may elect to waive the period of notice or any portion thereof and accept Executive’s resignation prior to the end of the notice period.

11.    COORDINATION WITH RELEASE. Notwithstanding any provision herein to the contrary, the provisions of this Section 11 shall apply to the payment of benefits under Sections 8 and 9 (the “Severance Payments”). The Severance Payments shall be made only if Executive shall have executed, on or prior to the Release Expiration Date (as defined below), a General Release in form and substance reasonably acceptable to the Company and Executive (the “Release”) and any waiting periods contained in the Release shall have expired. In any instance where the execution of a Release is required, the Company shall deliver the Release to the Executive within eight (8) days following the date of the Executive’s Separation from Service. If Executive fails to execute and deliver the Release on or prior to the Release Expiration Date or timely revokes Executive’s acceptance of the Release thereafter, Executive shall not be entitled to any Severance Payments. The Severance Payments shall be made immediately upon the expiration of any waiting periods contained in the Release, or if no waiting periods are applicable, within two (2) business days following Executive’s execution and delivery of the Release to the Company; provided, however, notwithstanding anything herein to the contrary, in any case where the date the Separation from Service and the Release Expiration Date fall in two separate taxable years, any Severance Payments that are treated as deferred compensation for purposes of Section 409A of the Code shall be made in the later taxable year. For purposes of this Section 11, the “Release Expiration Date” shall mean the later of (i) the date of the Executive’s Separation from Service, and (ii) the date that is twenty-one (21) days following

the date on which the Company timely delivers a Release to the Executive for the Executive’s execution, or in the event that the Executive’s Separation from Service is “in connection with an exit incentive or other employment termination program” (as such phrase is defined in the Age Discrimination in Employment Act of 1967), the date that is forty-five (45) days following such delivery date.

12.    RESTRICTIVE COVENANTS.

a. Confidential Information. Executive agrees not to disclose, either during the time he is employed by the Company or following the termination of his employment at the Company, any confidential information concerning the Company or AMSURG, including, but not limited to, customer lists, business plans, contract terms, financial costs, sales data, or business opportunities whether for existing, new or developing businesses.

b. Non-Compete. For a period of two (2) years following the date of the termination of Executive’s employment with the Company other than in the event of a termination by the Executive for Good Reason, Executive agrees that he will not, either as an individual for his own account, as a partner or joint venturer, or as an employee, agent, Executive, director, consultant, owner or otherwise, without the written consent of the Company, own, finance, operate, manage, design, build, solicit prospects for or otherwise enter into or engage in any phase of:

(i) the ambulatory surgery business,

(ii) any business the products, services, or activities of which include the provision of medical services, including without limitation, the provision of anesthesia services, pain management services, emergency medicine services, gynecological and obstetrical services, primary medical care services, neonatology services, pediatric services, perinatology services and radiology services,

(iii) any business the products, services, or activities of which include the provision of administrative services for medical services, including without limitation, quality assurance services, utilization management services, billing services, recruitment services and medical management information services, or

(iv) any other line of business in which the Company is engaged on the date of termination of Executive’s employment with the Company (for purposes of clarification of this Section 12(b)(iv), the Company shall not be deemed to be engaged in a line of business if the Company provides the goods or services that constitute such line of business solely to business units, segments or subsidiaries of the Company or facilities owned or operated by the Company),

in the case of each of (i), (ii), (iii), and (iv) above in any state within the United States or in any foreign country or territory in which the Company or any of its subsidiaries, parents, or affiliates conducts business as of the date of termination of Executive’s employment with the Company. The Company and Executive acknowledge and agree that the provisions of this Section 12(b) shall not restrict Executive from accepting employment or otherwise being involved with a business (such as a company that owns or operates hospitals or health systems) other than United Surgical Partners International, Inc., Surgical Care Affiliates, Inc., Envision Healthcare Holdings, Inc., MEDNAX, Inc., TeamHealth Holdings, Inc., and their respective parents, subsidiaries, and affiliates that has a unit, division, segment or subsidiary that competes with the Company as described above in this Section 12(b) so long as Executive does not directly participate in the management of the unit, division, segment or subsidiary that competes with the business of the Company as described in subsections (i), (ii), (iii), and (iv) above. For purposes of Sections 12(b)(i), 12(b)(ii), 12(b)(iii), and 12(b)(iv) above, references to the Company shall include all subsidiaries and affiliates of the Company, including but not limited to AMSURG.

c. Non-Solicitation. Upon termination or expiration of his employment, whether voluntary or involuntary, Executive agrees not to directly or indirectly solicit business of the type described in Sections 12(b)(i), 12(b)(ii), 12(b)(iii), and 12(b)(iv) above from any entity, organization or person which has contracted with the Company, which has been doing business with the Company, or from which the Executive knew or had reason to know that the Company was soliciting or going to solicit business at the time of Executive’s termination, for a two-year-year period from the date of Executive’s termination of his employment with the Company. For purposes of this Section 12(c), references to the Company shall include all subsidiaries and affiliates of the Company, including but not limited to AMSURG.

d. Enforcement. Executive and the Company acknowledge and agree that any of the covenants contained in this Section 12 may be specifically enforced through injunctive relief, but such right to injunctive relief shall not preclude Company from other remedies which may be available to it. In case any of the provisions contained in this Agreement shall for any reason be held to be invalid, illegal, or unenforceable in any respect, including without limitation geographic scope, duration or functional coverage, any such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement, but this Agreement shall be construed

as if such invalid, illegal, or unenforceable provision had been limited or modified (consistent with its general intent) to the extent necessary to make it valid, legal and enforceable, or if it shall not be possible to so limit or modify such invalid, illegal or unenforceable provision or part of a provision, this Agreement shall be construed as if such invalid, illegal or unenforceable provision or part of a provision had never been contained in this Agreement.

e. Termination. Notwithstanding any provision to the contrary otherwise contained in this Agreement, the agreements and covenants contained in this Section 12 shall not terminate upon Executive’s termination of his employment with the Company or upon the termination of this Agreement under any other provision of this Agreement.

13.    VACATION. During each year of this Agreement, Executive shall be entitled to not less than twenty five (25) paid vacation days per year, which shall accrue monthly.

14.    BENEFITS. In addition to the benefits specifically provided for herein, Executive shall be entitled to participate in all benefit plans maintained by the Company for employees generally according to the terms of such plans.

15.    NOTICES. Any notice required or permitted to be given under this Agreement shall be sufficient if in writing, and if sent by registered or certified mail to his residence in the case of Executive, or to its principal office in the case of the Company.

16.    WAIVER OF BREACH. The waiver by either party of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach by the other party.

17.    ATTORNEYS’ FEES. In the event that either party initiates legal proceedings to enforce any provision of this Agreement or resolve any dispute hereunder, and Executive is the prevailing party, then the Company shall be responsible for payment of the Executive’s reasonable attorneys’ fees incurred in connection therewith.

18.    ASSIGNMENT. The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon the successors and assigns of the Company. The Executive acknowledges that AMSURG is an intended third party beneficiary of this Agreement. The Executive acknowledges that the services to be rendered by him are unique and personal, and the Executive may not assign any of his rights or delegate any of his duties or obligations under this Agreement.

19.    ENTIRE AGREEMENT. Executive agrees and acknowledges that this Agreement provides for employment protections and compensation, including but not limited to the equity incentive awards referenced in Section 4(a) and Section 4(d) and the severance awards referenced in Sections 8-9, which are greater than those provided in the Prior Agreement and which constitute valuable consideration for the obligations described herein. This Agreement contains the entire agreement of the parties with respect to the matters addressed herein, and supersedes and replaces the Prior Agreement in its entirety. It may not be changed orally but only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension or discharge is sought. This Agreement shall be governed by the laws of the State of Tennessee.

20.    HEADINGS. The sections, subjects and headings in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement.

21.    DEFINITIONS. For purposes of this Agreement the following definitions shall apply:

a. “Change in Control” shall mean the occurrence of any of the following:

(i) the acquisition of at least a majority of the outstanding shares of Common Stock (or securities convertible into Common Stock) of AMSURG by any person, entity or group (as used in Section 13(d)(3) and Rule 13d-5(b)(1) under the Exchange Act);

(ii) the merger or consolidation of AMSURG with or into another corporation or other entity, or any share exchange or similar transaction involving AMSURG and another corporation or other entity, if as a result of such merger, consolidation, share exchange or other transaction, the persons who owned at least a majority of the Common Stock of AMSURG prior to the consummation of such transaction do not own at least a majority of the Common Stock of the surviving entity after the consummation of such transaction;

(iii) the sale of all, or substantially all, of the assets of AMSURG; or

(iv) any change in the composition of the Board of Directors of AMSURG, such that persons who at the beginning of any period of up to two years constituted at least a majority of the Board of Directors of AMSURG, or persons whose nomination was approved by such majority, cease to constitute at least a majority of the Board of Directors of AMSURG at the end of such period.

b. Unless otherwise stated, “Company” shall mean Sheridan Healthcare, Inc., any successor entity or their successors or assigns.

c. “Good Reason” shall exist if:

(i) there is a material diminution in the nature or the scope of Executive’s authority and responsibilities;

(ii) there is a material diminution in Executive’s rate of base salary or overall compensation (for reasons other than AMSURG or Company performance or stock price);

(iii) the Company changes the principal location in which Executive is required to perform services outside a twenty (20) mile radius of such location without Executive’s consent; or

(iv) the Company engages in any other action or inaction that constitutes a material breach of this Agreement by the Company.

A termination under the circumstances listed above shall be for “Good Reason” only if (A) Executive notifies the Company of the existence of the condition that otherwise constitutes Good Reason within ninety (90) days of the initial existence of the condition, (B) the Company fails to remedy the condition within forty-five (45) days following its receipt of Executive’s notice of Good Reason and (C) the Executive Separates from Service from the Company due to the condition within twelve (12) months of the initial existence of such condition.

d. “Separation from Service” shall mean the date on which the Company and Executive reasonably anticipate that no further services will be performed after such date, or that the level of bona fide services Executive will perform after such date will permanently decrease to no more than 20% of the average level of bona fide services performed over the immediately preceding 36-month period. Whether a Separation from Service occurs shall be interpreted consistent with Section 1.409A-1(h) of the U.S. Treasury Regulations.

e. “Performance Termination” shall mean the termination of Executive’s employment by the Company without Cause (as defined in Section 7) following the failure of AMSURG or the Company to achieve at least 85% of the budgeted level of earnings from continuing operations before income taxes (Corporate Pre-Tax Profits) or other similar budget measure approved by the Board of Directors of AMSURG (as such measure may be adjusted by the Board during any fiscal year) and designated by the Board of Directors as the budget measure for purposes of this definition of “Performance Termination,” during any two fiscal years during a consecutive three fiscal year period. The determination whether AMSURG or the Company has failed to achieve any such budget measure for a fiscal year shall be based upon AMSURG’s audited financial statements for such fiscal year. In making a determination whether AMSURG or the Company has failed to achieve any such budget measure for a fiscal year, the Board shall consider the impact of changes in general economic conditions, legal or regulatory changes generally affecting the industry in which AMSURG and/or the Company operates, and adverse weather incidents or other acts of God that are not within the control of AMSURG and the Company. In the event the Board of Directors determines that AMSURG or the Company has failed to achieve such budget measure in any fiscal year, the Board will give the Executive written notice of such fact within five (5) business days following the filing of the Annual Report on Form 10-K for AMSURG for such fiscal year. In the event the Board of Directors determines to terminate Executive’s employment without Cause pursuant to a Performance Termination, the Board must give Executive notice of such termination before the later of (i) 180 days after the end of the second fiscal year end of AMSURG or the Company, as applicable, in which AMSURG or the Company failed to meet such budget measures and (ii) the date of the annual meeting of AMSURG’s shareholders following the end of the second fiscal year of AMSURG or the Company, as applicable, in which AMSURG or the Company failed to meet such budget measures.

22.    DELAY OF PAYMENTS. It is intended that (1) each installment of the payments provided under this Agreement is a separate “payment” for purposes of Section 409A of the Code, and (2) that the payments satisfy, to the greatest extent possible, the exemptions from the application of Section 409A of the Code, including those provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(9)(iii), and 1.409A-1(b)(9)(v). Notwithstanding anything to the contrary in this Agreement, if the Company determines (i) that on the date Executive’s employment with the Company terminates or at such other time that the Company determines to be relevant, Executive is a “specified employee” (as such term is defined under Treasury Regulation 1.409A-1(i)(1)) of the Company and (ii) that any payments to be provided to Executive pursuant to this Agreement are or may become subject to the additional tax under Section 409A(a)(1)(B) of the Code or any other taxes or penalties imposed under Section 409A of the Code (“Section 409A Taxes”) if provided at the time otherwise required under this Agreement then such payments shall be delayed until the date that is six months after the date of Executive’s Separation from Service with the Company, or, if earlier, the date of the Executive’s death.Any payments delayed pursuant to this Section 22 shall be made in a lump sum on the first day of the seventh month following Executive’s Separation from Service, or, if earlier, the date of the Executive’s death (the “Section 409A Payment Date”). In addition, to the extent that any reimbursement, fringe benefit or other, similar plan or arrangement in which the Executive participates during the term of the Executive’s employment under this Agreement or thereafter provides for a “deferral of compensation” within the meaning of Section 409A of the Code, (i) the amount eligible for reimbursement or payment under such plan or arrangement in one calendar year may not affect the amount eligible for reimbursement or payment in any other calendar year (except that a plan providing medical or health benefits may impose a generally applicable limit on the amount that may be reimbursed or paid), (ii) subject to any shorter time periods provided herein or the applicable plans or arrangements, any reimbursement or payment of an expense under such plan or arrangement must be made on or before the last day of the calendar year following the calendar year in which the expense was incurred, and (iii) such right to reimbursement or payment shall not be subject to liquidation or exchange for another benefit.

23.    HEALTH BENEFITS. The costs of the Company’s portion of any post termination health or life insurance premiums due under this Agreement shall be included in the Executive’s gross income to the extent the provision of such benefits is deemed to be discriminatory under Section 105(h) of the Code.

24.    DEEMED RESIGNATION.    In the event Executive’s employment under this Agreement is terminated for any reason, unless otherwise determined by the Board of Directors of AMSURG, Executive shall be deemed, without any further action on the part of Executive, to have automatically resigned as a director of the Company and as an officer and director, if applicable, of all subsidiaries and affiliates of the Company.

25.    Section 280G Limitation.

a. Notwithstanding any other provision to the contrary, if any payments or benefits Executive would receive from the Company pursuant to this Agreement or otherwise (collectively, the “Payments”) would, either separately or in the aggregate, (i) constitute “parachute payments” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Payments will be equal to the Reduced Amount (defined below). The “Reduced Amount” will be either (1) the entire amount of the Payments, or (2) an amount equal to the largest portion of the Payments that would result in no portion of any of the Payments (after reduction) being subject to the Excise Tax, whichever amount after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes), results in the Executive’s receipt, on an after-tax basis, of the greatest amount of the Payments. If a reduction in the Payments is to be made so that the amount of the Payments equals the Reduced Amount, the Payments will be paid only to the extent permitted under the Reduced Amount alternative; provided, that in the event the Reduced Amount is paid, the cash payments set forth in Section 9 shall be reduced as required by the operation of this Section 25.

b. The Company shall engage the accounting firm engaged by the Company for general audit purposes at least 20 business days prior to the effective date of the Change in Control to perform any calculation necessary to determine the amount, if any, payable to Executive pursuant to Section 9, as limited by this Section 25. If the accounting firm so engaged by the Company is also serving as accountant or auditor for the individual, entity or group that will control the Company following the Change in Control, the Company may appoint a nationally recognized accounting firm other than the accounting firm engaged by the Company for general audit purposes to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.

c. The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and Executive within 20 days after the date on which such accounting firm has been engaged to make such determinations or within such other time period as agreed to

by the Company and Executive. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.

d. Notwithstanding the foregoing, in determining the reduction, if any, that shall occur as a result of this Section 25, the amounts payable or benefits to be provided to Executive shall be reduced such that the economic loss to Executive as a result of the Excise Tax elimination is minimized. In applying this principle, the reduction shall be made in a manner consistent with the requirements of Section 409A of the Code and where two economically equivalent amounts are subject to reduction but payable at different times, such amounts shall be reduced on a pro rata basis but not below zero.

e. In the event that following the payment of any Payments pursuant to Section 9, as reduced, if applicable, as required by the operation of Section 25(a)-(d), the Internal Revenue Service (the “IRS”) determines that Executive is liable for the Excise Tax as a result of the receipt of such Payments or Reduced Amount, as applicable, then Executive shall be obligated to pay back to the Company, within 30 days after final IRS determination, an amount of the Payments or Reduced Amount, as applicable, equal to the “Repayment Amount.” The Repayment Amount shall be the smallest such amount, if any, as shall be required to be paid to the Company so that the Executive’s net proceeds with respect to the Payments or Reduced Amount, as applicable, (after taking into account the payment of the Excise Tax imposed on such Payments or Reduced Amount, as applicable) shall be maximized. Notwithstanding the foregoing, the Repayment Amount shall be zero if a Repayment Amount of more than zero would not eliminate the Excise Tax imposed on the Payments or Reduced Amount. If the Excise Tax is not eliminated pursuant to this paragraph, Executive shall pay the Excise Tax.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first written.

/s/ Robert Coward    

Robert Coward

Sheridan Healthcare, Inc.

/s/ Christopher A. Holden    

Name: Christopher A. Holden

Title: Chief Executive Officer

AmSurg Corp.

EX-31.1

Exhibit 31.1

Certifications

I, Christopher A. Holden, certify that:

1. I have reviewed this quarterly report on Form 10-Q of AmSurg Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 6, 2015

By:	/s/ Christopher A. Holden
Name:	Christopher A. Holden
Title:	President and Chief Executive Officer

EX-31.2

Exhibit 31.2

Certifications

I, Claire M. Gulmi, certify that:

1. I have reviewed this quarterly report on Form 10-Q of AmSurg Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 6, 2015

By:	/s/ Claire M. Gulmi
Name:	Claire M. Gulmi
Title:	Executive Vice President and
	Chief Financial Officer

EX-32.1

Exhibit 32.1

AMSURG CORP.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of AmSurg Corp. (the “Company”) on Form 10-Q for the period ending March 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Christopher A. Holden

Christopher A. Holden

President and Chief Executive

Officer of the Company

May 6, 2015

/s/ Claire M. Gulmi

Claire M. Gulmi

Executive Vice President and

Chief Financial Officer of the Company

May 6, 2015

XML

Investments in Unconsolidated Affiliates (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	$ 79,311,000		$ 75,475,000
Equity in earnings of unconsolidated affiliates	2,651,000	764,000
Gain (loss) on deconsolidation	(223,000)	2,045,000
Goodwill, Written off Related to Sale of Business Unit	1,069,000
Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	79,300,000		75,500,000
Ambulatory Services [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Investments in unconsolidated affiliates	1,300,000	1,200,000
Proceeds from divestiture of interest in consolidated subsidiaries		$ 600,000
Ambulatory Services [Member] | Controlling Interest [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Number consolidated centers contributed to joint venture	1	1
Ambulatory Services [Member] | Noncontrolling Interest In Centers [Member] | Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Number of joint venture entities acquired	1	1

XML

Shareholder's Equity (Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share) (Details) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net earnings (loss) from continuing operations attributable to AmSurg Corp. common shareholders (Numerator)	$ 18,774	$ 17,392
Net earnings (loss) from continuing operations attributable to AmSurg Corp. common shareholders (basic), shares (Denominator)	47,572,000	31,716,000
Effect of dilutive securities, options and non-vested shares	333,000	404,000
Net earnings (loss) from continuing operations attributable to AmSurg Corp. (diluted), shares (Denominator)	47,905,000	32,120,000
Net earnings (loss) from continuing operations attributable to AmSurg Corp. common shareholders (basic), (usd per share)	$ 0.39	$ 0.55
Net earnings (loss) from continuing operations attributable to AmSurg Corp. common shareholders (diluted), (usd per share)	$ 0.39	$ 0.54
Mandatory Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of anti-dilutive shares	3,200,000

XML

Long-Term Debt (Redemption Price) (Details) (Senior Notes [Member])	3 Months Ended
	Mar. 31, 2015
2015 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	104.219%
2016 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	102.813%
2017 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	101.406%
2017 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	104.219%
2018 and thereafter [Member] | 5.625% Senior Unsecured Notes due 2020 [Member]
Redemption price as percent of the principal amount	100.00%
2018 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	102.813%
2019 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	101.406%
2020 and thereafter [Member] | 5.625% Senior Unsecured Notes due 2022 [Member]
Redemption price as percent of the principal amount	100.00%

XML

Commitments and Contingencies (Details) (USD $) In Millions, unless otherwise specified	0 Months Ended
	Jan. 16, 2015 sqft	May 01, 2017 sqft	Sep. 01, 2016 sqft
Schedule Of Operating Leases Square Footage [Line Items]
Lease square footage	222,000
Annual rent expense	$ 2.7
Scenario, Forecast [Member]
Schedule Of Operating Leases Square Footage [Line Items]
Lease square footage		55,000	167,000

XML

Long-Term Debt (Narrative) (Details) (USD $)	3 Months Ended	0 Months Ended	6 Months Ended
	Mar. 31, 2015	Jul. 16, 2014	Jul. 15, 2014	Dec. 31, 2014	Nov. 20, 2012	May 28, 2010
Fixed Interest Rate [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term Debt	1,383,600,000
Long-term Debt, Fair Value	1,419,300,000
Variable Interest Rate [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term Debt, Fair Value	865,300,000
5.625% Senior Unsecured Notes due 2020 [Member] | Senior Notes [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term Debt	250,000,000			250,000,000
Senior Unsecured Debt
Face amount					250,000,000.0
Interest rate					5.625%
Redeemable principal percentage	35.00%
Senior Secured Debt
Face amount					250,000,000.0
Interest rate					5.625%
5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Long-term Debt	1,100,000,000			1,100,000,000
Senior Unsecured Debt
Face amount		1,100,000,000.0
Interest rate		5.625%
Redeemable principal percentage	35.00%
Senior Secured Debt
Face amount		1,100,000,000.0
Interest rate		5.625%
8.04% Senior Secured Notes due 2020 [Member] | Senior Notes [Member]
Senior Unsecured Debt
Face amount						75,000,000.0
Senior Secured Debt
Face amount						75,000,000.0
Period Prior to November 30, 2015 [Member] | 5.625% Senior Unsecured Notes due 2020 [Member] | Senior Notes [Member]
Senior Unsecured Debt
Redemption price as percent of the principal amount	105.625%
Period Prior to July 15, 2017 [Member] | 5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Senior Unsecured Debt
Redemption price as percent of the principal amount	105.625%
Senior Secured Credit Facility - Term Loan [Member]
Term Loan and Credit Facility
Borrowing capacity of new revolving credit agreement		870,000,000.0
Quarterly principal payment as a percent of face amount		0.25%
Annual principal payment		8,700,000
Revolving Credit Facility [Member]
Term Loan and Credit Facility
Borrowing capacity of new revolving credit agreement		300,000,000.0	475,000,000.0
Unused capacity commitment fee, percentage		0.375%
Senior Secured Credit Facility [Member]
Term Loan and Credit Facility
Maximum increase in borrowing capacity		$ 300,000,000.0
Base Rate [Member] | Senior Secured Credit Facility - Term Loan [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread		2.00%
Base Rate [Member] | Senior Secured Credit Facility - Term Loan [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread		1.75%
Base Rate [Member] | Revolving Credit Facility [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread		2.00%	1.00%
Base Rate [Member] | Revolving Credit Facility [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread		1.75%	0.25%
LIBOR [Member] | Senior Secured Credit Facility - Term Loan [Member]
Term Loan and Credit Facility
Floor rate		0.75%
Current variable rate	3.75%
LIBOR [Member] | Senior Secured Credit Facility - Term Loan [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread		3.00%
LIBOR [Member] | Senior Secured Credit Facility - Term Loan [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread		2.75%
LIBOR [Member] | Revolving Credit Facility [Member] | Maximum [Member]
Term Loan and Credit Facility
Basis spread		3.00%	2.00%
LIBOR [Member] | Revolving Credit Facility [Member] | Minimum [Member]
Term Loan and Credit Facility
Basis spread		2.75%	1.25%

XML

Revenue Recognition (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015		Mar. 31, 2014
Revenue, Major Customer [Line Items]
Provision for uncollectibles	$ (73,999)		$ (5,216)
Net revenue	570,445		259,561
Ambulatory Services [Member]
Revenue, Major Customer [Line Items]
Percentage of revenues from governmental healthcare programs	25.00%		25.00%
Net revenue	283,910		259,561
Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	323,298	[1]
Contract and other revenue	30,989	[1]
Provision for uncollectibles	(67,752)	[1]	0
Net revenue	286,535	[1]	0
Medicare [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	38,173	[1]
Medicaid [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	13,972	[1]
Commercial and Managed Care [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	212,027	[1]
Self-Pay [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Net fee for service revenue	$ 59,126	[1]
Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	100.00%	[1]
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	112.80%	[1]
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Medicare [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	13.30%	[1]
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Medicaid [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	4.90%	[1]
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Commercial and Managed Care [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	74.00%	[1]
Health Care Organization, Patient Service Revenue [Member] | Sales Revenue, Net [Member] | Self-Pay [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	20.60%	[1]
Contract and Other Revenue [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	10.80%	[1]
Provision for Uncollectibles [Member] | Sales Revenue, Net [Member] | Physician Services [Member]
Revenue, Major Customer [Line Items]
Percent of net revenue, over	(23.60%)	[1]

[1] On July 16, 2014, we completed the acquisition of Sheridan. As such, historical amounts for periods prior to that date are not included.

XML

Financial Information for the Company and Its Subsidiaries (Balance Sheets) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Assets
Cash and cash equivalents	$ 116,156	$ 208,079	$ 47,116	$ 50,840
Restricted cash and marketable securities	10,957	10,219
Accounts receivable, net	244,002	233,053
Supplies inventory	20,473	19,974
Prepaid and other current assets	97,361	115,362
Total current assets	488,949	586,687
Property and equipment, net	183,446	180,448
Investments in and receivables from unconsolidated affiliates	79,311	75,475
Goodwill	3,500,668	3,381,149
Intangible assets, net	1,306,267	1,273,879
Other assets	25,368	25,886
Total assets	5,584,009	5,523,524
Liabilities and Equity
Current portion of long-term debt	18,858	18,826
Accounts payable	25,808	29,585
Accrued salaries and benefits	144,607	140,044
Accrued interest	17,857	29,644
Other accrued liabilities	75,701	67,986
Total current liabilities	282,831	286,085
Long-term debt	2,229,994	2,232,186
Deferred income taxes	648,444	633,480
Other long-term liabilities	92,485	89,443
Intercompany payable	0	0
Noncontrolling interests – redeemable	183,459	184,099
Equity:
Total AmSurg Corp. equity	1,701,676	1,679,547
Noncontrolling interests – non-redeemable	445,120	418,684
Total equity	2,146,796	2,098,231
Total liabilities and equity	5,584,009	5,523,524
Consolidation, Eliminations [Member]
Assets
Cash and cash equivalents	0	0	0	0
Restricted cash and marketable securities	0	0
Accounts receivable, net	0	0
Supplies inventory	0	0
Prepaid and other current assets	(5,719)	(4,818)
Total current assets	(5,719)	(4,818)
Property and equipment, net	0	0
Investments in and receivables from unconsolidated affiliates	(5,582,217)	(5,425,210)
Goodwill	1,950,704	1,890,168
Intangible assets, net	0	0
Other assets	0	(1,466)
Total assets	(3,637,232)	(3,541,326)
Liabilities and Equity
Current portion of long-term debt	0	0
Accounts payable	(4,927)	(4,080)
Accrued salaries and benefits	0	0
Accrued interest	0	0
Other accrued liabilities	(792)	(738)
Total current liabilities	(5,719)	(4,818)
Long-term debt	(30,985)	(28,412)
Deferred income taxes	0	(1,466)
Other long-term liabilities	0	0
Intercompany payable	(1,228,157)	(1,227,989)
Noncontrolling interests – redeemable	120,666	120,555
Equity:
Total AmSurg Corp. equity	(2,892,406)	(2,774,257)
Noncontrolling interests – non-redeemable	399,369	375,061
Total equity	(2,493,037)	(2,399,196)
Total liabilities and equity	(3,637,232)	(3,541,326)
Parent Company [Member]
Assets
Cash and cash equivalents	30,118	134,351	5,562	6,710
Restricted cash and marketable securities	0	0
Accounts receivable, net	0	0
Supplies inventory	0	0
Prepaid and other current assets	51,155	47,997
Total current assets	81,273	182,348
Property and equipment, net	11,910	10,391
Investments in and receivables from unconsolidated affiliates	4,025,683	3,912,804
Goodwill	0	0
Intangible assets, net	66,001	67,678
Other assets	3,734	3,323
Total assets	4,188,601	4,176,544
Liabilities and Equity
Current portion of long-term debt	8,700	8,700
Accounts payable	2,255	1,849
Accrued salaries and benefits	19,652	25,035
Accrued interest	17,840	29,621
Other accrued liabilities	7,272	8,051
Total current liabilities	55,719	73,256
Long-term debt	2,204,775	2,206,950
Deferred income taxes	218,564	209,400
Other long-term liabilities	7,867	7,391
Intercompany payable	0	0
Noncontrolling interests – redeemable	0	0
Equity:
Total AmSurg Corp. equity	1,701,676	1,679,547
Noncontrolling interests – non-redeemable	0	0
Total equity	1,701,676	1,679,547
Total liabilities and equity	4,188,601	4,176,544
Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	38,681	23,471	0	0
Restricted cash and marketable securities	0	0
Accounts receivable, net	130,807	123,772
Supplies inventory	286	301
Prepaid and other current assets	32,196	58,388
Total current assets	201,970	205,932
Property and equipment, net	8,665	9,972
Investments in and receivables from unconsolidated affiliates	1,635,845	1,587,881
Goodwill	1,549,964	1,490,981
Intangible assets, net	1,237,487	1,203,218
Other assets	1,040	943
Total assets	4,634,971	4,498,927
Liabilities and Equity
Current portion of long-term debt	0	0
Accounts payable	224	35
Accrued salaries and benefits	111,525	101,395
Accrued interest	0	0
Other accrued liabilities	39,909	44,305
Total current liabilities	151,658	145,735
Long-term debt	0	0
Deferred income taxes	429,880	425,546
Other long-term liabilities	65,622	63,616
Intercompany payable	1,228,136	1,219,979
Noncontrolling interests – redeemable	0	0
Equity:
Total AmSurg Corp. equity	2,759,675	2,644,051
Noncontrolling interests – non-redeemable	0	0
Total equity	2,759,675	2,644,051
Total liabilities and equity	4,634,971	4,498,927
Non-Guarantor Subsidiaries [Member]
Assets
Cash and cash equivalents	47,357	50,257	41,554	44,130
Restricted cash and marketable securities	10,957	10,219
Accounts receivable, net	113,195	109,281
Supplies inventory	20,187	19,673
Prepaid and other current assets	19,729	13,795
Total current assets	211,425	203,225
Property and equipment, net	162,871	160,085
Investments in and receivables from unconsolidated affiliates	0	0
Goodwill	0	0
Intangible assets, net	2,779	2,983
Other assets	20,594	23,086
Total assets	397,669	389,379
Liabilities and Equity
Current portion of long-term debt	10,158	10,126
Accounts payable	28,256	31,781
Accrued salaries and benefits	13,430	13,614
Accrued interest	17	23
Other accrued liabilities	29,312	16,368
Total current liabilities	81,173	71,912
Long-term debt	56,204	53,648
Deferred income taxes	0	0
Other long-term liabilities	18,996	18,436
Intercompany payable	21	8,010
Noncontrolling interests – redeemable	62,793	63,544
Equity:
Total AmSurg Corp. equity	132,731	130,206
Noncontrolling interests – non-redeemable	45,751	43,623
Total equity	178,482	173,829
Total liabilities and equity	$ 397,669	$ 389,379

XML

Dispositions (Tables)

3 Months Ended

Mar. 31, 2015

Discontinued Operations and Disposal Groups [Abstract]

Results Of Operations Of Centers Discontinued

Results of operations and associated gain (loss) on disposal of the centers discontinued for the three months ended March 31, 2014 are as follows (in thousands):

	Three Months Ended   March 31, 2014
Revenues	$	4,594
Earnings before income taxes	540
Results of discontinued operations, net of tax:
Earnings from operations of discontinued interests in surgery centers	430
Loss on disposal of discontinued interests in surgery centers	(362		)
Net earnings from discontinued operations	68
Less: Net earnings from discontinued operations attributable to noncontrolling interests	265
Net loss from discontinued operations attributable to AmSurg Corp. common shareholders	$	(197	)

XML

Shareholders' Equity (Share-Based Activity) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Equity [Abstract]
Share-based compensation expense	$ 3,709	$ 2,458
Fair value of shares vested	11,474	9,175
Cash received from option exercises	1,746	488
Tax benefit from option exercises	$ 3,317	$ 1,727

XML

Goodwill And Intangible Assets (Changes In Carrying Amount Of Goodwill) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015
Goodwill [Roll Forward]
Balance, beginning of period	$ 3,381,149
Goodwill acquired, including post acquisition adjustments	120,588
Goodwill disposed, including impact of deconsolidation transactions	(1,069)
Balance, end of period	$ 3,500,668

XML

Acquisitions (Revs and Earnings) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Business Acquisition [Line Items]
Revenues	$ 570,445	$ 259,561
Net earnings	68,755	60,114
Less: Net earnings attributable to noncontrolling interests	47,717	42,919
Net earnings attributable to AmSurg Corp. shareholders	21,038	17,195
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Revenues	14,989	1,031
Net earnings	2,613	245
Less: Net earnings attributable to noncontrolling interests	761	151
Net earnings attributable to AmSurg Corp. shareholders	$ 1,852	$ 94

XML

Shareholder's Equity (Schedule of Stock Option Activity (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period, Number of Shares	158,721
Options exercised, Number of Shares	(76,962)
Options terminated, Number of Shares	(5,000)
Outstanding at end of period, Number of Shares	76,759	158,721
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Outstanding at beginning of period, Weighted Average Exercise Price	$ 22.89
Options exercised, Weighted Average Exercise Price	$ 22.68
Options terminated, Weighted Average Exercise Price	$ 25.76
Outstanding at end of period, Weighted Average Exercise Price	$ 22.92	$ 22.89
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding at beginning of period, Weighted Average Remaining Contractual Life (in years)	256 days	1 year 256 days
Outstanding at end of period, Weighted Average Remaining Contractual Life (in years)	256 days	1 year 256 days

XML

Long-Term Debt (Components Of Long-Term Debt) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Other debt due through 2025	$ 19,854	$ 20,156
Capitalized lease arrangements due through 2026	15,523	15,206
Long-term debt and capitalized lease arrangements	2,248,852	2,251,012
Less current portion	18,858	18,826
Long-term debt	2,229,994	2,232,186
Term Loan [Member]
Debt Instrument [Line Items]
Long-term Debt	863,475	865,650
5.625% Senior Unsecured Notes due 2020 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term Debt	250,000	250,000
5.625% Senior Unsecured Notes due 2022 [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Long-term Debt	$ 1,100,000	$ 1,100,000

XML

Accounts Receivable

3 Months Ended

Mar. 31, 2015

Receivables [Abstract]

Accounts Receivable

Accounts Receivable

The Company manages accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. The Company tests its analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, on a contract by contract basis, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company’s billing operations to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. The Company also supplements its allowance for doubtful accounts policy for its physician services quarterly using a hindsight calculation that utilizes write-off data for all payor classes during the previous 12-month period to estimate the allowance for doubtful accounts at a point in time. Changes in these estimates are charged or credited to the consolidated statements of earnings in the period of change. Material changes in estimates may result from unforeseen write-offs of patient or third party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by the Company. Significant changes in payor mix, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on the Company’s estimates and significantly affect its results of operations and cash flows.

Due to the nature of the Company's operations, it is required to separate the presentation of its bad debt expense on the consolidated statement of earnings. The Company records the portion of its bad debts associated with its physician services segment as a component of net revenue in the accompanying consolidated statement of earnings, and the remaining portion, which is associated with its ambulatory services segment, is recorded as a component of other operating expenses in the accompanying consolidated statement of earnings. The bifurcation is a result of the Company's ability to assess the ultimate collection of the patient service revenue associated with its ambulatory services segment before services are provided. The Company's ambulatory services segment is generally able to verify a patient's insurance coverage and ability to pay before services are provided as those services are pre-scheduled and non-emergent. Bad debt expense for the ambulatory services segment is included in other operating expenses and was approximately $6.2 million for the three months ended March 31, 2015 and $5.2 million for the three months ended March 31, 2014. Bad debt expense related to physician services was $67.8 million for the three months ended March 31, 2015.

At March 31, 2015 and December 31, 2014 allowances for doubtful accounts were $124.6 million and $113.4 million, respectively. The change in the allowance for doubtful accounts is primarily a result of subsequent operations from acquisitions completed during the period. At March 31, 2015, approximately 72% of the Company’s allowance for doubtful accounts was related to receivables for fee for service patient visits. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance. Concentration of credit risk is limited by the diversity and number of facilities, patients, payors, and by the geographic dispersion of the Company's operations.

XML

Goodwill And Intangible Assets (Summary Of Intangible Assets) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	$ 237,995	$ 237,995
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,134,020	1,085,129
Accumulated Amortization	(65,748)	(49,245)
Net	1,068,272	1,035,884
Total intangible assets, gross carrying amount	1,372,015	1,323,124
Accumulated Amortization	(65,748)	(49,245)
Total intangible assets, net	1,306,267	1,273,879
Customer relationships with hospitals [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,015,763	971,645
Accumulated Amortization	(34,545)	(22,145)
Net	981,218	949,500
Accumulated Amortization	(34,545)	(22,145)
Deferred financing cost [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	59,660	59,574
Accumulated Amortization	(7,225)	(5,151)
Net	52,435	54,423
Accumulated Amortization	(7,225)	(5,151)
Capitalized software [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	54,529	50,387
Accumulated Amortization	(21,136)	(19,197)
Net	33,393	31,190
Accumulated Amortization	(21,136)	(19,197)
Agreements, contracts, and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,068	3,523
Accumulated Amortization	(2,842)	(2,752)
Net	1,226	771
Accumulated Amortization	(2,842)	(2,752)
Trade name [Member]
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	228,000	228,000
Restrictive covenant arrangements [Member]
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangible assets	$ 9,995	$ 9,995

XML

Shareholders' Equity (Tables)

3 Months Ended

Mar. 31, 2015

Equity [Abstract]

Share-Based Activity

Other information pertaining to share-based activity during the three months ended March 31, 2015 and 2014 was as follows (in thousands):

	Three Months Ended March 31,
	2015		2014
Share-based compensation expense	$	3,709	$	2,458
Fair value of shares vested	11,474		9,175
Cash received from option exercises	1,746		488
Tax benefit from option exercises	3,317		1,727

Schedule Of Changes In Non-Vested Restricted Shares

A summary of the status of non-vested restricted shares at March 31, 2015 and changes during the three months ended March 31, 2015 is as follows:

			Weighted
	Number		Average
	of Shares		Grant Price
Non-vested shares at December 31, 2014	668,109		$	33.51
Shares granted	295,527		55.40
Shares vested	(208,701	)	26.62
Shares forfeited	(5,328	)	35.06
Non-vested shares at March 31, 2015	749,607		$	44.05

Schedule Of Stock Option Activity

A summary of stock option activity for the three months ended March 31, 2015 is summarized as follows:

					Weighted
			Weighted		Average
			Average		Remaining
	Number		Exercise		Contractual
	of Shares		Price		Term (in years)
Outstanding at December 31, 2014	158,721		$	22.89	1.7
Options exercised with total intrinsic value of $2.9 million	(76,962	)	22.68
Options terminated	(5,000	)	25.76
Outstanding, Vested and Exercisable at March 31, 2015 with an aggregate intrinsic value of $3.0 million	76,759		$	22.92	0.7

Schedule Of Reconciliation Of Numerator And Denominators Of Basic And Diluted Earnings Per Share

The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts):

	Three Months Ended March 31,
	Earnings		Shares	Per Share
	(Numerator)		(Denominator)	Amount
2015:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	18,774	47,572	$	0.39
Effect of dilutive securities, options and non-vested shares	—		333
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	18,774	47,905	$	0.39
2014:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	17,392	31,716	$	0.55
Effect of dilutive securities, options and non-vested shares	—		404
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	17,392	32,120	$	0.54

XML

Long-Term Debt (Tables)

3 Months Ended

Mar. 31, 2015

Debt Disclosure [Abstract]

Components Of Long-Term Debt

Long-term debt at March 31, 2015 and December 31, 2014 consisted of the following (in thousands):

	March 31,		December 31,
	2015		2014
Term loan	$	863,475	$	865,650
5.625% Senior Unsecured Notes due 2020	250,000		250,000
5.625% Senior Unsecured Notes due 2022	1,100,000		1,100,000
Other debt due through 2025	19,854		20,156
Capitalized lease arrangements due through 2026	15,523		15,206
	2,248,852		2,251,012
Less current portion	18,858		18,826
Long-term debt	$	2,229,994	$	2,232,186

Redemption Price Percentage

The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below:  

Period	Redemption Price
2015	104.219	%
2016	102.813	%
2017	101.406	%
2018 and thereafter	100.000	%

The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below:

Period	Redemption Price
2017	104.219	%
2018	102.813	%
2019	101.406	%
2020 and thereafter	100.000	%

XML

Segment Reporting (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended			6 Months Ended
	Mar. 31, 2015 segment		Mar. 31, 2014	Jul. 15, 2014 segment	Dec. 31, 2014
Segment Reporting [Abstract]
Number of reportable segments	2			1
Segment Reporting Information [Line Items]
Net revenue	$ 570,445		$ 259,561
Adjusted EBITDA	93,755		46,006
Earnings from continuing operations attributable to noncontrolling interests	47,717		42,654
Interest expense, net	(30,247)		(6,960)
Depreciation and amortization	(22,818)		(8,259)
Share-based compensation	(3,709)		(2,458)
Transaction costs	(1,471)		0
Gain (loss) on deconsolidation	(223)		2,045
Earnings from continuing operations before income taxes	83,004		73,028
Acquisition and Capital Expenditures	141,361		12,076
Assets	5,584,009				5,523,524
Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Net revenue	283,910		259,561
Adjusted EBITDA	47,308		46,006
Acquisition and Capital Expenditures	54,096		12,076
Physician Services [Member]
Segment Reporting Information [Line Items]
Net revenue	286,535	[1]	0
Adjusted EBITDA	46,447		0
Acquisition and Capital Expenditures	$ 87,265		$ 0

[1] On July 16, 2014, we completed the acquisition of Sheridan. As such, historical amounts for periods prior to that date are not included.

XML

Accrued Professional Liabilities - Components of Reserves (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Estimated losses under self-insured programs	$ 26,199
Incurred but not reported losses	31,342
Total accrued professional liabilities	57,541	53,785
Less estimated losses payable within one year	10,957
Total	$ 46,584

XML

Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2015

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

	Three Months Ended March 31,
	2015			2014
Net Revenue:
Ambulatory Services	$	283,910		$	259,561
Physician Services	286,535			—
Total	$	570,445		$	259,561
Adjusted EBITDA:
Ambulatory Services	$	47,308		$	46,006
Physician Services	46,447			—
Total	$	93,755		$	46,006
Adjusted EBITDA:	$	93,755		$	46,006
Earnings from continuing operations attributable to noncontrolling interests	47,717			42,654
Interest expense, net	(30,247		)	(6,960		)
Depreciation and amortization	(22,818		)	(8,259		)
Share-based compensation	(3,709		)	(2,458		)
Transaction costs	(1,471		)	—
Gain (loss) on deconsolidation	(223		)	2,045
Earnings from continuing operations before income taxes	$	83,004		$	73,028
Acquisition and Capital Expenditures:
Ambulatory Services	$	54,096		$	12,076
Physician Services	87,265			—
Total	$	141,361		$	12,076

XML

Financial Information for the Company and Its Subsidiaries (Tables)

3 Months Ended

Mar. 31, 2015

Condensed Financial Information of Parent Company Only Disclosure [Abstract]

Condensed Consolidating Balance Sheet

Condensed Consolidating Balance Sheet - March 31, 2015 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Assets
Current assets:
Cash and cash equivalents	$	30,118	$	38,681	$	47,357	$	—		$	116,156
Restricted cash and marketable securities	—		—		10,957		—			10,957
Accounts receivable, net	—		130,807		113,195		—			244,002
Supplies inventory	—		286		20,187		—			20,473
Prepaid and other current assets	51,155		32,196		19,729		(5,719		)	97,361
Total current assets	81,273		201,970		211,425		(5,719		)	488,949
Property and equipment, net	11,910		8,665		162,871		—			183,446
Investments in and receivables from unconsolidated affiliates	4,025,683		1,635,845		—		(5,582,217		)	79,311
Goodwill	—		1,549,964		—		1,950,704			3,500,668
Intangible assets, net	66,001		1,237,487		2,779		—			1,306,267
Other assets	3,734		1,040		20,594		—			25,368
Total assets	$	4,188,601	$	4,634,971	$	397,669	$	(3,637,232	)	$	5,584,009
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	8,700	$	—	$	10,158	$	—		$	18,858
Accounts payable	2,255		224		28,256		(4,927		)	25,808
Accrued salaries and benefits	19,652		111,525		13,430		—			144,607
Accrued interest	17,840		—		17		—			17,857
Other accrued liabilities	7,272		39,909		29,312		(792		)	75,701
Total current liabilities	55,719		151,658		81,173		(5,719		)	282,831
Long-term debt	2,204,775		—		56,204		(30,985		)	2,229,994
Deferred income taxes	218,564		429,880		—		—			648,444
Other long-term liabilities	7,867		65,622		18,996		—			92,485
Intercompany payable	—		1,228,136		21		(1,228,157		)	—
Noncontrolling interests – redeemable	—		—		62,793		120,666			183,459
Equity:
Total AmSurg Corp. equity	1,701,676		2,759,675		132,731		(2,892,406		)	1,701,676
Noncontrolling interests – non-redeemable	—		—		45,751		399,369			445,120
Total equity	1,701,676		2,759,675		178,482		(2,493,037		)	2,146,796
Total liabilities and equity	$	4,188,601	$	4,634,971	$	397,669	$	(3,637,232	)	$	5,584,009

Condensed Consolidating Balance Sheet - December 31, 2014 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Assets
Current assets:
Cash and cash equivalents	$	134,351	$	23,471	$	50,257	$	—		$	208,079
Restricted cash and marketable securities	—		—		10,219		—			10,219
Accounts receivable, net	—		123,772		109,281		—			233,053
Supplies inventory	—		301		19,673		—			19,974
Prepaid and other current assets	47,997		58,388		13,795		(4,818		)	115,362
Total current assets	182,348		205,932		203,225		(4,818		)	586,687
Property and equipment, net	10,391		9,972		160,085		—			180,448
Investments in and receivables from unconsolidated affiliates	3,912,804		1,587,881		—		(5,425,210		)	75,475
Goodwill	—		1,490,981		—		1,890,168			3,381,149
Intangible assets, net	67,678		1,203,218		2,983		—			1,273,879
Other assets	3,323		943		23,086		(1,466		)	25,886
Total assets	$	4,176,544	$	4,498,927	$	389,379	$	(3,541,326	)	$	5,523,524
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	8,700	$	—	$	10,126	$	—		$	18,826
Accounts payable	1,849		35		31,781		(4,080		)	29,585
Accrued salaries and benefits	25,035		101,395		13,614		—			140,044
Accrued interest	29,621		—		23		—			29,644
Other accrued liabilities	8,051		44,305		16,368		(738		)	67,986
Total current liabilities	73,256		145,735		71,912		(4,818		)	286,085
Long-term debt	2,206,950		—		53,648		(28,412		)	2,232,186
Deferred income taxes	209,400		425,546		—		(1,466		)	633,480
Other long-term liabilities	7,391		63,616		18,436		—			89,443
Intercompany payable	—		1,219,979		8,010		(1,227,989		)	—
Noncontrolling interests – redeemable	—		—		63,544		120,555			184,099
Equity:
Total AmSurg Corp. equity	1,679,547		2,644,051		130,206		(2,774,257		)	1,679,547
Noncontrolling interests – non-redeemable	—		—		43,623		375,061			418,684
Total equity	1,679,547		2,644,051		173,829		(2,399,196		)	2,098,231
Total liabilities and equity	$	4,176,544	$	4,498,927	$	389,379	$	(3,541,326	)	$	5,523,524

Condensed Consolidating Statement of Operations

Condensed Consolidating Statement of Earnings - For the Three Months Ended March 31, 2015 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	7,091		$	285,579		$	286,629		$	(8,854	)	$	570,445
Operating expenses:
Salaries and benefits	17,643			211,601			73,063			(128		)	302,179
Supply cost	—			396			42,188			—			42,584
Other operating expenses	6,634			29,611			63,051			(8,726		)	90,570
Transaction costs	268			1,203			—			—			1,471
Depreciation and amortization	834			14,307			7,677			—			22,818
Total operating expenses	25,379			257,118			185,979			(8,854		)	459,622
Loss on deconsolidation	(188		)	(188		)	(35		)	188			(223		)
Equity in earnings of unconsolidated affiliates	60,387			54,583			—			(112,319		)	2,651
Operating income	41,911			82,856			100,615			(112,131		)	113,251
Interest expense, net	11,886			17,754			607			—			30,247
Earnings from operations before income taxes	30,025			65,102			100,008			(112,131		)	83,004
Income tax expense	8,987			4,903			359			—			14,249
Net earnings	21,038			60,199			99,649			(112,131		)	68,755
Net earnings attributable to noncontrolling interests	—			—			47,717			—			47,717
Net earnings attributable to AmSurg Corp. shareholders	21,038			60,199			51,932			(112,131		)	21,038
Preferred stock dividends	(2,264		)	—			—			—			(2,264		)
Net earnings attributable to AmSurg Corp. common shareholders	$	18,774		$	60,199		$	51,932		$	(112,131	)	$	18,774

Condensed Consolidating Statement of Earnings - For the Three Months Ended March 31, 2014 (In thousands)
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Net revenue	$	6,127		$	—	$	258,043	$	(4,609	)	$	259,561
Operating expenses:
Salaries and benefits	14,485			—		67,785		(121		)	82,149
Supply cost	—			—		37,805		—			37,805
Other operating expenses	4,166			—		54,491		(4,488		)	54,169
Depreciation and amortization	825			—		7,434		—			8,259
Total operating expenses	19,476			—		167,515		(4,609		)	182,382
Gain on deconsolidation	2,045			2,045		—		(2,045		)	2,045
Equity in earnings of unconsolidated affiliates	48,052			48,052		—		(95,340		)	764
Operating income	36,748			50,097		90,528		(97,385		)	79,988
Interest expense	6,452			—		508		—			6,960
Earnings from continuing operations before income taxes	30,296			50,097		90,020		(97,385		)	73,028
Income tax expense	12,704			—		278		—			12,982
Net earnings from continuing operations	17,592			50,097		89,742		(97,385		)	60,046
Net earnings (loss) from discontinued operations	(397		)	—		465		—			68
Net earnings	17,195			50,097		90,207		(97,385		)	60,114
Net earnings attributable to noncontrolling interests	—			—		42,919		—			42,919
Net earnings attributable to AmSurg Corp. common shareholders	$	17,195		$	50,097	$	47,288	$	(97,385	)	$	17,195
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	17,592		$	50,097	$	47,088	$	(97,385	)	$	17,392
Discontinued operations, net of income tax	(397		)	—		200		—			(197		)
Net earnings attributable to AmSurg Corp. common shareholders	$	17,195		$	50,097	$	47,288	$	(97,385	)	$	17,195

Condensed Consolidating Statement of Cash Flows

Condensed Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2015 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by (used in) operating activities	$	(33,779	)	$	91,981		$	102,821		$	(62,196	)	$	98,827
Cash flows from investing activities:
Acquisitions and related expenses	(62,056		)	(127,047		)	—			62,525			(126,578		)
Acquisition of property and equipment	(2,678		)	(2,538		)	(9,567		)	—			(14,783		)
Other	—			(1,322		)	1,102			—			(220		)
Net cash flows used in investing activities	(64,734		)	(130,907		)	(8,465		)	62,525			(141,581		)
Cash flows from financing activities:
Proceeds from long-term borrowings	—			—			2,227			—			2,227
Repayment on long-term borrowings	(2,175		)	—			(3,038		)	—			(5,213		)
Distributions to owners, including noncontrolling interests	—			(10,241		)	(99,157		)	62,196			(47,202		)
Capital contributions	—			62,056			—			(62,056		)	—
Cash dividends for preferred shares	(2,264		)	—			—			—			(2,264		)
Changes in intercompany balances with affiliates, net	(2,573		)	—			2,573			—			—
Other financing activities, net	1,292			2,321			139			(469		)	3,283
Net cash flows provided by (used in) financing activities	(5,720		)	54,136			(97,256		)	(329		)	(49,169		)
Net increase (decrease) in cash and cash equivalents	(104,233		)	15,210			(2,900		)	—			(91,923		)
Cash and cash equivalents, beginning of period	134,351			23,471			50,257			—			208,079
Cash and cash equivalents, end of period	$	30,118		$	38,681		$	47,357		$	—		$	116,156

Condensed Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2014 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	18,482		$	48,096		$	96,257		$	(93,016	)	$	69,819
Cash flows from investing activities:
Acquisitions and related expenses	—			(5,082		)	—			44			(5,038		)
Acquisition of property and equipment	(1,237		)	—			(5,801		)	—			(7,038		)
Proceeds from sale of interests in surgery centers	—			1,111			—			—			1,111
Other	(629		)	211			—			—			(418		)
Net cash flows used in investing activities	(1,866		)	(3,760		)	(5,801		)	44			(11,383		)
Cash flows from financing activities:
Proceeds from long-term borrowings	30,000			—			1,945			—			31,945
Repayment on long-term borrowings	(47,679		)	—			(3,174		)	—			(50,853		)
Distributions to owners, including noncontrolling interests	—			(44,920		)	(91,290		)	93,016			(43,194		)
Changes in intercompany balances with affiliates, net	556			—			(556		)	—			—
Other financing activities, net	(641		)	584			43			(44		)	(58		)
Net cash flows used in financing activities	(17,764		)	(44,336		)	(93,032		)	92,972			(62,160		)
Net decrease in cash and cash equivalents	(1,148		)	—			(2,576		)	—			(3,724		)
Cash and cash equivalents, beginning of period	6,710			—			44,130			—			50,840
Cash and cash equivalents, end of period	$	5,562		$	—		$	41,554		$	—		$	47,116

XML

Revenue Recognition

3 Months Ended

Mar. 31, 2015

Revenue Recognition [Abstract]

Revenue Recognition

Revenue Recognition

Ambulatory Services

Ambulatory services revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers.  Such revenues are recognized when the related surgical procedures are performed.  Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor.

Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid.  During the three months ended March 31, 2015 and 2014, the Company derived approximately 25% of its ambulatory services revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs.  Concentration of credit risk with respect to other payors is limited due to the large number of such payors.

Physician Services

Physician services revenues primarily consists of fee for service revenue and contract revenue and are derived principally from the provision of physician services to patients of the healthcare facilities the Company serves. Contract revenue represents income earned from the Company's hospital customers to subsidize contract costs when payments from third-party payors are inadequate to support such costs.

The Company records revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors. The Company also recognizes revenue for services provided during the period that have not been billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patients’ healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections.

The Company's provision for uncollectibles includes its estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. The Company records net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries).

Net revenue for the physician services segment consists of the following major payors (in thousands):

	Three Months Ended March 31, 2015 (1)
Medicare	$	38,173		13.3	%
Medicaid	13,972			4.9
Commercial and managed care	212,027			74.0
Self-pay	59,126			20.6
Net fee for service revenue	323,298			112.8
Contract and other revenue	30,989			10.8
Provision for uncollectibles	(67,752		)	(23.6	)
Net revenue for physician services	$	286,535		100.0	%

(1) On July 16, 2014, we completed the acquisition of Sheridan. As such, historical amounts for periods prior to that date are not included.

XML

Basis of Presentation (Details) (USD $)	Mar. 31, 2015 center	Dec. 31, 2014
Ownership Interests [Line Items]
Number of ownership interests of less than 51%	13
Restricted Cash and Marketable Securities
Restricted cash and marketable securities, total	$ 30,300,000
Restricted cash and marketable securities, current	10,957,000	10,219,000
Restricted cash and investments, noncurrent	19,300,000
Restricted marketable securities	$ 3,000,000
Consolidated [Member]
Ownership Interests [Line Items]
Number of ownership interests of less than 51%	2
Nonconsolidated [Member]
Ownership Interests [Line Items]
Number of ownership interests of less than 51%	11

XML

Dispositions (Results Of Operations Of Centers Discontinued) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]
Revenues		$ 4,594
Earnings before income taxes		540
Results of discontinued operations, net of tax:
Earnings from operations of discontinued interests in surgery centers		430
Loss on disposal of discontinued interests in surgery centers		(362)
Net earnings from discontinued operations	0	68
Less: Net earnings from discontinued operations attributable to noncontrolling interests		265
Net loss from discontinued operations attributable to AmSurg Corp. common shareholders	0	(197)
Cash proceeds from disposal	$ 0	$ 1,111

XML

Shareholder's Equity (Schedule of Stock Option Activity-Additional) (Details) (USD $) In Millions, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Total intrinsic value with options exercised	$ 2.9
Aggregate intrinsic value of options outstanding	3.0
Total intrinsic value of options vested or expected to vest	3.0
Vested or expected to vest at end of period, Number of Shares	76,759
Vested or expected to vest at end of period, weighted average exercise price	$ 22.92
Vested or expected to vest at end of period, Weighted Average Remaining Contractual Life (in years)	256 days
Total Intrinsic value of options exercisable	$ 3.0
Exercisable at end of period, Number of Shares	76,759
Exercisable at end of period, Weighted Average Exercise Price	$ 22.92
Exercisable at end of period, Weighted Average Remaining Contractual Life (in years)	256 days

XML

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Assets
Cash and cash equivalents	$ 116,156	$ 208,079
Restricted cash and marketable securities	10,957	10,219
Accounts receivable, net of allowance of $124,606 and $113,357, respectively	244,002	233,053
Supplies inventory	20,473	19,974
Prepaid and other current assets	97,361	115,362
Total current assets	488,949	586,687
Property and equipment, net	183,446	180,448
Investments in unconsolidated affiliates	79,311	75,475
Goodwill	3,500,668	3,381,149
Intangible assets, net	1,306,267	1,273,879
Other assets	25,368	25,886
Total assets	5,584,009	5,523,524
Liabilities and Equity
Current portion of long-term debt	18,858	18,826
Accounts payable	25,808	29,585
Accrued salaries and benefits	144,607	140,044
Accrued interest	17,857	29,644
Other accrued liabilities	75,701	67,986
Total current liabilities	282,831	286,085
Long-term debt	2,229,994	2,232,186
Deferred income taxes	648,444	633,480
Other long-term liabilities	92,485	89,443
Commitments and contingencies
Noncontrolling interests – redeemable	183,459	184,099
Equity:
Mandatory convertible preferred stock, no par value, 5,000 shares authorized, 1,725 shares issued and outstanding	166,632	166,632
Common stock, no par value, 70,000 shares authorized, 48,413 and 48,113 shares issued and outstanding, respectively	888,748	885,393
Retained earnings	646,296	627,522
Total AmSurg Corp. equity	1,701,676	1,679,547
Noncontrolling interests – non-redeemable	445,120	418,684
Total equity	2,146,796	2,098,231
Total liabilities and equity	$ 5,584,009	$ 5,523,524

XML

Accrued Professional Liabilities - Rollforward of Reserves (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015
Self Insurance Reserve [Roll Forward]
Balance at December 31, 2014	$ 53,785
Assumed liabilities through acquisitions	4,301
Provision related to current period reserves	3,300
Payments for current period reserves	(1,551)
Payments for prior period reserves	(2,294)
Balance at March 31, 2015	$ 57,541

XML

Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net earnings	$ 68,755	$ 60,114
Adjustments to reconcile net earnings to net cash flows provided by operating activities:
Depreciation and amortization	22,818	8,259
Amortization of deferred loan costs	2,074	498
Provision for uncollectibles	73,999	5,216
Net loss on sale of long-lived assets	0	604
Loss (gain) on deconsolidation	223	(2,045)
Share-based compensation	3,709	2,458
Excess tax benefit from share-based compensation	(3,317)	(1,727)
Deferred income taxes	3,334	11,933
Equity in earnings of unconsolidated affiliates	(2,651)	(764)
Increases (decreases) in cash and cash equivalents, net of acquisitions and dispositions:
Accounts receivable	(74,214)	(6,867)
Supplies inventory	(30)	(245)
Prepaid and other current assets	13,842	(3,638)
Accounts payable	(2,526)	(3,578)
Accrued expenses and other liabilities	(7,886)	(606)
Other, net	697	207
Net cash flows provided by operating activities	98,827	69,819
Cash flows from investing activities:
Acquisitions and related expenses	(126,578)	(5,038)
Acquisition of property and equipment	(14,783)	(7,038)
Proceeds from sale of interests in surgery centers	0	1,111
Other	(220)	(418)
Net cash flows used in investing activities	(141,581)	(11,383)
Cash flows from financing activities:
Proceeds from long-term borrowings	2,227	31,945
Repayment on long-term borrowings	(5,213)	(50,853)
Distributions to noncontrolling interests	(47,202)	(43,194)
Cash dividends for preferred shares	(2,264)	0
Proceeds from issuance of common stock upon exercise of stock options	1,746	488
Repurchase of common stock	(3,684)	(2,857)
Excess tax benefit from share-based compensation	3,317	1,727
Other	1,904	584
Net cash flows used in financing activities	(49,169)	(62,160)
Net decrease in cash and cash equivalents	(91,923)	(3,724)
Cash and cash equivalents, beginning of period	208,079	50,840
Cash and cash equivalents, end of period	116,156	47,116
Supplemental cash flow information:
Interest payments	40,043	3,132
Income tax paid (received)	$ (88)	$ 65

XML

Financial Information for the Company and Its Subsidiaries (Cash Flow Statements) (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net cash flows provided by (used in) operating activities	$ 98,827	$ 69,819
Cash flows from investing activities:
Acquisitions and related expenses	(126,578)	(5,038)
Acquisition of property and equipment	(14,783)	(7,038)
Proceeds from sale of interests in surgery centers	0	1,111
Other	(220)	(418)
Net cash flows used in investing activities	(141,581)	(11,383)
Cash flows from financing activities:
Proceeds from long-term borrowings	2,227	31,945
Repayment on long-term borrowings	(5,213)	(50,853)
Distributions to owners, including noncontrolling interests	(47,202)	(43,194)
Capital contributions	0
Cash dividends for preferred shares	(2,264)	0
Changes in intercompany balances with affiliates, net	0	0
Other financing activities, net	3,283	(58)
Net cash flows used in financing activities	(49,169)	(62,160)
Net decrease in cash and cash equivalents	(91,923)	(3,724)
Cash and cash equivalents, beginning of period	208,079	50,840
Cash and cash equivalents, end of period	116,156	47,116
Consolidation, Eliminations [Member]
Cash flows from operating activities:
Net cash flows provided by (used in) operating activities	(62,196)	(93,016)
Cash flows from investing activities:
Acquisitions and related expenses	62,525	44
Acquisition of property and equipment	0	0
Proceeds from sale of interests in surgery centers		0
Other	0	0
Net cash flows used in investing activities	62,525	44
Cash flows from financing activities:
Proceeds from long-term borrowings	0	0
Repayment on long-term borrowings	0	0
Distributions to owners, including noncontrolling interests	62,196	93,016
Capital contributions	(62,056)
Cash dividends for preferred shares	0
Changes in intercompany balances with affiliates, net	0	0
Other financing activities, net	(469)	(44)
Net cash flows used in financing activities	(329)	92,972
Net decrease in cash and cash equivalents	0	0
Cash and cash equivalents, beginning of period	0	0
Cash and cash equivalents, end of period	0	0
Parent Company [Member]
Cash flows from operating activities:
Net cash flows provided by (used in) operating activities	(33,779)	18,482
Cash flows from investing activities:
Acquisitions and related expenses	(62,056)	0
Acquisition of property and equipment	(2,678)	(1,237)
Proceeds from sale of interests in surgery centers		0
Other	0	(629)
Net cash flows used in investing activities	(64,734)	(1,866)
Cash flows from financing activities:
Proceeds from long-term borrowings	0	30,000
Repayment on long-term borrowings	(2,175)	(47,679)
Distributions to owners, including noncontrolling interests	0	0
Capital contributions	0
Cash dividends for preferred shares	(2,264)
Changes in intercompany balances with affiliates, net	(2,573)	556
Other financing activities, net	1,292	(641)
Net cash flows used in financing activities	(5,720)	(17,764)
Net decrease in cash and cash equivalents	(104,233)	(1,148)
Cash and cash equivalents, beginning of period	134,351	6,710
Cash and cash equivalents, end of period	30,118	5,562
Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by (used in) operating activities	91,981	48,096
Cash flows from investing activities:
Acquisitions and related expenses	(127,047)	(5,082)
Acquisition of property and equipment	(2,538)	0
Proceeds from sale of interests in surgery centers		1,111
Other	(1,322)	211
Net cash flows used in investing activities	(130,907)	(3,760)
Cash flows from financing activities:
Proceeds from long-term borrowings	0	0
Repayment on long-term borrowings	0	0
Distributions to owners, including noncontrolling interests	(10,241)	(44,920)
Capital contributions	62,056
Cash dividends for preferred shares	0
Changes in intercompany balances with affiliates, net	0	0
Other financing activities, net	2,321	584
Net cash flows used in financing activities	54,136	(44,336)
Net decrease in cash and cash equivalents	15,210	0
Cash and cash equivalents, beginning of period	23,471	0
Cash and cash equivalents, end of period	38,681	0
Non-Guarantor Subsidiaries [Member]
Cash flows from operating activities:
Net cash flows provided by (used in) operating activities	102,821	96,257
Cash flows from investing activities:
Acquisitions and related expenses	0	0
Acquisition of property and equipment	(9,567)	(5,801)
Proceeds from sale of interests in surgery centers		0
Other	1,102	0
Net cash flows used in investing activities	(8,465)	(5,801)
Cash flows from financing activities:
Proceeds from long-term borrowings	2,227	1,945
Repayment on long-term borrowings	(3,038)	(3,174)
Distributions to owners, including noncontrolling interests	(99,157)	(91,290)
Capital contributions	0
Cash dividends for preferred shares	0
Changes in intercompany balances with affiliates, net	2,573	(556)
Other financing activities, net	139	43
Net cash flows used in financing activities	(97,256)	(93,032)
Net decrease in cash and cash equivalents	(2,900)	(2,576)
Cash and cash equivalents, beginning of period	50,257	44,130
Cash and cash equivalents, end of period	$ 47,357	$ 41,554

XML

Acquisitions (Narrative) (Details) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jul. 16, 2014	Jul. 02, 2014	Jul. 15, 2014	Dec. 31, 2014
Business Acquisition [Line Items]
Transaction costs	$ 1,471,000	$ 0
Acquisitions and related expenses, net	126,578,000	5,038,000
Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Cash paid to acquire business			2,100,000,000
Value of common stock issued for acquisition			272,000,000
Common Stock [Member]
Business Acquisition [Line Items]
Issuance of common stock (in shares)				9,775,000
Common Stock [Member] | Sheridan Healthcare [Member]
Business Acquisition [Line Items]
Shares of common stock issued for acquisition			5,713,909
Mandatory Convertible Preferred Stock [Member]
Business Acquisition [Line Items]
Issuance of common stock (in shares)				1,725,000
Senior Secured Credit Facility - Term Loan [Member]
Business Acquisition [Line Items]
Maximum borrowing capacity			870,000,000.0
Revolving Credit Facility [Member]
Business Acquisition [Line Items]
Maximum borrowing capacity			300,000,000.0		475,000,000.0
Senior Notes [Member] | 2022 Senior Unsecured Notes [Member]
Business Acquisition [Line Items]
Face amount			1,100,000,000.0
Interest rate			5.625%
Ambulatory Services [Member]
Business Acquisition [Line Items]
Acquisitions and related expenses, net	41,900,000	5,000,000
Ambulatory Services [Member] | Controlling Interest [Member]
Business Acquisition [Line Items]
Number of business acquisitions	1	1
Physician Services [Member] | Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Cash paid to acquire business	84,700,000
Business Combination, Contingent Consideration, Liability	24,600,000					20,700,000
Number of business acquisitions	3
Contingent consideration arrangements, low	21,000,000
Contingent consideration arrangements, high	$ 26,000,000

XML

Basis of Presentation (Policies)

3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

Principles of Consolidation

These unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial reporting and in accordance with Rule 10-01 of Regulation S-X.  In the opinion of management, the unaudited interim consolidated financial statements contained in this report reflect all adjustments, consisting of only normal recurring accruals, which are necessary for a fair presentation of the financial position and the results of operations for the interim periods presented.  The results of operations for any interim period are not necessarily indicative of results for the full year. The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s 2014 Annual Report on Form 10-K.

Ambulatory Services

AmSurg Corp. (the Company), through its wholly-owned subsidiaries, owns interests, primarily 51%, in limited partnerships (LPs) and limited liability companies (LLCs) which own and operate ambulatory surgery centers (ASCs, surgery centers or centers).  The Company does not have an ownership interest in a LP or LLC greater than 51% which it does not consolidate.  The Company has ownership interests of less than 51% in 13 LPs and LLCs, 2 of which it consolidates as the Company has substantive participation rights and 11 of which it does not consolidate as the Company’s rights are limited to protective rights only.  The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries and the consolidated LPs and LLCs.  Consolidation of such LPs and LLCs is necessary as the Company’s wholly-owned subsidiaries have primarily 51% or more of the financial interest of the LPs and LLCs, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the LPs and LLCs, and have control of the entities.  The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests.  Intercompany profits, transactions and balances have been eliminated.  All LPs and LLCs and noncontrolling partners are referred to herein as “partnerships” and “partners”, respectively.

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity.  However, for instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required.  Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of earnings; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary are measured at fair value.  Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows. 

Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests.  The partners of the Company’s center partnerships typically are organized as general partnerships, LPs or LLCs that are not subject to federal income tax.  Each partner shares in the pre-tax earnings of the center in which it is a partner.  Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings.  However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its tax expense.  In addition, distributions from the partnerships are made to both the Company’s wholly-owned subsidiaries and the partners on a pre-tax basis.

Physician Services

On July 16, 2014, the Company completed its acquisition of Sheridan Healthcare (Sheridan). Sheridan is a national provider of multi-specialty physician and administrative services to hospitals, ambulatory surgery centers and other healthcare facilities. Sheridan focuses on delivering comprehensive physician services, primarily in the areas of anesthesiology, children's services, radiology and emergency medicine to healthcare facilities. Through its contracts with healthcare facilities, Sheridan is authorized to bill and collect charges for fee for service medical services rendered by its healthcare professionals and employees in exchange for the provision of services to the patients of these facilities. Contract revenue is earned directly from hospital customers through a variety of payment arrangements that are established when payments from third-party payors are inadequate to support the costs of providing the services required under the contract. Sheridan also provides physician services and manages office-based practices in the areas of gynecology, obstetrics and perinatology. The consolidated financial statements include the accounts of Sheridan and its wholly-owned subsidiaries along with the accounts of affiliated professional corporations (PCs) with which Sheridan currently has management arrangements. Sheridan's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. These arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at the sole discretion of the Company. The Company has a contractual right to transfer the ownership of the PCs at any time to any person it designates as the nominee shareholder. The Company has the right to receive income, both as ongoing fees and as proceeds from the sale of its interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the Company’s interest in the PCs. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs. In addition, the agreements provide that the Company has the right, but not the obligation, to purchase, or to designate a person(s) to purchase, the stock of the PCs for a nominal amount. Separately, in its sole discretion, the Company has the right to assign its interest in the management and purchase agreements. Based upon the provisions of these agreements, the Company has determined that the PCs are variable interest entities and that the Company is the primary beneficiary as defined in the accounting guidance for consolidation.

Restricted Cash

Restricted Cash and Marketable Securities

As of March 31, 2015, the Company had $30.3 million of restricted cash and marketable securities in the accompanying consolidated balance sheets, which is restricted for the purpose of satisfying the obligations of the Company's wholly-owned captive insurance company. The Company has reflected $19.3 million of its restricted cash and marketable securities as a component of other assets in the accompanying consolidated balance sheets. The remaining $11.0 million is reflected as a component of total current assets in the accompanying consolidated balance sheets as such amount is available to satisfy the claims payments estimated to occur in the next twelve months.

Reclassifications

Reclassifications

Certain prior year amounts in the accompanying consolidated financial statements and these notes have been reclassified to reflect the impact of additional discontinued operations as further discussed in note 6.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board (FASB) issued ASU 2014-08 “Presentation of Financial Statements and Property, Plant and Equipment,” which raised the threshold for a disposal to qualify as a discontinued operation and requires certain new disclosures for individually material disposals that do not meet the new definition of a discontinued operation. The ASU’s intent is to reduce the number of disposals reported as discontinued operations by focusing on strategic shifts that have or will have a major effect on the Company’s operations and financial results rather than routine disposals that are not a change in the Company’s strategy. The guidance is effective for interim and annual periods beginning after December 15, 2014, with earlier adoption permitted.  From time to time, the Company will dispose of certain of its entities due to management’s assessment of the Company’s strategy in the market and due to limited growth opportunities at those entities. Historically, these dispositions were classified as discontinued operations and recorded separately from continuing operations. The Company adopted this ASU effective January 1, 2015 and did not have any disposals during the three months ended March 31, 2015.  The Company does not believe this ASU will have a material impact on the Company’s consolidated financial position or cash flows.

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. In April 2015, the FASB proposed a one-year deferral of the ASU. The guidance in ASU 2014-09 would be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. Early adoption would be permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows.

In February 2015, the FASB issued ASU No. 2015-02, "Consolidations (Topic 810) - Amendments to the Consolidation Analysis". The new guidance makes amendments to the current consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities will be considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Revenue Recognition

Ambulatory Services

Ambulatory services revenues consist of billing for the use of the centers’ facilities directly to the patient or third-party payor and, at certain of the Company’s centers (primarily centers that perform gastrointestinal endoscopy procedures), billing for anesthesia services provided by medical professionals employed or contracted by the Company’s centers.  Such revenues are recognized when the related surgical procedures are performed.  Revenues exclude any amounts billed for physicians’ surgical services, which are billed separately by the physicians to the patient or third-party payor.

Revenues from ambulatory services are recognized on the date of service, net of estimated contractual adjustments from third-party medical service payors including Medicare and Medicaid.  During the three months ended March 31, 2015 and 2014, the Company derived approximately 25% of its ambulatory services revenues from governmental healthcare programs, primarily Medicare and managed Medicare programs.  Concentration of credit risk with respect to other payors is limited due to the large number of such payors.

Physician Services

Physician services revenues primarily consists of fee for service revenue and contract revenue and are derived principally from the provision of physician services to patients of the healthcare facilities the Company serves. Contract revenue represents income earned from the Company's hospital customers to subsidize contract costs when payments from third-party payors are inadequate to support such costs.

The Company records revenue at the time services are provided, net of a contractual allowance and a provision for uncollectibles. Revenue less the contractual allowance represents the net revenue expected to be collected from third-party payors (including managed care, commercial and governmental payors such as Medicare and Medicaid) and patients insured by these payors. The Company also recognizes revenue for services provided during the period that have not been billed. Expected collections are estimated based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patients’ healthcare plan, mandated payment rates under the Medicare and Medicaid programs, and historical cash collections.

The Company's provision for uncollectibles includes its estimate of uncollectible balances due from uninsured patients, uncollectible co-pay and deductible balances due from insured patients and special charges, if any, for uncollectible balances due from managed care, commercial and governmental payors. The Company records net revenue from uninsured patients at its estimated realizable value, which includes a provision for uncollectible balances, based on historical cash collections (net of recoveries)

Accounts Receivable

The Company manages accounts receivable by regularly reviewing its accounts and contracts and by providing appropriate allowances for contractual adjustments and uncollectible amounts. Some of the factors considered by management in determining the amount of such allowances are the historical trends of cash collections, contractual and bad debt write-offs, accounts receivable agings, established fee schedules, contracts with payors, changes in payor mix and procedure statistics. Actual collections of accounts receivable in subsequent periods may require changes in the estimated contractual allowance and provision for uncollectibles. The Company tests its analysis by comparing cash collections to net patient revenues and monitoring self-pay utilization. In addition, when actual collection percentages differ from expected results, on a contract by contract basis, supplemental detailed reviews of the outstanding accounts receivable balances may be performed by the Company’s billing operations to determine whether there are facts and circumstances existing that may cause a different conclusion as to the estimate of the collectability of that contract’s accounts receivable from the estimate resulting from using the historical collection experience. The Company also supplements its allowance for doubtful accounts policy for its physician services quarterly using a hindsight calculation that utilizes write-off data for all payor classes during the previous 12-month period to estimate the allowance for doubtful accounts at a point in time. Changes in these estimates are charged or credited to the consolidated statements of earnings in the period of change. Material changes in estimates may result from unforeseen write-offs of patient or third party accounts receivable, unsuccessful disputes with managed care payors, adverse macro-economic conditions which limit patients’ ability to meet their financial obligations for the care provided by physicians, or broad changes to government regulations that adversely impact reimbursement rates for services provided by the Company. Significant changes in payor mix, business office operations, general economic conditions and health care coverage provided by federal or state governments or private insurers may have a significant impact on the Company’s estimates and significantly affect its results of operations and cash flows.

Acquisitions

The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination.  The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control.  The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination.  Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.

Investments in Unconsolidated Affiliates

Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.

Earnings per Share

Basic net earnings attributable to AmSurg Corp. common stockholders, per common share, excludes dilution and is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to AmSurg common stockholders, per common share is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable (1) upon the vesting of restricted stock awards as determined under the treasury stock method and (2) upon conversion of the Company's 5.250% Mandatory Convertible Preferred Stock as determined under the if-converted method. For purposes of calculating diluted earnings per share, preferred stock dividends have been subtracted from both net earnings from continuing operations attributable to AmSurg Corp. and net earnings attributable to AmSurg Corp. common shareholders in periods in which utilizing the if-converted method would be anti-dilutive.

Income Taxes

The Company files a consolidated federal income tax return.  Income taxes are accounted for under the asset and liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes.  In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its consolidated statement of earnings.  The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.

Insurance Programs

Insurance Programs

Given the nature of the services provided, the Company and its subsidiaries are subject to professional and general liability claims and related lawsuits in the ordinary course of business. The Company maintains professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. In addition, the captive provides stop loss coverage for the Company’s self-insured employee health program. The assets, liabilities and results of operations of the wholly-owned captive are consolidated in the accompanying consolidated financial statements. The liabilities for self-insurance in the accompanying consolidated balance sheets include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. The Company also obtains professional liability insurance on a claims-made basis from third party insurers for its surgery centers and certain of its owned practices and employed physicians.

Segments

Prior to the Sheridan acquisition, the Company operated its centers as individual components of one operating and reportable segment. Upon completion of the Sheridan acquisition, the Company operates in two major lines of business - the operation of ambulatory surgery centers and providing multi-specialty outsourced physician services, which have been identified as its operating and reportable segments. Through the ambulatory services segment, the Company acquires, develops and operates ambulatory surgery centers in partnership with physicians. Through the physician services segment, the Company provides outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, children’s services, emergency medicine and radiology.

The Company’s financial information by operating segment is prepared on an internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the performance of the operating segments. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker which is its Chief Executive Officer.

XML

Acquisitions (Fair Value Of Total Consideration Transferred And Major Class Of Consideration) (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2015		Dec. 31, 2014	Mar. 31, 2014
Business Acquisition [Line Items]
Goodwill	$ 3,500,668		$ 3,381,149
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Accounts receivable	11,355	[1]		417
Other current assets	4,091	[1]		81
Property and equipment	3,465	[1]		429
Goodwill	117,141	[1]		8,260
Intangible assets	44,663	[1]		0
Other long-term assets	35	[1]		0
Accounts payable	(1,023)	[1]		(125)
Other accrued liabilities	(6,774)	[1]		(39)
Deferred income taxes	(12,190)	[1]		0
Other long-term liabilities	(4,301)	[1]		0
Long-term debt	(735)	[1]		0
Total fair value	155,727	[1]		9,023
Less: Fair value attributable to noncontrolling interests	23,649	[1]		3,985
Acquisition date fair value of total consideration transferred	$ 132,078	[1]		$ 5,038

[1] Represents the preliminary allocation of fair value of acquired assets and liabilities associated with these acquisitions at March 31, 2015.

XML

Acquisitions (Tables)

3 Months Ended

Mar. 31, 2015

Business Combinations [Abstract]

Fair Value Of Total Consideration Transferred And Major Class Of Consideration

The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisitions completed in the three months ended March 31, 2015 and 2014, including post acquisition date adjustments recorded to purchase price allocations, are as follows (in thousands): 

	Three Months Ended March 31,
	2015 (1)			2014
Accounts receivable	$	11,355		$	417
Other current assets	4,091			81
Property and equipment	3,465			429
Goodwill	117,141			8,260
Intangible assets	44,663			—
Other long-term assets	35			—
Accounts payable	(1,023		)	(125		)
Other accrued liabilities	(6,774		)	(39		)
Deferred income taxes	(12,190		)	—
Other long-term liabilities	(4,301		)	—
Long-term debt	(735		)	—
Total fair value	155,727			9,023
Less:  Fair value attributable to noncontrolling interests	23,649			3,985
Acquisition date fair value of total consideration transferred	$	132,078		$	5,038

(1) Represents the preliminary allocation of fair value of acquired assets and liabilities associated with these acquisitions at March 31, 2015.

Revenues And Net Earnings Associated With Acquisitions

evenue and net earnings included in the three months ended March 31, 2015 and 2014 associated with completed acquisitions are as follows (in thousands):

	Three Months Ended March 31,
	2015		2014
Net revenue	$	14,989	$	1,031
Net earnings	2,613		245
Less:  Net earnings attributable to noncontrolling interests	761		151
Net earnings attributable to AmSurg Corp. common shareholders	$	1,852	$	94

Consolidated Pro Forma Results Of Acquisition

The unaudited consolidated pro forma results for the three months ended March 31, 2015 and 2014, assuming all acquisitions completed prior to March 31, 2015 had been consummated on January 1, 2014, and all 2014 acquisitions had been consummated on January 1, 2013 are as follows (in thousands):

	Three Months Ended March 31,
	2015		2014
Net revenue	$	581,696	$	551,877
Net earnings	71,267		59,152
Amounts attributable to AmSurg Corp. common shareholders:
Net earnings	23,140		13,571
Net earnings per common share:
Basic	$	0.44	$	0.24
Diluted	$	0.44	$	0.24

XML

Basis of Presentation

3 Months Ended

Mar. 31, 2015

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation    

These unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial reporting and in accordance with Rule 10-01 of Regulation S-X.  In the opinion of management, the unaudited interim consolidated financial statements contained in this report reflect all adjustments, consisting of only normal recurring accruals, which are necessary for a fair presentation of the financial position and the results of operations for the interim periods presented.  The results of operations for any interim period are not necessarily indicative of results for the full year. The accompanying unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s 2014 Annual Report on Form 10-K.

Ambulatory Services

AmSurg Corp. (the Company), through its wholly-owned subsidiaries, owns interests, primarily 51%, in limited partnerships (LPs) and limited liability companies (LLCs) which own and operate ambulatory surgery centers (ASCs, surgery centers or centers).  The Company does not have an ownership interest in a LP or LLC greater than 51% which it does not consolidate.  The Company has ownership interests of less than 51% in 13 LPs and LLCs, 2 of which it consolidates as the Company has substantive participation rights and 11 of which it does not consolidate as the Company’s rights are limited to protective rights only.  The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries and the consolidated LPs and LLCs.  Consolidation of such LPs and LLCs is necessary as the Company’s wholly-owned subsidiaries have primarily 51% or more of the financial interest of the LPs and LLCs, are the general partner or majority member with all the duties, rights and responsibilities thereof, are responsible for the day-to-day management of the LPs and LLCs, and have control of the entities.  The responsibilities of the Company’s noncontrolling partners (LPs and noncontrolling members) are to supervise the delivery of medical services, with their rights being restricted to those that protect their financial interests, such as approval of the acquisition of significant assets or the incurrence of debt which they are generally required to guarantee on a pro rata basis based upon their respective ownership interests.  Intercompany profits, transactions and balances have been eliminated.  All LPs and LLCs and noncontrolling partners are referred to herein as “partnerships” and “partners”, respectively.

Ownership interests in consolidated subsidiaries held by parties other than the Company are identified and generally presented in the consolidated financial statements within the equity section but separate from the Company’s equity.  However, for instances in which certain redemption features that are not solely within the control of the Company are present, classification of noncontrolling interests outside of permanent equity is required.  Consolidated net income attributable to the Company and to the noncontrolling interests are identified and presented on the consolidated statements of earnings; changes in ownership interests are accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary are measured at fair value.  Certain transactions with noncontrolling interests are also classified within financing activities in the statements of cash flows. 

Center profits and losses of consolidated entities are allocated to the Company’s partners in proportion to their ownership percentages and reflected in the aggregate as net earnings attributable to noncontrolling interests.  The partners of the Company’s center partnerships typically are organized as general partnerships, LPs or LLCs that are not subject to federal income tax.  Each partner shares in the pre-tax earnings of the center in which it is a partner.  Accordingly, the earnings attributable to noncontrolling interests in each of the Company’s consolidated partnerships are generally determined on a pre-tax basis, and total net earnings attributable to noncontrolling interests are presented after net earnings.  However, the Company considers the impact of the net earnings attributable to noncontrolling interests on earnings before income taxes in order to determine the amount of pre-tax earnings on which the Company must determine its tax expense.  In addition, distributions from the partnerships are made to both the Company’s wholly-owned subsidiaries and the partners on a pre-tax basis.

Physician Services

On July 16, 2014, the Company completed its acquisition of Sheridan Healthcare (Sheridan). Sheridan is a national provider of multi-specialty physician and administrative services to hospitals, ambulatory surgery centers and other healthcare facilities. Sheridan focuses on delivering comprehensive physician services, primarily in the areas of anesthesiology, children's services, radiology and emergency medicine to healthcare facilities. Through its contracts with healthcare facilities, Sheridan is authorized to bill and collect charges for fee for service medical services rendered by its healthcare professionals and employees in exchange for the provision of services to the patients of these facilities. Contract revenue is earned directly from hospital customers through a variety of payment arrangements that are established when payments from third-party payors are inadequate to support the costs of providing the services required under the contract. Sheridan also provides physician services and manages office-based practices in the areas of gynecology, obstetrics and perinatology. The consolidated financial statements include the accounts of Sheridan and its wholly-owned subsidiaries along with the accounts of affiliated professional corporations (PCs) with which Sheridan currently has management arrangements. Sheridan's agreements with these PCs provide that the term of the arrangements is permanent, subject only to termination by the Company, except in the case of gross negligence, fraud or bankruptcy of the Company. These arrangements are captive in nature as a majority of the outstanding voting equity instruments of the PCs are owned by nominee shareholders appointed at the sole discretion of the Company. The Company has a contractual right to transfer the ownership of the PCs at any time to any person it designates as the nominee shareholder. The Company has the right to receive income, both as ongoing fees and as proceeds from the sale of its interest in the PCs, in an amount that fluctuates based on the performance of the PCs and the change in the fair value of the Company’s interest in the PCs. The Company has exclusive responsibility for the provision of all non-medical services required for the day-to-day operation and management of the PCs and establishes the guidelines for the employment and compensation of the physicians and other employees of the PCs. In addition, the agreements provide that the Company has the right, but not the obligation, to purchase, or to designate a person(s) to purchase, the stock of the PCs for a nominal amount. Separately, in its sole discretion, the Company has the right to assign its interest in the management and purchase agreements. Based upon the provisions of these agreements, the Company has determined that the PCs are variable interest entities and that the Company is the primary beneficiary as defined in the accounting guidance for consolidation.

Restricted Cash and Marketable Securities

As of March 31, 2015, the Company had $30.3 million of restricted cash and marketable securities in the accompanying consolidated balance sheets, which is restricted for the purpose of satisfying the obligations of the Company's wholly-owned captive insurance company. The Company has reflected $19.3 million of its restricted cash and marketable securities as a component of other assets in the accompanying consolidated balance sheets. The remaining $11.0 million is reflected as a component of total current assets in the accompanying consolidated balance sheets as such amount is available to satisfy the claims payments estimated to occur in the next twelve months. As of March 31, 2015, the Company had $3.0 million included in restricted cash and marketable securities, consisting of certificates of deposit with maturities less than 180 days, which approximates fair value.

Reclassifications

Certain prior year amounts in the accompanying consolidated financial statements and these notes have been reclassified to reflect the impact of additional discontinued operations as further discussed in note 6.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Pronouncements

In April 2014, the Financial Accounting Standards Board (FASB) issued ASU 2014-08 “Presentation of Financial Statements and Property, Plant and Equipment,” which raised the threshold for a disposal to qualify as a discontinued operation and requires certain new disclosures for individually material disposals that do not meet the new definition of a discontinued operation. The ASU’s intent is to reduce the number of disposals reported as discontinued operations by focusing on strategic shifts that have or will have a major effect on the Company’s operations and financial results rather than routine disposals that are not a change in the Company’s strategy. The guidance is effective for interim and annual periods beginning after December 15, 2014, with earlier adoption permitted.  From time to time, the Company will dispose of certain of its entities due to management’s assessment of the Company’s strategy in the market and due to limited growth opportunities at those entities. Historically, these dispositions were classified as discontinued operations and recorded separately from continuing operations. The Company adopted this ASU effective January 1, 2015 and did not have any disposals during the three months ended March 31, 2015.  The Company does not believe this ASU will have a material impact on the Company’s consolidated financial position or cash flows.

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers,” which will eliminate the transaction and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach using the following steps: identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract and recognize revenue when (or as) the entity satisfies a performance obligation. In April 2015, the FASB proposed a one-year deferral of the ASU. The guidance in ASU 2014-09 would be effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods therein. Early adoption would be permitted for annual reporting periods beginning after December 15, 2016, including interim periods therein. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows.

In February 2015, the FASB issued ASU No. 2015-02, "Consolidations (Topic 810) - Amendments to the Consolidation Analysis". The new guidance makes amendments to the current consolidation guidance, including introducing a separate consolidation analysis specific to limited partnerships and other similar entities. Under this analysis, limited partnerships and other similar entities will be considered a variable-interest entity unless the limited partners hold substantive kick-out rights or participating rights. The standard is effective for annual periods beginning after December 15, 2015. The Company has yet to assess the impact, if any, this ASU will have on the Company's consolidated financial position, results of operations or cash flows.

XML

Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 124,606	$ 113,357
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	1,725,000	1,725,000
Preferred stock, shares outstanding	1,725,000	1,725,000
Common stock, shares authorized	70,000,000	70,000,000
Common Stock, Shares, Issued	70,000,000	70,000,000
Common stock, shares outstanding	48,413,000	48,113,000

XML

Income Taxes

3 Months Ended

Mar. 31, 2015

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes

The Company files a consolidated federal income tax return.  Income taxes are accounted for under the asset and liability method.  Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

The Company applies recognition thresholds and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return as it relates to accounting for uncertainty in income taxes.  In addition, it is the Company’s policy to recognize interest accrued and penalties, if any, related to unrecognized benefits as income tax expense in its consolidated statement of earnings.  The Company does not expect significant changes to its tax positions or liability for tax uncertainties during the next 12 months.

The Company and its subsidiaries file U.S. federal and various state tax returns.  With few exceptions, the Company is no longer subject to U.S. federal or state income tax examinations for years prior to 2011.

XML

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	May 06, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Registrant Name	AMSURG CORP
Entity Central Index Key	0000895930
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		48,413,184

XML

Commitments And Contingencies

3 Months Ended

Mar. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments And Contingencies

Commitments and Contingencies

Litigation

From time to time the Company is named as a party to legal claims and proceedings in the ordinary course of business. The Company's management is not aware of any claims or proceedings that are expected to have a material adverse impact on the Company's consolidated financial condition, results of operations or cash flows.

Insurance Programs

Given the nature of the services provided, the Company and its subsidiaries are subject to professional and general liability claims and related lawsuits in the ordinary course of business. The Company maintains professional insurance with third-party insurers generally on a claims-made basis, subject to self-insured retentions, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. In addition, the captive provides stop loss coverage for the Company’s self-insured employee health program. The assets, liabilities and results of operations of the wholly-owned captive are consolidated in the accompanying consolidated financial statements. The liabilities for self-insurance in the accompanying consolidated balance sheets include estimates of the ultimate costs related to both reported claims on an individual and aggregate basis and unreported claims. The Company also obtains professional liability insurance on a claims-made basis from third party insurers for its surgery centers and certain of its owned practices and employed physicians.

The Company’s reserves for professional liability claims within the self-insured retention are based upon periodic actuarial calculations. These actuarial estimates consider historical claims frequency and severity, loss development patterns and other actuarial assumptions and are not discounted to present value.

The Company also maintains insurance for director and officer liability, workers’ compensation liability and property damage.  Certain policies are subject to deductibles.  In addition to the insurance coverage provided, the Company indemnifies its officers and directors for actions taken on behalf of the Company and its subsidiaries. 

Redeemable Noncontrolling Interests

Certain of the Company’s wholly-owned subsidiaries, as general partners in the LPs, are responsible for all debts incurred but unpaid by the LPs. As manager of the operations of the LPs, the Company has the ability to limit potential liabilities by curtailing operations or taking other operating actions.

In the event of a change in current law that would prohibit the physicians’ current form of ownership in the partnerships, the Company would be obligated to purchase the physicians’ interests in a substantial majority of the Company’s partnerships.  The purchase price to be paid in such event would be determined by a pre-defined formula, as specified in the partnership agreements.  The Company believes the likelihood of a change in current law that would trigger such purchases was remote as of March 31, 2015. As a result, the noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are classified as noncontrolling interests – redeemable on the Company’s consolidated balance sheets.

Physician Services Division Headquarters Operating Lease

On January 16, 2015, the Company entered into an agreement to lease approximately 222,000 square feet of office space in Plantation, Florida which it intends to be the future headquarters of the Company’s Physician Services Division. The Company expects to occupy approximately 167,000 square feet of office space by September 1, 2016 and an additional approximately 55,000 square feet of space commencing May 1, 2017. The initial term of this lease agreement is set to expire in February 2029. The Company expects to take possession in June of 2015 to begin tenant improvements. As the lease is expected to be operating in nature, the Company will begin to recognize rent expense on a straight line basis when possession is obtained. Annual rent expense is expected to be approximately $2.7 million.

XML

Consolidated Statements Of Earnings (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015		Mar. 31, 2014
Revenues	$ 638,197		$ 259,561
Provision for uncollectibles	(73,999)		(5,216)
Net revenue	570,445		259,561
Operating expenses:
Salaries and benefits	302,179		82,149
Supply cost	42,584		37,805
Other operating expenses	90,570		54,169
Transaction costs	1,471		0
Depreciation and amortization	22,818		8,259
Total operating expenses	459,622		182,382
Gain (loss) on deconsolidation	(223)		2,045
Equity in earnings of unconsolidated affiliates	2,651		764
Operating income	113,251		79,988
Interest expense, net	30,247		6,960
Earnings from continuing operations before income taxes	83,004		73,028
Income tax expense	14,249		12,982
Net earnings from continuing operations	68,755		60,046
Net earnings from discontinued operations	0		68
Net earnings	68,755		60,114
Less net earnings attributable to noncontrolling interests	47,717		42,919
Net earnings attributable to AmSurg Corp. shareholders	21,038		17,195
Preferred stock dividends	(2,264)		0
Net earnings attributable to AmSurg Corp. common shareholders	18,774		17,195
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	18,774		17,392
Loss from discontinued operations, net of income tax	0		(197)
Net earnings attributable to AmSurg Corp. common shareholders	18,774		17,195
Basic earnings per share attributable to AmSurg Corp. common shareholders:
Net earnings (loss) from continuing operations (usd per share)	$ 0.39		$ 0.55
Net earnings (loss) from discontinued operations (usd per share)	$ 0.00		$ (0.01)
Net earnings (loss) (usd per share)	$ 0.39		$ 0.54
Diluted earnings per share attributable to AmSurg Corp. common shareholders:
Net earnings (loss) from continuing operations (usd per share)	$ 0.39		$ 0.54
Net earnings (loss) from discontinued operations (usd per share)	$ 0.00		$ (0.01)
Net earnings (loss) (usd per share)	$ 0.39		$ 0.54
Weighted average number of shares and share equivalents outstanding:
Basic (in shares)	47,572		31,716
Diluted (in shares)	47,905		32,120
Physician Services [Member]
Provision for uncollectibles	(67,752)	[1]	0
Net revenue	$ 286,535	[1]	$ 0

[1] On July 16, 2014, we completed the acquisition of Sheridan. As such, historical amounts for periods prior to that date are not included.

XML

Dispositions

3 Months Ended

Mar. 31, 2015

Discontinued Operations and Disposal Groups [Abstract]

Dispositions

Dispositions

During the three months ended March 31, 2014, the Company initiated the disposition of centers due to management’s assessment of the Company’s strategy in the market and due to the limited growth opportunities at these centers. The Company did not dispose of any centers during the three months ended March 31, 2015. For disposals occurring in 2014 and prior, the results of operations of discontinued centers have been classified as discontinued operations in all periods presented. As of January 1, 2015, the Company adopted ASU 2014-08 which raised the threshold for a disposal to qualify as a discontinued operation. As a result, the Company expects that such future disposals of its centers will no longer meet the definition to be accounted for as discontinued operations, and any gain or loss from such disposals will be included in continuing operations.

Results of operations and associated gain (loss) on disposal of the centers discontinued for the three months ended March 31, 2014 are as follows (in thousands):

	Three Months Ended   March 31, 2014
Revenues	$	4,594
Earnings before income taxes	540
Results of discontinued operations, net of tax:
Earnings from operations of discontinued interests in surgery centers	430
Loss on disposal of discontinued interests in surgery centers	(362		)
Net earnings from discontinued operations	68
Less: Net earnings from discontinued operations attributable to noncontrolling interests	265
Net loss from discontinued operations attributable to AmSurg Corp. common shareholders	$	(197	)

Cash proceeds from disposal for the three months ended March 31, 2014 were $1.1 million.

XML

Investments in Unconsolidated Affiliates

3 Months Ended

Mar. 31, 2015

Equity Method Investments and Joint Ventures [Abstract]

Investments in Unconsolidated Affiliates

Investments in Unconsolidated Affiliates

Investments in unconsolidated affiliates in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. Equity method investments are initially recorded at cost, unless such investments are a result of the Company entering into a transaction whereby the Company loses control of a previously controlled entity but retains a noncontrolling interest. Such transactions, which result in the deconsolidation of a previously consolidated entity, are measured at fair value. These investments are included as investments in unconsolidated affiliates in the accompanying consolidated balance sheets. The Company’s share of the profits and losses from these investments is reported in equity in earnings of unconsolidated affiliates in the accompanying consolidated statement of earnings. The Company monitors its investments for other-than-temporary impairment by considering factors such as current economic and market conditions and the operating performance of the companies and records reductions in carrying values when necessary.

As of March 31, 2015 and December 31, 2014, the Company has recorded in the accompanying consolidated balance sheets its investments in unconsolidated affiliates of $79.3 million and $75.5 million, respectively. The Company's earnings from these investments during the three months ended March 31, 2015 and 2014, which are reflected in the accompanying consolidated statements of earnings, were approximately $2.7 million and $0.8 million, respectively.

During the three months ended March 31, 2015, the Company's ambulatory services division entered into a transaction whereby it contributed its controlling interest in one center in exchange for a noncontrolling interest in an entity that owned one ASC prior to the transaction and, after the completion of the transaction, controls the contributed center and the center it previously owned. During the three months ended March 31, 2014, the Company's ambulatory services division entered into a transaction whereby it contributed a controlling interest in one center in exchange for $0.6 million and a noncontrolling interest in an entity jointly owned by a hospital that, after the completion of the transaction, controls the contributed center and one additional center. Management of the Company believes these structures provide both economies of scale and potential future growth opportunities in the markets in which the centers are located. 

As a result of these transactions, the Company recorded in the accompanying consolidated balance sheets, as a component of investments in unconsolidated affiliates, the fair value of the Company's investment in the entities which control the contributed centers of approximately $1.3 million and $1.2 million as of the three months ended March 31, 2015 and 2014, respectively.

In each of these transactions, the gain or loss on deconsolidation was determined based on the difference between the fair value of the Company’s noncontrolling interest in the new entity and the carrying value of both the tangible and intangible assets of the contributed centers immediately prior to each transaction. During the three months ended March 31, 2015, the fair value of the Company’s noncontrolling interest was based on estimates of the expected future earnings. Accordingly, the Company recognized a net loss on deconsolidation in the accompanying consolidated statements of earnings of approximately $0.2 million during the three months ended March 31, 2015, which resulted primarily from the allocation of $1.1 million of goodwill, and a net gain of $2.0 million during the three months ended March 31, 2014.

XML

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2015

Revenue Recognition [Abstract]

Schedule of Revenue and Fees by Segment and Major Payors

Net revenue for the physician services segment consists of the following major payors (in thousands):

	Three Months Ended March 31, 2015 (1)
Medicare	$	38,173		13.3	%
Medicaid	13,972			4.9
Commercial and managed care	212,027			74.0
Self-pay	59,126			20.6
Net fee for service revenue	323,298			112.8
Contract and other revenue	30,989			10.8
Provision for uncollectibles	(67,752		)	(23.6	)
Net revenue for physician services	$	286,535		100.0	%

(1) On July 16, 2014, we completed the acquisition of Sheridan. As such, historical amounts for periods prior to that date are not included.

XML

Segment Reporting

3 Months Ended

Mar. 31, 2015

Segment Reporting [Abstract]

Segment Reporting

Segment Reporting

Prior to the Sheridan acquisition, the Company operated its centers as individual components of one operating and reportable segment. Upon completion of the Sheridan acquisition, the Company operates in two major lines of business - the operation of ambulatory surgery centers and providing multi-specialty outsourced physician services, which have been identified as its operating and reportable segments. Through the ambulatory services segment, the Company acquires, develops and operates ambulatory surgery centers in partnership with physicians. Through the physician services segment, the Company provides outsourced physician services in multiple specialties to hospitals, ambulatory surgery centers and other healthcare facilities, primarily in the areas of anesthesiology, children’s services, emergency medicine and radiology.

The Company’s financial information by operating segment is prepared on an internal management reporting basis that the chief operating decision maker uses to allocate resources and assess the performance of the operating segments. The Company’s operating segments have been defined based on the separate financial information that is regularly produced and reviewed by the Company’s chief operating decision maker which is its Chief Executive Officer. The following table presents financial information for each reportable segment (in thousands):

	Three Months Ended March 31,
	2015			2014
Net Revenue:
Ambulatory Services	$	283,910		$	259,561
Physician Services	286,535			—
Total	$	570,445		$	259,561
Adjusted EBITDA:
Ambulatory Services	$	47,308		$	46,006
Physician Services	46,447			—
Total	$	93,755		$	46,006
Adjusted EBITDA:	$	93,755		$	46,006
Earnings from continuing operations attributable to noncontrolling interests	47,717			42,654
Interest expense, net	(30,247		)	(6,960		)
Depreciation and amortization	(22,818		)	(8,259		)
Share-based compensation	(3,709		)	(2,458		)
Transaction costs	(1,471		)	—
Gain (loss) on deconsolidation	(223		)	2,045
Earnings from continuing operations before income taxes	$	83,004		$	73,028
Acquisition and Capital Expenditures:
Ambulatory Services	$	54,096		$	12,076
Physician Services	87,265			—
Total	$	141,361		$	12,076

XML

Long-Term Debt

3 Months Ended

Mar. 31, 2015

Debt Disclosure [Abstract]

Long-Term Debt

Long-term Debt

Long-term debt at March 31, 2015 and December 31, 2014 consisted of the following (in thousands):

	March 31,		December 31,
	2015		2014
Term loan	$	863,475	$	865,650
5.625% Senior Unsecured Notes due 2020	250,000		250,000
5.625% Senior Unsecured Notes due 2022	1,100,000		1,100,000
Other debt due through 2025	19,854		20,156
Capitalized lease arrangements due through 2026	15,523		15,206
	2,248,852		2,251,012
Less current portion	18,858		18,826
Long-term debt	$	2,229,994	$	2,232,186

The fair value of fixed rate long-term debt, with a carrying value of $1,383.6 million, was $1,419.3 million at March 31, 2015. The fair value of variable rate long-term debt approximates its carrying value of $865.3 million at March 31, 2015.  With the exception of the Company’s 2020 and 2022 Senior Unsecured Notes, the fair value of fixed rate debt (Level 2) is determined based on an estimation of discounted future cash flows of the debt at rates currently quoted or offered to the Company for similar debt instruments of comparable maturities by its lenders.  The fair value of the Company’s 2020 and 2022 Senior Unsecured Notes (Level 1) is determined based on quoted prices in an active market.

a.     Term Loan and Credit Facility

On July 16, 2014, the Company terminated its revolving credit facility and entered into a new credit facility that is comprised of an $870.0 million term loan and a $300.0 million revolving credit facility.

The term loan matures on July 16, 2021 and bears interest at a rate equal to, at the Company’s option, the alternative base rate as defined in the agreement (ABR) plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00%, with a LIBOR floor of 0.75%, or a combination thereof (3.75% on March 31, 2015). The term loan requires quarterly principal payments of 0.25% of the face amount totaling $8.7 million annually.

The new revolving credit facility matures on July 16, 2019 and permits the Company to borrow up to $300.0 million at an interest rate equal to, at the Company’s option, the ABR plus 1.75% to 2.00% or LIBOR plus 2.75% to 3.00%, or a combination thereof; and provides for a fee of 0.375% of unused commitments. The Company has the option to increase borrowings under the new senior secured credit facility by an aggregate amount not to exceed the greater of $300.0 million and an unlimited amount as long as certain financial covenants are met and lender approval is obtained. The new senior credit facility contains certain covenants relating to the ratio of debt to operating performance measurements and interest coverage ratios and is secured by a pledge of the stock of the Company’s wholly-owned subsidiaries and certain of the Company’s partnership and membership interests in the LPs and LLCs. As of March 31, 2015, the Company was in compliance with the covenants contained in the term loan and credit facility and had not drawn upon the revolving credit facility.

Prior to entering into the Company's new credit facility, the Company maintained a revolving credit facility which had a maturity of June 2018 and permitted the Company to borrow up to $475.0 million at an interest rate equal to either the base rate plus 0.25% to 1.00% or LIBOR plus 1.25% to 2.00%, or a combination thereof. On July 3, 2014, the Company utilized proceeds received from its common and preferred stock offerings to repay its outstanding obligation under the existing revolving credit facility.

b.     Senior Unsecured Notes

2020 Senior Unsecured Notes

On November 20, 2012, the Company completed a private offering of $250.0 million aggregate principal amount of 5.625% senior unsecured notes due 2020 (the 2020 Senior Unsecured Notes).  On May 31, 2013, the Company completed an offer to exchange the outstanding 2020 Senior Unsecured Notes for an equal amount of such notes that are registered under the Securities Act of 1933, as amended (the Securities Act). The net proceeds from the issuance of the 2020 Senior Unsecured Notes were used to reduce the outstanding indebtedness under the Company’s revolving credit agreement. The 2020 Senior Unsecured Notes are general unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized wholly-owned domestic subsidiaries. The 2020 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2020 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on May 30 and November 30, through the maturity date of November 30, 2020.

Prior to November 30, 2015, the Company may redeem up to 35% of the aggregate principal amount of the 2020 Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings.  On or after November 30, 2015, the Company may redeem the 2020 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on November 30 of the years indicated below:  

Period	Redemption Price
2015	104.219	%
2016	102.813	%
2017	101.406	%
2018 and thereafter	100.000	%

The 2020 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. Based on the terms of the 2020 Senior Unsecured Notes, the Company has adequate ability to meet its obligations to pay dividends as required under the terms of its mandatory convertible preferred stock. The Company was in compliance with the covenants contained in the indenture relating to the 2020 Senior Unsecured Notes at March 31, 2015.

2022 Senior Unsecured Notes

On July 16, 2014, the Company completed a private offering of $1.1 billion aggregate principal amount of 5.625% senior unsecured notes due 2022 (the 2022 Senior Unsecured Notes). On February 19, 2015, the Company completed an offer to exchange the outstanding 2022 Senior Unsecured Notes, for an equal amount of such notes that are registered under the Securities Act. The 2022 Senior Unsecured Notes are general unsecured obligations of the Company and are guaranteed by the Company and existing and subsequently acquired or organized wholly-owned domestic subsidiaries (the Guarantors). The 2022 Senior Unsecured Notes are pari passu in right of payment with all the existing and future senior debt of the Company and senior to all existing and future subordinated debt of the Company. Interest on the 2022 Senior Unsecured Notes accrues at the rate of 5.625% per annum and is payable semi-annually in arrears on January 15 and July 15, beginning on January 15, 2015, and ending on the maturity date of July 15, 2022.

Prior to July 15, 2017, the Company may redeem up to 35% of the aggregate principal amount of the 2022 Senior Unsecured Notes at a redemption price of 105.625% of the principal amount thereof, plus accrued and unpaid interest and liquidated damages, if any, using proceeds of one or more equity offerings. On or after July 15, 2017, the Company may redeem the 2022 Senior Unsecured Notes in whole or in part. The redemption price for such a redemption (expressed as percentages of principal amount) is set forth below, plus accrued and unpaid interest and liquidated damages, if any, if redeemed during the twelve-month period beginning on July 15 of the years indicated below:

Period	Redemption Price
2017	104.219	%
2018	102.813	%
2019	101.406	%
2020 and thereafter	100.000	%

The 2022 Senior Unsecured Notes contain certain covenants which, among other things, limit, but may not restrict, the Company’s ability to enter into or guarantee additional borrowings, sell preferred stock, pay dividends and repurchase stock. Based on the terms of the 2022 Senior Unsecured Notes, the Company has adequate ability to meet its obligations to pay dividends as required under the terms of its mandatory preferred stock. The Company was in compliance with the covenants contained in the indenture relating to the 2022 Senior Unsecured Notes at March 31, 2015.

c.     Senior Secured Notes

During 2010, the Company issued $75.0 million principal amount of senior secured notes (the Senior Secured Notes) pursuant to a note purchase agreement.  The Senior Secured Notes had a maturity date of May 28, 2020. On July 16, 2014, the Company redeemed the Senior Secured Notes utilizing proceeds received from its common and preferred stock offerings.

XML

Subsequent Events (Details) (Physician Practices [Member], Subsequent Event [Member], USD $) In Millions, unless otherwise specified	0 Months Ended
	Apr. 01, 2015 physician_practice
Physician Practices [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of centers acquired	1
Consideration transferred	$ 16.5

XML

Goodwill And Intangible Assets

3 Months Ended

Mar. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill And Intangible Assets

Goodwill and Intangible Assets

The changes in the carrying amount of goodwill for the three months ended March 31, 2015 are as follows (in thousands):

Balance at December 31, 2014	$	3,381,149
Goodwill acquired, including post acquisition adjustments	120,588
Goodwill disposed, including impact of deconsolidation transactions	(1,069		)
Balance at March 31, 2015	$	3,500,668

Although the determination of goodwill generated as a result of the Sheridan transaction is still under evaluation as of March 31, 2015, the ambulatory services segment and the physician services segment had approximately $2.0 billion and $1.5 billion, respectively, of goodwill. During the three months ended March 31, 2015, goodwill increased $60.5 million for the ambulatory services segment primarily due to the acquisition of a center, net of one deconsolidation. During the three months ended March 31, 2015, goodwill increased by $59.0 million for the physician services segment primarily due to the acquisition of three physician practices. For the three months ended March 31, 2015 and 2014, respectively, approximately $49.4 million and $4.7 million of goodwill recorded was deductible for tax purposes.

Intangible assets at March 31, 2015 and December 31, 2014 consisted of the following (in thousands):

	March 31, 2015							December 31, 2014
	Gross							Gross
	Carrying		Accumulated					Carrying		Accumulated
	Amount		Amortization			Net		Amount		Amortization			Net
Amortizable intangible assets:
Customer relationships with hospitals	$	1,015,763	$	(34,545	)	$	981,218	$	971,645	$	(22,145	)	$	949,500
Deferred financing cost	59,660		(7,225		)	52,435		59,574		(5,151		)	54,423
Capitalized software	54,529		(21,136		)	33,393		50,387		(19,197		)	31,190
Agreements, contracts and other	4,068		(2,842		)	1,226		3,523		(2,752		)	771
Total amortizable intangible assets	1,134,020		(65,748		)	1,068,272		1,085,129		(49,245		)	1,035,884
Non-amortizable intangible assets:
Trade name	228,000		—			228,000		228,000		—			228,000
Restrictive covenant arrangements	9,995		—			9,995		9,995		—			9,995
Total non-amortizable intangible assets	237,995		—			237,995		237,995		—			237,995
Total intangible assets	$	1,372,015	$	(65,748	)	$	1,306,267	$	1,323,124	$	(49,245	)	$	1,273,879

Approximately $44.1 million of intangible assets related to customer relationships were recorded during the three months ended March 31, 2015 and are estimated to be amortized over a weighted average period of 20 years with no expected residual values.

Amortization of intangible assets for the three months ended March 31, 2015 and 2014 was $16.6 million and $0.6 million, respectively. Estimated amortization of intangible assets for the remainder of 2015 and each of the following five years and thereafter is $50.8 million, $67.0 million, $65.7 million, $64.7 million, $62.0 million, $59.6 million and $698.5 million, respectively.  The Company expects to recognize amortization of all intangible assets over a weighted average period of 18.1 years with no expected residual values.

XML

Accrued Professional Liabilities

3 Months Ended

Mar. 31, 2015

Payables and Accruals [Abstract]

Accounts Professional Liabilities

Accrued Professional Liabilities

The Company maintains professional liability insurance policies with third-party insurers generally on a claims-made basis, subject to self-insured retention, exclusions and other restrictions. A substantial portion of the professional liability loss risks are being provided by a third-party insurer which is fully reinsured by the Company's wholly-owned captive insurance subsidiary. The Company records an estimate of liabilities for self-insured amounts and claims incurred but not reported based on an actuarial valuation using historical loss patterns, which are not discounted.

At March 31, 2015, the Company's accrued professional liabilities are presented in the accompanying consolidated balance sheets as a component of other accrued liabilities and other long-term liabilities as follows (in thousands):

	March 31, 2015
Estimated losses under self-insured programs	$	26,199
Incurred but not reported losses	31,342
Total accrued professional liabilities	57,541
Less estimated losses payable within one year	10,957
Total	$	46,584

The changes to the Company's estimated losses under self-insured programs as of March 31, 2015 were as follows (in thousands):

Balance at December 31, 2014	$	53,785
Assumed liabilities through acquisitions	4,301
Provision related to current period reserves	3,300
Payments for current period reserves	(1,551		)
Payments for prior period reserves	(2,294		)
Balance at March 31, 2015	$	57,541

XML

Shareholders' Equity

3 Months Ended

Mar. 31, 2015

Equity [Abstract]

Shareholders' Equity

Shareholders’ Equity

a.   Common Stock

On July 2, 2014, the Company issued 9,775,000 shares of its common stock in a public offering, at $45.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $18.5 million. Proceeds from the issuance were used to satisfy certain debt obligations with the remaining amount utilized to fund a portion of the Sheridan acquisition. In addition, on July 16, 2014, the Company issued 5,713,909 shares of its common stock in a private offering to the former owners of Sheridan as part of the total consideration for the Sheridan acquisition.

On August 9, 2013, the Board of Directors authorized a stock purchase program for up to $40.0 million of the Company’s shares of common stock which expired on February 9, 2015. During the three months ended March 31, 2015, the Company did not purchase any shares under the stock repurchase program.

In addition, the Company repurchases shares by withholding a portion of employee restricted stock that vested to cover payroll withholding taxes in accordance with the restricted stock agreements.  During the three months ended March 31, 2015 and 2014, the Company repurchased 67,000 shares and 68,014 shares, respectively, of common stock for approximately $3.7 million and $2.9 million, respectively.

b. Mandatory Convertible Preferred Stock

On July 2, 2014, the Company issued 1,725,000 shares of its mandatory convertible preferred stock in a public offering, at $100.00 per share, prior to underwriting discounts, commissions and other related offering expenses of approximately $5.9 million.

The mandatory convertible preferred stock pays dividends at an annual rate of 5.25% of the initial liquidation preference of $100 per share. Dividends accrue and cumulate from the date of issuance and, to the extent lawful and declared by the Company's Board of Directors, will be paid on each January 1, April 1, July 1 and October 1 in cash or, at the Company's election (subject to certain limitations), by delivery of any combination of cash and shares of common stock. Each share of the mandatory convertible preferred stock has a liquidation preference of $100, plus an amount equal to accrued and unpaid dividends. Each share of the mandatory convertible preferred stock will automatically convert on July 1, 2017 (subject to postponement in certain cases), into between 1.8141 and 2.2222 shares of common stock (the “minimum conversion rate” and “maximum conversion rate,” respectively), each subject to adjustment. The number of shares of common stock issuable on conversion will be determined based on the average volume weighted average price per share of the Company's common stock over the 20 consecutive trading day period commencing on and including the 22nd scheduled trading day prior to July 1, 2017. At any time prior to July 1, 2017, holders may elect to convert all or a portion of their shares of mandatory convertible preferred stock into shares of common stock at the minimum conversion rate. If any holder elects to convert shares of mandatory convertible preferred stock during a specified period beginning on the effective date of a fundamental change the conversion rate will be adjusted under certain circumstances and such holder will also be entitled to a fundamental change dividend make-whole amount.

On March 3, 2015, the Company's Board of Directors declared a dividend of $1.3125 per share in cash, or $2.3 million, for the Company’s 5.25% Mandatory Convertible Preferred Stock. As of March 31, 2015, the dividend was funded to the paying agent to be paid to shareholders of record as of March 15, 2015.

c.   Stock Incentive Plans

In May 2014, the Company adopted the AmSurg Corp. 2014 Equity and Incentive Plan.  The Company also has unvested restricted stock and fully vested options outstanding under the AmSurg Corp. 2006 Stock Incentive Plan, as amended, and the AmSurg Corp. 1997 Stock Incentive Plan, as amended, under which no additional awards may be granted.  Under these plans, the Company has granted restricted stock and non-qualified options to purchase shares of common stock to employees and outside directors from its authorized but unissued common stock.  At March 31, 2015, 1,200,000 shares were authorized for grant under the 2014 Equity and Incentive Plan and 773,718 shares were available for future equity grants.  Restricted stock granted to outside directors vests on the first anniversary of the date of grant.  Restricted stock granted to employees vests over four years in three equal installments beginning on the second anniversary of the date of grant. The fair value of restricted stock is determined based on the closing bid price of the Company’s common stock on the grant date.  Under Company policy, shares held by outside directors and senior management are subject to certain holding restrictions and anti-pledging activities.

No options have been issued subsequent to 2008 and all outstanding options are fully vested.  Options were granted at market value on the date of the grant and vested over four years.  Outstanding options have a term of ten years from the date of grant.

Other information pertaining to share-based activity during the three months ended March 31, 2015 and 2014 was as follows (in thousands):

	Three Months Ended March 31,
	2015		2014
Share-based compensation expense	$	3,709	$	2,458
Fair value of shares vested	11,474		9,175
Cash received from option exercises	1,746		488
Tax benefit from option exercises	3,317		1,727

As of March 31, 2015, the Company had total unrecognized compensation cost of approximately $24.9 million related to non-vested awards, which the Company expects to recognize through 2018 and over a weighted average period of 1.4 years.

For the three months ended March 31, 2015 and 2014, there were no options that were anti-dilutive.

A summary of the status of non-vested restricted shares at March 31, 2015 and changes during the three months ended March 31, 2015 is as follows:

			Weighted
	Number		Average
	of Shares		Grant Price
Non-vested shares at December 31, 2014	668,109		$	33.51
Shares granted	295,527		55.40
Shares vested	(208,701	)	26.62
Shares forfeited	(5,328	)	35.06
Non-vested shares at March 31, 2015	749,607		$	44.05

In addition to the non-vested restricted shares, during the three months ended March 31, 2015, the Company granted 68,945 performance-based restricted stock units to certain of its officers and physician employees. The fair value of our common stock on the grant date of these performance-based units was $55.40. The vesting of these restricted stock units is contingent on the Company’s achievement of a specified one-year financial performance goal for the year ended December 31, 2015. The performance-based restricted stock units will vest ratably over a three year period from the grant date. If the financial performance goal is not achieved, the restricted stock units will be forfeited. The number of performance-based units that ultimately vest will range from 0% to 150% of the units granted, depending on the Company’s level of achievement with respect to the financial performance goal. At March 31, 2015, the Company believes the performance-based units will vest at approximately 100%.

A summary of stock option activity for the three months ended March 31, 2015 is summarized as follows:

					Weighted
			Weighted		Average
			Average		Remaining
	Number		Exercise		Contractual
	of Shares		Price		Term (in years)
Outstanding at December 31, 2014	158,721		$	22.89	1.7
Options exercised with total intrinsic value of $2.9 million	(76,962	)	22.68
Options terminated	(5,000	)	25.76
Outstanding, Vested and Exercisable at March 31, 2015 with an aggregate intrinsic value of $3.0 million	76,759		$	22.92	0.7

The aggregate intrinsic value represents the total pre-tax intrinsic value received by the option holders on the exercise date or that would have been received by the option holders had all holders of in-the-money outstanding options at March 31, 2015 exercised their options at the Company’s closing stock price on March 31, 2015.

d. Earnings per Share

Basic net earnings attributable to AmSurg Corp. common stockholders, per common share, excludes dilution and is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net earnings attributable to AmSurg common stockholders, per common share is computed by dividing net earnings attributable to AmSurg Corp. common stockholders by the weighted-average number of common shares outstanding during the period plus any potential dilutive common share equivalents, including shares issuable (1) upon the vesting of restricted stock awards as determined under the treasury stock method and (2) upon conversion of the Company's 5.250% Mandatory Convertible Preferred Stock as determined under the if-converted method. For purposes of calculating diluted earnings per share, preferred stock dividends have been subtracted from both net earnings from continuing operations attributable to AmSurg Corp. and net earnings attributable to AmSurg Corp. common shareholders in periods in which utilizing the if-converted method would be anti-dilutive. For the three months ended March 31, 2015, approximately 3.2 million common share equivalents related to the Mandatory Convertible Preferred Stock were anti-dilutive and therefore are excluded from the dilutive weighted average number of shares outstanding.

The following is a reconciliation of the numerator and denominators of basic and diluted earnings per share (in thousands, except per share amounts):

	Three Months Ended March 31,
	Earnings		Shares	Per Share
	(Numerator)		(Denominator)	Amount
2015:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	18,774	47,572	$	0.39
Effect of dilutive securities, options and non-vested shares	—		333
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	18,774	47,905	$	0.39
2014:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (basic)	$	17,392	31,716	$	0.55
Effect of dilutive securities, options and non-vested shares	—		404
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders (diluted)	$	17,392	32,120	$	0.54

XML

Accounts Receivable (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2015		Mar. 31, 2014	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense	$ 73,999		$ 5,216
Allowances for accounts receivable	124,606			113,357
Product Concentration Risk [Member] | Allowance for Doubtful Accounts [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts related to fee for service patient visits	72.00%
Ambulatory Services [Member] | Other Operating Expenses [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense	6,200		5,200
Physician Services [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Bad debt expense	$ 67,752	[1]	$ 0

[1] On July 16, 2014, we completed the acquisition of Sheridan. As such, historical amounts for periods prior to that date are not included.

XML

Shareholders Equity (Schedule Of Changes In Non-Vested Restricted Shares) (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested shares at beginning of period, Number of Shares	668,109
Shares granted, Number of Shares	295,527
Shares vested, Number of Shares	(208,701)
Shares forfeited, Number of Shares	(5,328)
Non-vested shares at end of period, Number of Shares	749,607
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested shares at beginning of period, Weighted Average Grant Price	$ 33.51
Shares granted, Weighted Average Grant Price	$ 55.40
Shares vested, Weighted Average Grant Price	$ 26.62
Shares forfeited, Weighted Average Grant Price	$ 35.06
Non-vested shares at end of period, Weighted Average Grant Price	$ 44.05

XML

Subsequent Events

3 Months Ended

Mar. 31, 2015

Subsequent Events [Abstract]

Subsequent Events

Subsequent Events

The Company assessed events occurring subsequent to March 31, 2015 for potential recognition and disclosure in the consolidated financial statements.  In April 2015, the Company acquired one physician practice for an aggregate purchase price of approximately $16.5 million. Other than the items described above, no events have occurred that would require adjustment to or disclosure in the consolidated financial statements.

XML

Goodwill And Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Changes In Carrying Amount Of Goodwill

The changes in the carrying amount of goodwill for the three months ended March 31, 2015 are as follows (in thousands):

Balance at December 31, 2014	$	3,381,149
Goodwill acquired, including post acquisition adjustments	120,588
Goodwill disposed, including impact of deconsolidation transactions	(1,069		)
Balance at March 31, 2015	$	3,500,668

Schedule of Finite-Lived Intangible Assets

Intangible assets at March 31, 2015 and December 31, 2014 consisted of the following (in thousands):

	March 31, 2015							December 31, 2014
	Gross							Gross
	Carrying		Accumulated					Carrying		Accumulated
	Amount		Amortization			Net		Amount		Amortization			Net
Amortizable intangible assets:
Customer relationships with hospitals	$	1,015,763	$	(34,545	)	$	981,218	$	971,645	$	(22,145	)	$	949,500
Deferred financing cost	59,660		(7,225		)	52,435		59,574		(5,151		)	54,423
Capitalized software	54,529		(21,136		)	33,393		50,387		(19,197		)	31,190
Agreements, contracts and other	4,068		(2,842		)	1,226		3,523		(2,752		)	771
Total amortizable intangible assets	1,134,020		(65,748		)	1,068,272		1,085,129		(49,245		)	1,035,884
Non-amortizable intangible assets:
Trade name	228,000		—			228,000		228,000		—			228,000
Restrictive covenant arrangements	9,995		—			9,995		9,995		—			9,995
Total non-amortizable intangible assets	237,995		—			237,995		237,995		—			237,995
Total intangible assets	$	1,372,015	$	(65,748	)	$	1,306,267	$	1,323,124	$	(49,245	)	$	1,273,879

XML

Shareholder's Equity (Narrative) (Details) (USD $)	0 Months Ended	3 Months Ended		0 Months Ended
	Mar. 03, 2015	Mar. 31, 2015	Mar. 31, 2014	Jul. 02, 2014	Jul. 16, 2014	Aug. 09, 2013
Common Stock:
Stock repurchased program authorized by the board of directors						$ 40,000,000.0
Mandatory Convertible Preferred Stock
Preferred stock dividends	2,300,000	2,264,000	0
Stock Incentive Plans:
Number of shares authorized for grant under share incentive plan		1,200,000
Shares available for future grants/issuance under stock incentive plan		773,718
Unrecognized compensation cost on non vested awards		24,900,000
Weighted average period		1 year 4 months 26 days
Number of units granted		295,527
Grant date value of common stock		$ 55.40
Stock Repurchased To Cover Employee Tax Withholdings [Member]
Common Stock:
Repurchase of common stock, shares		67,000	68,014
Repurchase of common stock		3,700,000	2,900,000
Stock Options [Member]
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Options term		10 years
Employees [Member] | Restricted Stock [Member]
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Number of installments in restricted stock granted.		3
Mandatory Convertible Preferred Stock [Member]
Stock Incentive Plans:
Number of anti-dilutive options		3,200,000
Stock Options [Member]
Stock Incentive Plans:
Number of anti-dilutive options		0	0
Common Stock [Member]
Issuance of stock (in shares)				9,775,000
Issuance of stock, price per share				$ 45.00
Stock offering expenses				18,500,000
Mandatory Convertible Preferred Stock [Member]
Issuance of stock (in shares)				1,725,000
Issuance of stock, price per share				$ 100.00
Stock offering expenses				$ 5,900,000
Mandatory Convertible Preferred Stock
Dividend rate		5.25%
Initial liquidation preference (usd per share)		$ 100
Consecutive trading day		20 days
Dividends declared (usd per share)	$ 1.3125
Sheridan Healthcare [Member] | Common Stock [Member]
Common Stock:
Shares of common stock issued for acquisition					5,713,909
Minimum [Member] | Mandatory Convertible Preferred Stock [Member]
Mandatory Convertible Preferred Stock
Conversion rate		1.8141
Maximum [Member] | Mandatory Convertible Preferred Stock [Member]
Mandatory Convertible Preferred Stock
Conversion rate		2.2222
Performance-based Restricted Stock Units [Member]
Stock Incentive Plans:
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Number of units granted		68,945
Grant date value of common stock		$ 55.40
Performance goal period for vesting		1 year
Projected vesting percentage		100.00%
Performance-based Restricted Stock Units [Member] | Minimum [Member]
Stock Incentive Plans:
Projected vesting percentage		0.00%
Performance-based Restricted Stock Units [Member] | Maximum [Member]
Stock Incentive Plans:
Projected vesting percentage		150.00%

XML

Goodwill And Intangible Assets (Narrative) (Details) (USD $)	3 Months Ended
	Mar. 31, 2015		Mar. 31, 2014	Dec. 31, 2014
Segment Reporting Information [Line Items]
Goodwill	$ 3,500,668,000			$ 3,381,149,000
Increase in goodwill	120,588,000
Goodwill deductible for tax purposes	49,400,000		4,700,000
Amortization of Intangible Assets	16,600,000		600,000
Estimated amortization of intangible assets, remainder of 2014	50,800,000
Estimated amortization of intangible assets, 2015	67,000,000
Estimated amortization of intangible assets, 2016	65,700,000
Estimated amortization of intangible assets, 2017	64,700,000
Estimated amortization of intangible assets, 2018	62,000,000
Estimated amortization of intangible assets, 2019	59,600,000
Estimated amortization of intangible assets, 2020 and thereafter	698,500,000
Weighted average amortization period	18 years 37 days
Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Goodwill	2,000,000,000
Increase in goodwill	60,500,000
Physician Services [Member]
Segment Reporting Information [Line Items]
Goodwill	1,500,000,000
Increase in goodwill	59,000,000
Series of Individually Immaterial Business Acquisitions [Member]
Segment Reporting Information [Line Items]
Goodwill	117,141,000	[1]	8,260,000
Intangible assets	44,663,000	[1]	0
Series of Individually Immaterial Business Acquisitions [Member] | Physician Services [Member]
Segment Reporting Information [Line Items]
Number of business acquisitions	3
Controlling Interest [Member] | Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Number of business acquisitions	1		1
Controlling Interest [Member] | Joint Venture [Member] | Ambulatory Services [Member]
Segment Reporting Information [Line Items]
Number consolidated centers contributed to joint venture	1		1
Customer relationships with hospitals [Member]
Segment Reporting Information [Line Items]
Amount estimated to be amortized over weighted average period	$ 44,100,000
Weighted average period of amortization	20 years

[1] Represents the preliminary allocation of fair value of acquired assets and liabilities associated with these acquisitions at March 31, 2015.

XML

Consolidated Statements Of Changes In Equity (USD $) In Thousands, except Share data, unless otherwise specified	Total	Common Stock [Member]	Mandatory Convertible Preferred Stock [Member]	Retained Earnings [Member]	Non-Controlling Interests - Non-Redeemable [Member]	Total Equity (Permanent) [Member]	Non-controlling Interests - Redeemable (Temporary Equity) [Member]
Balance at Dec. 31, 2013		$ 185,873		$ 578,324	$ 361,359	$ 1,125,556	$ 177,697
Balance (in shares) at Dec. 31, 2013		32,353,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	60,114			17,195	12,219	29,414	30,700
Issuance of restricted common stock (in shares)		200,000
Stock options exercised		488				488
Stock options exercised (in shares)		20,000
Stock repurchased		(2,857)				(2,857)
Stock repurchased (in shares)		(68,000)
Share-based compensation		2,458				2,458
Tax benefit related to exercise of stock options		1,727				1,727
Acquisitions and other transactions impacting noncontrolling interests		286			3,690	3,976	0
Distributions to noncontrolling interests, net of capital contributions					(12,753)	(12,753)	(30,441)
Disposals and other transactions impacting noncontrolling interests		(1,081)			(1,291)	(2,372)	(273)
Balance at Mar. 31, 2014		186,894	0	595,519	363,224	1,145,637	177,683
Balance (in shares) at Mar. 31, 2014		32,505,000	0
Balance at Dec. 31, 2014	2,098,231	885,393	166,632	627,522	418,684	2,098,231	184,099
Balance (in shares) at Dec. 31, 2014		48,113,000	1,725,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	68,755			21,038	15,037	36,075	32,680
Issuance of restricted common stock (in shares)		296,000
Cancellation of restricted common stock (in shares)		(6,000)
Stock options exercised		1,746				1,746
Stock options exercised (in shares)	76,962	77,000
Stock repurchased		(3,684)				(3,684)
Stock repurchased (in shares)		(67,000)
Share-based compensation		3,709				3,709
Tax benefit related to exercise of stock options		3,317				3,317
Dividends paid on preferred stock				(2,264)		(2,264)
Acquisitions and other transactions impacting noncontrolling interests		144			23,012	23,156	(646)
Distributions to noncontrolling interests, net of capital contributions					(14,564)	(14,564)	(32,544)
Disposals and other transactions impacting noncontrolling interests		(1,877)			2,951	1,074	(130)
Balance at Mar. 31, 2015	$ 2,146,796	$ 888,748	$ 166,632	$ 646,296	$ 445,120	$ 2,146,796	$ 183,459
Balance (in shares) at Mar. 31, 2015		48,413,000	1,725,000

XML

Acquisitions

3 Months Ended

Mar. 31, 2015

Business Combinations [Abstract]

Acquisitions

Acquisitions

The Company accounts for its business combinations under the fundamental requirements of the acquisition method of accounting and under the premise that an acquirer be identified for each business combination.  The acquirer is the entity that obtains control of one or more businesses in the business combination and the acquisition date is the date the acquirer achieves control.  The assets acquired, liabilities assumed and any noncontrolling interests in the acquired business at the acquisition date are recognized at their fair values as of that date, and the direct costs incurred in connection with the business combination are recorded and expensed separately from the business combination.  Acquisitions in which the Company is able to exert significant influence but does not have control are accounted for using the equity method.

Sheridan Acquisition

On July 16, 2014, the Company completed the acquisition of Sheridan in a cash and stock transaction. At closing, the Company paid approximately $2.1 billion in cash and issued 5,713,909 shares of its common stock to the former owners of Sheridan in exchange for all of the outstanding equity interests of Sheridan. The shares issued to Sheridan were valued at approximately $272.0 million based on the closing price of the Company's common stock on July 16, 2014. The acquisition of Sheridan enhances the growth profile and diversity of the Company focusing on complementary specialties across the healthcare continuum.

The accounting for the acquisition of Sheridan is expected to be completed during the second quarter of 2015. The Company continues to obtain information relative to the fair values of assets acquired, liabilities assumed and any noncontrolling interests in the transaction. Acquired assets and assumed liabilities include, but are not limited to, fixed assets, licenses, intangible assets and professional liabilities. The valuations are based on appraisal reports, discounted cash flow analyses, actuarial analyses or other appropriate valuation techniques to determine the fair value of the assets acquired or liabilities assumed.

Ambulatory Services Acquisitions

During each of the three months ended March 31, 2015 and 2014, the Company, through a wholly-owned subsidiary, acquired a controlling interest in one surgery center. The aggregate amount paid for the centers acquired and for settlement of purchase price payable obligations during the three months ended March 31, 2015 and 2014 was approximately $41.9 million and $5.0 million, respectively, and was paid in cash and funded by a combination of operating cash flow and borrowings under the Company’s revolving credit facility.  The total fair value of an acquisition includes an amount allocated to goodwill, which results from the centers’ favorable reputations in their markets, their market positions and their ability to deliver quality care with high patient satisfaction consistent with the Company’s business model.

Physician Services Acquisitions

The Company completed the acquisition of three physician group practices in the three months ended March 31, 2015. The total consideration consisted of cash of $84.7 million, which was funded at closing through operating cash flow. As a result of certain acquisitions completed during the year ended December 31, 2014, the Company has agreed to pay as additional consideration, the exact amounts of which are contingent on the acquired entity achieving future performance metrics. As of March 31, 2015 and December 31, 2014, the Company had accrued $24.6 million and $20.7 million, respectively, as a component of accrued liabilities and other long-term liabilities in the accompanying consolidated balance sheets which represents management's estimate of the fair values of the contingent consideration. As of March 31, 2015, the Company estimates it may have to pay between $21.0 to $26.0 million in future contingent payments for acquisitions made prior to December 31, 2014 based upon the current projected financial performance or anticipated achievement of other targets of the acquired operations. The current estimate of future contingent payments could increase or decrease depending upon the actual performance of the acquisition over each respective measurement period. The acquisitions completed during the three months ended March 31, 2015 did not result in any contingent consideration.

The Company utilizes Level 3 inputs, which include unobservable data, to measure the fair value of the contingent consideration. The fair value was determined utilizing future forecasts of both earnings and other performance metrics which are expected to be achieved during the performance period, in accordance with each respective purchase agreement. In estimating the fair value, management developed various scenarios and weighted the probable outcome of each scenario using a range of expected probability specific to each agreement. Management utilized a market rate to discount the results of such analysis in order to record the present value of the expected future payout. The timing of the payments of the additional consideration varies by agreement but is expected to occur within one to three years from the date of acquisition.

Purchase Price Allocations

The acquisition date fair value of the total consideration transferred and acquisition date fair value of each major class of consideration for the acquisitions completed in the three months ended March 31, 2015 and 2014, including post acquisition date adjustments recorded to purchase price allocations, are as follows (in thousands): 

	Three Months Ended March 31,
	2015 (1)			2014
Accounts receivable	$	11,355		$	417
Other current assets	4,091			81
Property and equipment	3,465			429
Goodwill	117,141			8,260
Intangible assets	44,663			—
Other long-term assets	35			—
Accounts payable	(1,023		)	(125		)
Other accrued liabilities	(6,774		)	(39		)
Deferred income taxes	(12,190		)	—
Other long-term liabilities	(4,301		)	—
Long-term debt	(735		)	—
Total fair value	155,727			9,023
Less:  Fair value attributable to noncontrolling interests	23,649			3,985
Acquisition date fair value of total consideration transferred	$	132,078		$	5,038

(1) Represents the preliminary allocation of fair value of acquired assets and liabilities associated with these acquisitions at March 31, 2015.

Fair value attributable to noncontrolling interests is based on significant inputs that are not observable in the market.  Key inputs used to determine the fair value include financial multiples used in the purchase of noncontrolling interests primarily from acquisitions of centers.  Such multiples, based on earnings, are used as a benchmark for the discount to be applied for the lack of control or marketability.  The fair value of noncontrolling interests for acquisitions where the purchase price allocation is not finalized may be subject to adjustment as the Company completes its initial accounting for acquired intangible assets. 

During the three months ended March 31, 2015, the Company incurred approximately $1.5 million of transaction costs. During the three months ended March 31, 2014, the transaction costs incurred by the Company were not significant.

Net revenue and net earnings included in the three months ended March 31, 2015 and 2014 associated with completed acquisitions are as follows (in thousands):

	Three Months Ended March 31,
	2015		2014
Net revenue	$	14,989	$	1,031
Net earnings	2,613		245
Less:  Net earnings attributable to noncontrolling interests	761		151
Net earnings attributable to AmSurg Corp. common shareholders	$	1,852	$	94

The unaudited consolidated pro forma results for the three months ended March 31, 2015 and 2014, assuming all acquisitions completed prior to March 31, 2015 had been consummated on January 1, 2014, and all 2014 acquisitions had been consummated on January 1, 2013 are as follows (in thousands):

	Three Months Ended March 31,
	2015		2014
Net revenue	$	581,696	$	551,877
Net earnings	71,267		59,152
Amounts attributable to AmSurg Corp. common shareholders:
Net earnings	23,140		13,571
Net earnings per common share:
Basic	$	0.44	$	0.24
Diluted	$	0.44	$	0.24

XML

Financial Information for the Company and Its Subsidiaries (Income Statements) (Details) (USD $) In Thousands, unless otherwise specified	0 Months Ended	3 Months Ended
	Mar. 03, 2015	Mar. 31, 2015	Mar. 31, 2014
Condensed Financial Statements, Captions [Line Items]
Revenues		$ 570,445	$ 259,561
Operating expenses:
Salaries and benefits		302,179	82,149
Supply cost		42,584	37,805
Other operating expenses		90,570	54,169
Transaction costs		1,471	0
Depreciation and amortization		22,818	8,259
Total operating expenses		459,622	182,382
Gain (loss) on deconsolidation		(223)	2,045
Equity in earnings of unconsolidated affiliates		2,651	764
Operating income		113,251	79,988
Interest expense, net		30,247	6,960
Earnings from continuing operations before income taxes		83,004	73,028
Income tax expense		14,249	12,982
Net earnings from continuing operations		68,755	60,046
Net earnings from discontinued operations		0	68
Net earnings		68,755	60,114
Less net earnings attributable to noncontrolling interests		47,717	42,919
Net earnings attributable to AmSurg Corp. shareholders		21,038	17,195
Preferred stock dividends	(2,300)	(2,264)	0
Net earnings attributable to AmSurg Corp. common shareholders		18,774	17,195
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax		18,774	17,392
Loss from discontinued operations, net of income tax		0	(197)
Net earnings attributable to AmSurg Corp. common shareholders		18,774	17,195
Consolidation, Eliminations [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues		(8,854)	(4,609)
Operating expenses:
Salaries and benefits		(128)	(121)
Supply cost		0	0
Other operating expenses		(8,726)	(4,488)
Transaction costs		0
Depreciation and amortization		0	0
Total operating expenses		(8,854)	(4,609)
Gain (loss) on deconsolidation		188	(2,045)
Equity in earnings of unconsolidated affiliates		(112,319)	(95,340)
Operating income		(112,131)	(97,385)
Interest expense, net		0	0
Earnings from continuing operations before income taxes		(112,131)	(97,385)
Income tax expense		0	0
Net earnings from continuing operations			(97,385)
Net earnings from discontinued operations			0
Net earnings		(112,131)	(97,385)
Less net earnings attributable to noncontrolling interests		0	0
Net earnings attributable to AmSurg Corp. shareholders		(112,131)	(97,385)
Preferred stock dividends		0
Net earnings attributable to AmSurg Corp. common shareholders		(112,131)
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax			(97,385)
Loss from discontinued operations, net of income tax			0
Net earnings attributable to AmSurg Corp. common shareholders		(112,131)
Parent Company [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues		7,091	6,127
Operating expenses:
Salaries and benefits		17,643	14,485
Supply cost		0	0
Other operating expenses		6,634	4,166
Transaction costs		268
Depreciation and amortization		834	825
Total operating expenses		25,379	19,476
Gain (loss) on deconsolidation		(188)	2,045
Equity in earnings of unconsolidated affiliates		60,387	48,052
Operating income		41,911	36,748
Interest expense, net		11,886	6,452
Earnings from continuing operations before income taxes		30,025	30,296
Income tax expense		8,987	12,704
Net earnings from continuing operations			17,592
Net earnings from discontinued operations			(397)
Net earnings		21,038	17,195
Less net earnings attributable to noncontrolling interests		0	0
Net earnings attributable to AmSurg Corp. shareholders		21,038	17,195
Preferred stock dividends		(2,264)
Net earnings attributable to AmSurg Corp. common shareholders		18,774
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax			17,592
Loss from discontinued operations, net of income tax			(397)
Net earnings attributable to AmSurg Corp. common shareholders		18,774
Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues		285,579	0
Operating expenses:
Salaries and benefits		211,601	0
Supply cost		396	0
Other operating expenses		29,611	0
Transaction costs		1,203
Depreciation and amortization		14,307	0
Total operating expenses		257,118	0
Gain (loss) on deconsolidation		(188)	2,045
Equity in earnings of unconsolidated affiliates		54,583	48,052
Operating income		82,856	50,097
Interest expense, net		17,754	0
Earnings from continuing operations before income taxes		65,102	50,097
Income tax expense		4,903	0
Net earnings from continuing operations			50,097
Net earnings from discontinued operations			0
Net earnings		60,199	50,097
Less net earnings attributable to noncontrolling interests		0	0
Net earnings attributable to AmSurg Corp. shareholders		60,199	50,097
Preferred stock dividends		0
Net earnings attributable to AmSurg Corp. common shareholders		60,199
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax			50,097
Loss from discontinued operations, net of income tax			0
Net earnings attributable to AmSurg Corp. common shareholders		60,199
Non-Guarantor Subsidiaries [Member]
Condensed Financial Statements, Captions [Line Items]
Revenues		286,629	258,043
Operating expenses:
Salaries and benefits		73,063	67,785
Supply cost		42,188	37,805
Other operating expenses		63,051	54,491
Transaction costs		0
Depreciation and amortization		7,677	7,434
Total operating expenses		185,979	167,515
Gain (loss) on deconsolidation		(35)	0
Equity in earnings of unconsolidated affiliates		0	0
Operating income		100,615	90,528
Interest expense, net		607	508
Earnings from continuing operations before income taxes		100,008	90,020
Income tax expense		359	278
Net earnings from continuing operations			89,742
Net earnings from discontinued operations			465
Net earnings		99,649	90,207
Less net earnings attributable to noncontrolling interests		47,717	42,919
Net earnings attributable to AmSurg Corp. shareholders		51,932	47,288
Preferred stock dividends		0
Net earnings attributable to AmSurg Corp. common shareholders		51,932
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax			47,088
Loss from discontinued operations, net of income tax			200
Net earnings attributable to AmSurg Corp. common shareholders		$ 51,932

XML

Accrued Professional Liabilities (Tables)

3 Months Ended

Mar. 31, 2015

Payables and Accruals [Abstract]

Schedule of Accrued Professional Liabilities

At March 31, 2015, the Company's accrued professional liabilities are presented in the accompanying consolidated balance sheets as a component of other accrued liabilities and other long-term liabilities as follows (in thousands):

	March 31, 2015
Estimated losses under self-insured programs	$	26,199
Incurred but not reported losses	31,342
Total accrued professional liabilities	57,541
Less estimated losses payable within one year	10,957
Total	$	46,584

Schedule of Self Insurance Reserve Roll Forward

The changes to the Company's estimated losses under self-insured programs as of March 31, 2015 were as follows (in thousands):

Balance at December 31, 2014	$	53,785
Assumed liabilities through acquisitions	4,301
Provision related to current period reserves	3,300
Payments for current period reserves	(1,551		)
Payments for prior period reserves	(2,294		)
Balance at March 31, 2015	$	57,541

XML

Acquisitions (Consolidated Pro Forma Results Of Acquisition) (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Business Combinations [Abstract]
Net revenues	$ 581,696	$ 551,877
Net earnings	71,267	59,152
Net earnings attributable to AmSurg Corp. common shareholders	$ 23,140	$ 13,571
Net earnings per common share, Basic (usd per share)	$ 0.44	$ 0.24
Net earnings per common share, Diluted (usd per share)	$ 0.44	$ 0.24

XML

Financial Information for the Company and Its Subsidiaries

3 Months Ended

Mar. 31, 2015

Condensed Financial Information of Parent Company Only Disclosure [Abstract]

Financial Information for the Company and Its Subsidiaries

Financial Information for the Company and Its Subsidiaries

The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are senior unsecured obligations of the Company and are guaranteed by its existing and subsequently acquired or organized 100% owned domestic subsidiaries.  The 2020 Senior Unsecured Notes and 2022 Senior Unsecured Notes are guaranteed on a full and unconditional and joint and several basis, with limited exceptions considered customary for such guarantees, including the release of the guarantee when a subsidiary's assets are sold. The following condensed consolidating financial statements present the Company (as parent issuer), the subsidiary guarantors, the subsidiary non-guarantors and consolidating adjustments. These condensed consolidating financial statements have been prepared and presented in accordance with Rule 3-10 of Regulation S-X “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.”  The operating and investing activities of the separate legal entities are fully interdependent and integrated. Accordingly, the results of the separate legal entities are not representative of what the operating results would be on a stand-alone basis.

Condensed Consolidating Balance Sheet - March 31, 2015 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Assets
Current assets:
Cash and cash equivalents	$	30,118	$	38,681	$	47,357	$	—		$	116,156
Restricted cash and marketable securities	—		—		10,957		—			10,957
Accounts receivable, net	—		130,807		113,195		—			244,002
Supplies inventory	—		286		20,187		—			20,473
Prepaid and other current assets	51,155		32,196		19,729		(5,719		)	97,361
Total current assets	81,273		201,970		211,425		(5,719		)	488,949
Property and equipment, net	11,910		8,665		162,871		—			183,446
Investments in and receivables from unconsolidated affiliates	4,025,683		1,635,845		—		(5,582,217		)	79,311
Goodwill	—		1,549,964		—		1,950,704			3,500,668
Intangible assets, net	66,001		1,237,487		2,779		—			1,306,267
Other assets	3,734		1,040		20,594		—			25,368
Total assets	$	4,188,601	$	4,634,971	$	397,669	$	(3,637,232	)	$	5,584,009
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	8,700	$	—	$	10,158	$	—		$	18,858
Accounts payable	2,255		224		28,256		(4,927		)	25,808
Accrued salaries and benefits	19,652		111,525		13,430		—			144,607
Accrued interest	17,840		—		17		—			17,857
Other accrued liabilities	7,272		39,909		29,312		(792		)	75,701
Total current liabilities	55,719		151,658		81,173		(5,719		)	282,831
Long-term debt	2,204,775		—		56,204		(30,985		)	2,229,994
Deferred income taxes	218,564		429,880		—		—			648,444
Other long-term liabilities	7,867		65,622		18,996		—			92,485
Intercompany payable	—		1,228,136		21		(1,228,157		)	—
Noncontrolling interests – redeemable	—		—		62,793		120,666			183,459
Equity:
Total AmSurg Corp. equity	1,701,676		2,759,675		132,731		(2,892,406		)	1,701,676
Noncontrolling interests – non-redeemable	—		—		45,751		399,369			445,120
Total equity	1,701,676		2,759,675		178,482		(2,493,037		)	2,146,796
Total liabilities and equity	$	4,188,601	$	4,634,971	$	397,669	$	(3,637,232	)	$	5,584,009

Condensed Consolidating Balance Sheet - December 31, 2014 (In thousands)
	Parent Issuer		Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Assets
Current assets:
Cash and cash equivalents	$	134,351	$	23,471	$	50,257	$	—		$	208,079
Restricted cash and marketable securities	—		—		10,219		—			10,219
Accounts receivable, net	—		123,772		109,281		—			233,053
Supplies inventory	—		301		19,673		—			19,974
Prepaid and other current assets	47,997		58,388		13,795		(4,818		)	115,362
Total current assets	182,348		205,932		203,225		(4,818		)	586,687
Property and equipment, net	10,391		9,972		160,085		—			180,448
Investments in and receivables from unconsolidated affiliates	3,912,804		1,587,881		—		(5,425,210		)	75,475
Goodwill	—		1,490,981		—		1,890,168			3,381,149
Intangible assets, net	67,678		1,203,218		2,983		—			1,273,879
Other assets	3,323		943		23,086		(1,466		)	25,886
Total assets	$	4,176,544	$	4,498,927	$	389,379	$	(3,541,326	)	$	5,523,524
Liabilities and Equity
Current liabilities:
Current portion of long-term debt	$	8,700	$	—	$	10,126	$	—		$	18,826
Accounts payable	1,849		35		31,781		(4,080		)	29,585
Accrued salaries and benefits	25,035		101,395		13,614		—			140,044
Accrued interest	29,621		—		23		—			29,644
Other accrued liabilities	8,051		44,305		16,368		(738		)	67,986
Total current liabilities	73,256		145,735		71,912		(4,818		)	286,085
Long-term debt	2,206,950		—		53,648		(28,412		)	2,232,186
Deferred income taxes	209,400		425,546		—		(1,466		)	633,480
Other long-term liabilities	7,391		63,616		18,436		—			89,443
Intercompany payable	—		1,219,979		8,010		(1,227,989		)	—
Noncontrolling interests – redeemable	—		—		63,544		120,555			184,099
Equity:
Total AmSurg Corp. equity	1,679,547		2,644,051		130,206		(2,774,257		)	1,679,547
Noncontrolling interests – non-redeemable	—		—		43,623		375,061			418,684
Total equity	1,679,547		2,644,051		173,829		(2,399,196		)	2,098,231
Total liabilities and equity	$	4,176,544	$	4,498,927	$	389,379	$	(3,541,326	)	$	5,523,524

Condensed Consolidating Statement of Earnings - For the Three Months Ended March 31, 2015 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Net revenue	$	7,091		$	285,579		$	286,629		$	(8,854	)	$	570,445
Operating expenses:
Salaries and benefits	17,643			211,601			73,063			(128		)	302,179
Supply cost	—			396			42,188			—			42,584
Other operating expenses	6,634			29,611			63,051			(8,726		)	90,570
Transaction costs	268			1,203			—			—			1,471
Depreciation and amortization	834			14,307			7,677			—			22,818
Total operating expenses	25,379			257,118			185,979			(8,854		)	459,622
Loss on deconsolidation	(188		)	(188		)	(35		)	188			(223		)
Equity in earnings of unconsolidated affiliates	60,387			54,583			—			(112,319		)	2,651
Operating income	41,911			82,856			100,615			(112,131		)	113,251
Interest expense, net	11,886			17,754			607			—			30,247
Earnings from operations before income taxes	30,025			65,102			100,008			(112,131		)	83,004
Income tax expense	8,987			4,903			359			—			14,249
Net earnings	21,038			60,199			99,649			(112,131		)	68,755
Net earnings attributable to noncontrolling interests	—			—			47,717			—			47,717
Net earnings attributable to AmSurg Corp. shareholders	21,038			60,199			51,932			(112,131		)	21,038
Preferred stock dividends	(2,264		)	—			—			—			(2,264		)
Net earnings attributable to AmSurg Corp. common shareholders	$	18,774		$	60,199		$	51,932		$	(112,131	)	$	18,774

Condensed Consolidating Statement of Earnings - For the Three Months Ended March 31, 2014 (In thousands)
	Parent Issuer			Guarantor Subsidiaries		Non-Guarantor Subsidiaries		Consolidating Adjustments			Total Consolidated
Net revenue	$	6,127		$	—	$	258,043	$	(4,609	)	$	259,561
Operating expenses:
Salaries and benefits	14,485			—		67,785		(121		)	82,149
Supply cost	—			—		37,805		—			37,805
Other operating expenses	4,166			—		54,491		(4,488		)	54,169
Depreciation and amortization	825			—		7,434		—			8,259
Total operating expenses	19,476			—		167,515		(4,609		)	182,382
Gain on deconsolidation	2,045			2,045		—		(2,045		)	2,045
Equity in earnings of unconsolidated affiliates	48,052			48,052		—		(95,340		)	764
Operating income	36,748			50,097		90,528		(97,385		)	79,988
Interest expense	6,452			—		508		—			6,960
Earnings from continuing operations before income taxes	30,296			50,097		90,020		(97,385		)	73,028
Income tax expense	12,704			—		278		—			12,982
Net earnings from continuing operations	17,592			50,097		89,742		(97,385		)	60,046
Net earnings (loss) from discontinued operations	(397		)	—		465		—			68
Net earnings	17,195			50,097		90,207		(97,385		)	60,114
Net earnings attributable to noncontrolling interests	—			—		42,919		—			42,919
Net earnings attributable to AmSurg Corp. common shareholders	$	17,195		$	50,097	$	47,288	$	(97,385	)	$	17,195
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax	$	17,592		$	50,097	$	47,088	$	(97,385	)	$	17,392
Discontinued operations, net of income tax	(397		)	—		200		—			(197		)
Net earnings attributable to AmSurg Corp. common shareholders	$	17,195		$	50,097	$	47,288	$	(97,385	)	$	17,195

Condensed Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2015 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by (used in) operating activities	$	(33,779	)	$	91,981		$	102,821		$	(62,196	)	$	98,827
Cash flows from investing activities:
Acquisitions and related expenses	(62,056		)	(127,047		)	—			62,525			(126,578		)
Acquisition of property and equipment	(2,678		)	(2,538		)	(9,567		)	—			(14,783		)
Other	—			(1,322		)	1,102			—			(220		)
Net cash flows used in investing activities	(64,734		)	(130,907		)	(8,465		)	62,525			(141,581		)
Cash flows from financing activities:
Proceeds from long-term borrowings	—			—			2,227			—			2,227
Repayment on long-term borrowings	(2,175		)	—			(3,038		)	—			(5,213		)
Distributions to owners, including noncontrolling interests	—			(10,241		)	(99,157		)	62,196			(47,202		)
Capital contributions	—			62,056			—			(62,056		)	—
Cash dividends for preferred shares	(2,264		)	—			—			—			(2,264		)
Changes in intercompany balances with affiliates, net	(2,573		)	—			2,573			—			—
Other financing activities, net	1,292			2,321			139			(469		)	3,283
Net cash flows provided by (used in) financing activities	(5,720		)	54,136			(97,256		)	(329		)	(49,169		)
Net increase (decrease) in cash and cash equivalents	(104,233		)	15,210			(2,900		)	—			(91,923		)
Cash and cash equivalents, beginning of period	134,351			23,471			50,257			—			208,079
Cash and cash equivalents, end of period	$	30,118		$	38,681		$	47,357		$	—		$	116,156

Condensed Consolidating Statement of Cash Flows - For the Three Months Ended March 31, 2014 (In thousands)
	Parent Issuer			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Total Consolidated
Cash flows from operating activities:
Net cash flows provided by operating activities	$	18,482		$	48,096		$	96,257		$	(93,016	)	$	69,819
Cash flows from investing activities:
Acquisitions and related expenses	—			(5,082		)	—			44			(5,038		)
Acquisition of property and equipment	(1,237		)	—			(5,801		)	—			(7,038		)
Proceeds from sale of interests in surgery centers	—			1,111			—			—			1,111
Other	(629		)	211			—			—			(418		)
Net cash flows used in investing activities	(1,866		)	(3,760		)	(5,801		)	44			(11,383		)
Cash flows from financing activities:
Proceeds from long-term borrowings	30,000			—			1,945			—			31,945
Repayment on long-term borrowings	(47,679		)	—			(3,174		)	—			(50,853		)
Distributions to owners, including noncontrolling interests	—			(44,920		)	(91,290		)	93,016			(43,194		)
Changes in intercompany balances with affiliates, net	556			—			(556		)	—			—
Other financing activities, net	(641		)	584			43			(44		)	(58		)
Net cash flows used in financing activities	(17,764		)	(44,336		)	(93,032		)	92,972			(62,160		)
Net decrease in cash and cash equivalents	(1,148		)	—			(2,576		)	—			(3,724		)
Cash and cash equivalents, beginning of period	6,710			—			44,130			—			50,840
Cash and cash equivalents, end of period	$	5,562		$	—		$	41,554		$	—		$	47,116